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SUMMARY.
Human neutrophils can be stimulated by a plethora of soluble and 
particulate stimuli, the majority of which interact with specific 
recognition sites (receptors) located on the plasma membrane. These 
agonists evoke a series of cellular responses including chemotaxis, 
aggregation, degranulation, superoxide generation and the formation 
of numerous lipid products, for example LTB^ and PAP, which are 
derived from membrane phospholipids. LTB4 and PAF interact with 
specific receptors on, and are themselves potent activators of, human 
neutrophils. Therefore, these lipids have the potential to act as 
endogenous mediators or amplifiers of neutrophil activation. The 
mechanisms by which agonist receptor occupancy lead to such cellular 
activation remain to be fully established. It remains possible that 
in neutrophils, as in some other cells, reactivity may be regulated 
by the production of at least two second messenger molecules,
1,2-diacylglycerol (HAG) and £ca^+Ji that are produced as a consequence 
of phospholipase C catalysed phosphoinositide hydrolysis. The precise 
nature and role of this receptor mediated sequence of events in the 
human neutrophil, particularly concerning LTB4 and PAF, still remains 
to be fully elucidated and is frequently controversial.
In this study I attempted to investigate the mechanism of action 
and interaction of the arachidonic acid metabolite, LTB4 , and the 
ether lipid, PAF, as mediators of neutrophil activation by comparing 
the responses elicited by these lipids to those evoked by other 
neutrophil stimuli, namely the chemotactic tripeptide, FMLP, the
XX
calcium ionophore, ionomycin and the phorbol eater, PMA. I also 
examined the possible involvement of G proteins and the role of
protein kinase C activation as stimulatory and regulatory mechanisms 
in the neutrophil. In addition, I explored the role of PAF and 
LTB4 as endogenous mediators or amplifiers of neutrophil activation 
induced by other agonists.
Neutrophil reactivity was assessed by:
a. Examining ultrastructural features using electron microscopy.
b. Monitoring aggregation photometrically using a standard 
platelet aggregometer.
c. Determining NAG and lysozyme release using a fluorimetric 
and a spectrophotometric technique respectively.
d. Measuring LTB4 generation by specific radioimmunoassay and 
the authenticity confirmed using reverse phase HPLC.
e. Observing changes in [ca2+]i using the fluorescent calcium 
indicator dye, quin2 .
f. Following inositol phospholipid metabolism in cells 
prelabelled with [^2pJ-orthophosphate and monitoring 
changes in the levels of [52p]-PtdA, [52p]-PtdIns, [ 52p]-PIP 
and [52p]-PIP2 .
Using these in vitro techniques, the major observations and 
conclusions are listed below:
1. The ultrastructural features associated with neutrophils 
activated by FMLP, PAF and LTB4 were similar. Control, 
unstimulated cells were generally rounded with smooth 
contours and the occasional extension of fine projections. 
Exposure of cells to agonists caused a marked plasma membrane 
ruffling followed by cell polarization and the formation of 
large lamellipodia. Pretreatment of neutrophils with the 
fungal metabolite, cytochalasin B, caused a marked vacuolation
XXI
and subsequent additions of agonists resulted in the formation 
of blebs giving the cells a bizarre appearance. Caution ought 
to be a priority when using or interpreting data generated by 
cytochalasin B.
2. LTB4, PAF and FMLP all caused a reversible, concentration- 
dependent neutrophil aggregation. The aggregatory response 
produced by ionomycin and PMA was also concentration-dependent 
but was slower in onset and irreversible.
3. The receptor directed agonists caused a cytochalasin B 
dependent release of NAG (an azurophil granule marker) and 
lysozyme (an azurophil and specific granule marker). The 
calcium ionophore induced the release of both markers independent 
of pretreatment with cytochalasin B. PMA could release lysozyme 
in the absence of the fungal metabolite but the phorbol ester 
only induced a limited cytochalasin B dependent release of NAG.
4 . Ionomycin elicited a concentration-dependent generation and 
release of LTB4 . FMLP and PAF only released barely detectable 
levels of the arachidonic acid metabolite.
5« All agonists except PMA caused a rapid concentration-dependent 
elevation of neutrophil £ca2+Ji. Ionomycin induced a greater 
maximal increase than the receptor directed agonists.
6 . FMLP, PAF and ionomycin caused a concentration-dependent
formation of J^2p]-PtdA. The responses induced by FMLP and 
PAF were not calcium dependent whereas [^2p]-PtdA formation 
produced by the calcium ionophore required the presence of 
external Ca2+ . LTB4 failed to elicit the formation of [^p]- 
PtdA or the degradation of p 2p]-PtdIns, p 2pJ-PIP or [^2pJ-PIP2 » 
The results presented in this study suggest that LTB4 may 
elicit cellular activation apparently independent of
XXII
phosphoinositide hydrolysis.
7. The concentration-response curves for MLP, PAF and LTB4- 
induced elevation of £ca^+Ji lie to the left of those for 
aggregation and degranulation. M L P  and PAF also caused an 
elevation of |Tca^ +Ji at concentrations lower than those 
required to elicit [^pJ-PtdA formation.
These data indicate that £ca^+Ji elevation per se cannot 
mediate human neutrophil responses to these agonists. 
Consequently, there may exist other mediator(s) that act in 
concert with £ca^+Ji elevation to promote neutrophil activation.
8. From the cumulated ionomycin concentration-response curves the 
^Ca^^ji thresholds for the various indices of heutrophil 
activation were estimated to be approximately 600nM for 
aggregation, 600nM for NAG release, 500nM for lysozyme release, 
800nM for [^p]-PtdA formation and 200nM for LTB4 biosynthesis.
9* Preincubation of cells with the phorbol ester, PMA, inhibited 
MLP-, PAF- and LTB^induced elevation of [ca^+J i and MLP- 
and PAF-induced [^p]-PtdA foimation. These results indicate 
that protein kinase C activation may subserve a bidirectional 
role in regulating cellular responsiveness.
10. Pertussis toxin-attenuated MLP-, PAF- and LTB4-induced 
aggregation, enzyme release, changes in [ca^+Ji and also 
inhibited MLP- and PAF-induced [^p]-PtdA foimation. The 
toxin, however, did not inhibit neutrophil activation elicited 
by the calcium ionophore or by the phorbol ester. These 
observations suggest that a pertussis sensitive process, 
presumably a guanine nucleotide regulatory binding protein 
(G protein) is involved in receptor mediated activation of 
human neutrophils.
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. The selective 5-lipoxygenase inhibitor, Revlon 5901» which 
attenuates LTB4 biosynthesis did not significantly inhibit 
agonist induced aggregation, NAG release and lysozyme release. 
The PAF receptor antagonist, kadsurenone, inhibited aggregation 
and degranulation, induced by the ether lipid but failed to 
inhibit the same neutrophil responses induced by other stimuli. 
Therefore, the release of LTB4 and PAF is unlikely to contribute 
to the activation of isolated neutrophils induced by other 
agonists.
This investigation has addressed a number pf aspects and 
questions in relation to the control of neutrophil activation 
induced by a number of stimulatory agonists, especially with 
the arachidonic acid metabolite, LTB4 and the ether lipid,
PAF. A detailed understanding of the mechanisms of action 
and interaction of such lipid mediators of neutrophil 
responsiveness may facilitate the development of therapeutic 
agents to specifically regulate or modulate neutrophil 
reactivity, thought to be important in various inflammatory 
conditions.
INTRODUCTION
2CHAPTER 1: THE NEUTROPHIL AND ITS ROLE IN INFLAMMATORY PROCESSES.
1. GENERAL INTRODUCTION.
The neutrophilic polymorphonuclear leucocyte (neutrophil) is the 
predominant leucocyte in human blood (approximately two-thirds of the 
total white cell population) and the first cell to appear at the site 
of acute inflammation. The main function of the neutrophil in the 
body is cellular defence against invading bacteria which it engulfs, 
digests and usually completely destroys. However, it is also 
suspected to have a function in general tissue repair and maintenance 
(Wilkinson & Lackie. 1979)- Although the neutrophil'has a unique 
structure and an impressive armamentarium of responses for bacterio­
static and bacteriocidal purposes, other leucocytes may have a 
similar or related array of responses. With this proviso and the 
fact that the main subject of this thesis is about human neutrophils, 
it is necessary to distinguish it from other leucocytes which will be 
referred to, for comparative purposes, on occasion. The term 
granulocytes is used collectively for the leucocytes of the myeloid 
series such as polymorphonuclear leucocytes comprising three cell 
types with differing staining properties with Romanowsky stains; the 
neutrophils have cytoplasmic granules that have a low affinity for 
both acidic and basic dyes, those of the eosinophil stain red or 
orange and the basophilic granules stain blue-black with Wright*s 
stain. The mononuclear phagocyte, also of the myeloid series, is 
the term used to describe the monocyte which circulates in the blood 
differentiating into the macrophage once it enters the tissues. The 
lymphocyte, a white blood cell of the lymphoid series and most common 
mononuclear cell, is involved in immunoglobulin generation (B-cells) 
or cell mediated immunity (T-cells).
32. NEUTROPHIL MORPHOLOGY.
Mature human neutrophils are easily identified from other 
circulating cells using Wright stained blood smears visualised under 
a light microscope. They are normally spherical and range in size 
from 12-15jum in diameter. The neutrophil has a characteristic multi- 
lobed (usually between 2-5 lobes) deep purple-staining nucleus. The 
lobes are rich in heterochromatin and are surrounded by a relatively 
wide perinuclear cistema, however, the functional significance of this 
nuclear segmentation is unclear. The pinkish cytoplasm is filled with 
small violet granules and with relatively few other cytoplasmic 
organelles.
Using electron microscopy and by cytochemical staining for 
myeloperoxidase (Graham & Kamovsky, 1966) two types of granules can 
be distinguished in human neutrophils. The azurophil (or primary) 
granules are larger (0*5um)» spherical or oval shaped and appear dark 
peroxidase positive whereas the specific (or secondary) granules, 
although more numerous, are smaller (0.2um), round or dumb-bell 
shaped and stain peroxidase negative.
The subcellular structures, with the notable exception of the 
granules, are fairly scarce within the neutrophil. The few (20-50 
per cell) mitochondria are tubular shaped, usually over lum long, 
between 100-150nm in diameter and are seen as round or oval cross- 
sections. The endoplasmic reticulum, both rough and smooth, is sparse 
and the Golgi-apparatus is small and presumably quiescent. Actin 
filaments constitute the major structural elements in the cell and 
comprise 10% of the total neutrophil protein. Immunological 
techniques have shown the presence of myosin distributed throughout 
the cytoplasm. (See figure 1).
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Figure 1.
The mature human polymorphonuclear neutrophil.
Several lobes of the nucleus (N) and numerous azurophil and 
specific granules, as well as glycogen granules, are scattered 
throughout the cytoplasm. A small golgi complex, a centriole, 
a fat globule, some rough endoplasmic reticulum (REM) and a few 
mitochondria are also visible. (JM x 27,500)
55. FOBMATION AND LIFE HISTORY OF THE NEUTROPHIL.
The neutrophil spends its life in three distinct phases; the 
bone marrow, the blood and within the tissues. Collectively, the 
bone marrow is the largest organ in the body comprising about 4*5% 
of total body weight where approximately 75% of all the nucleated 
cells are committed to the production of leucocytes. The marrow 
phase commences with the proliferation of committed stem cells, 
comprising of about 5 different mitotic stages and lasting up to 
10 days with mature cells being released 1-2 days later (Cronkite 
& Vincent, 1969; Athens, 1970). The bone marrow being a massive 
store of mature neutrophils (Dancey et al., 1976) not only maintains 
the physiological concentrations but can release elevated levels 
of neutrophils (neutrophilia) whenever the need arises, e.g. during 
inflammation or bacterial invasion.
The earliest stage of differentiation begins with pluripotential 
stem cells producing the first stage of the maturing neutrophil; 
the myeloblast. This cell is not capable of self-renewal and 
contains a large nucleus with dispersed chromatin exhibiting two to 
five nucleoli. The comparatively thin rim of cytoplasm contains 
the Golgi-apparatus, the endoplasmic reticulum, free ribosomes and 
a high number of mitochondria. The next cell in the maturation 
process is the promyelocyte being the largest of the series and 
responsible for the production of the azurophil granules. This 
cell contains a large nucleus, abundant rough endoplasmic reticulum, 
a strongly developed Golgi-apparatus and numerous mitochondria.
The azurophil granules are foimed and packaged in a similar manner 
to the formation of storage granules in other secretory cells 
(Meldolesi et al., 1978)*
M a tu re  - 
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Figure 2.
Diagrammatic representation of the stages of maturation of the 
human neutrophil.
The myelocyte, which is formed directly from the promyelocyte, 
is much smaller and responsible for the formation of the specific 
granules; no azurophil granules are formed in this cell. The next 
stage results in the development of the metamyelocyte and band forms 
which are smaller, nonproliferating and nonsecretory cells, which 
ultimately develop into the mature neutrophil. (Bainton , 1980 ; 
Baggiolini , 1980) (figure 2).
Neutrophils have a short sojourn in blood, hence the number of 
cells in circulating peripheral blood is relatively low. There are
Q
approximately 10 neutrophils/l circulating in the blood of the normal 
adult. Neutrophils circulate, on average, for only 10 hours, whereas 
platelets circulate for 10 days and the erythrocytes for 120 days.
The neutrophils then leave the blood vessels and enter the tissues 
where the cell's duration in this environment is uncertain but may 
be up to two days.
4. NEUTROPHILS IN VIVO.
Pathophysiological Role.
The main physiological function of the highly specialised 
neutrophil is to defend the body from invading organisms and other 
noxious agents. The body's natural reaction to an external 
destructive influence, e.g. trauma due to a cut, b u m  or bacterial 
infection, is to undergo an immediate response known as inflammation. 
The cardinal signs of the inflammatory response, i.e. heat, redness, 
swelling, pain and loss of function; and the relationship between 
leucocytes and inflammation have been known for de.CtxA^g . However, 
leucocytes have also been implicated in the more prolonged chronic 
inflammatory response (Metchnikoff, 1887; Weissmann, 1982). The 
morphological changes associated with these inflammatory symptoms 
are local vasodilation, an increased permeability to body fluid 
containing a high protein content, the accumulation of neutrophils by
8chemotaxis and diapedesis and damage or necrosis of tissue. An 
inflammatory response can be acute as in septic arthritis or gout, 
sub-acute or chronic as in different forms of rheumatic disease such 
as the progressive systemic sclerosis or rheumatoid arthritis. It 
is still unclear precisely what and how many factors affect, mediate 
or modulate both acute and chronic inflammatory reactions, but it is 
certain that neutrophils play a central and pivotal role in the 
physiological and pathological manifestions of inflammation. The 
neutrophil, once recruited to the site of injury, undergoes various 
responses to remove the offending material by phagocytosis, 
degranulation and superoxide formation (discussed in the following 
sections). Over-production of lytic enzymes and reactive oxygen 
radicals can not only affect foreign matter but can destroy host 
tissue.
There have been numerous in vivo models used to show the involve­
ment of polymorphonuclear leucocytes in various inflammatory conditions 
and to demonstrate their important role in the mediation of immuno- 
logically induced tissue injury. The first lesion shown to be 
dependent on neutrophils was the Arthus reaction (Humphrey, 1955; 
Williams et al., 1986). The specific depletion of neutrophils by 
either heterologous antineutrophil antisera or nitrogen mustard could 
attenuate or abort the Arthus reaction in a number of species.
Although there was the presence of antigen, antibody and complement 
components in the vessels of antiserum-treated animals, no microscopic 
evidence of vascular injury could be detected (Parish, 1969; Cochrane 
& Janoff, 1974; Crawford et al., 1985; Fletcher et al., 1986).
Other experimental models showing that immunological injury and 
tissue damage are dependent on neutrophils include the proteinuria
9associated with acute nephrotoxic vasculitis in rats and rabbits 
(Cochrane et al., 1965)» necrotizing arteritis of serum sickness in 
rabbits (Kniker & Cochrane, 1965)> the inflammation occurring during 
reverse passive Arthus (DeShazo et al., 1972; Williams et al., 1986) 
and pulmonary inflammation in monkeys (Revak et al., 1985) to name 
only a few. A great deal of evidence, derived from in vitro 
experiments examining the release of degradative substances, have 
implied that neutrophil-mediated tissue damage during inflammatory 
reactions involves numerous substances including lysosomal enzymes 
and toxic oxygen metabolites (Johnson & Ward, 1981; Till et al., 
1982; Klebenoff and Clark, 1978).
5. NEUTROPHIL REACTIVITY.
Neutrophils when exposed to a plethora of particulate and 
soluble stimuli, both in vivo or in vitro, will become activated and 
will evoke a series of cellular reactions. They undergo chemo- 
kinesis and chemotaxis, become adhesive and phagocytose appropriate 
material, release many destructive enzymes and produce reactive 
oxygen species. Also foimed are numerous lipid products including 
platelet-activating factor (PAR) and leukotrieneE^LTB^) which are 
derived from membrane phospholipids possibly via activation of 
phospholipase A2« These newly-formed lipids have the potential to 
act as potent independent activators of neutrophils or as endogenous 
amplifiers of neutrophil reactivity.
5.1 Chemokinesis and Chemotaxis.
Polymorphonuclear leucocytes have to actively leave the 
microcirculation and enter the tissues in order to perform their 
main physiological function of destroying invading bacteria. In 
the presence of an appropriate stimulus, neutrophils flowing in the
bloodstream will clump together, stick to the endothelial wall, crawl 
between the endothelial cells, progress through the interstitial matrix 
and eventually reach the site of injury. Neutrophils are among the 
most motile mammalian cells and are capable of migrating in the 
direction of a chemical gradient. This process is known as chemotaxis 
This phenomenon must be distinguished from chemokinesis in which cells 
move with more kinetic energy but in a random manner (Zigmond, 1978). 
Many factors, which vary in size and chemical composition, have been 
shown to be chemotactic for neutrophils. These include a fragment of 
the fifth component of complement (C5a) and C5a-des-Arg (Shin et al.,
1968), the bacterial derived tripeptide, M L P  (Schiffmann et al., 1975) 
the arachidonate metabolite, LTB4, (Palmer et al., 1980) and numerous 
denatured proteins: all probably acting via membrane receptors.
Neutrophil locomotion can be investigated either by measuring 
changes in the distribution of a population of cells or by micro­
scopically observing the motion of individual cells either directly or 
by use of time-lapse cinematography. Measuring the migration of a 
cell population can be achieved by use of an agarose gel matrix to 
allow the neutrophils to move between an underlying petri-dish and the 
gel; the movements are then analysed visually (Nelson et al., 1978). 
However, the most commonly used technique for measuring population 
movements is the Boyden chamber method. (Boyden, 1962). In this 
system neutrophils are added to an upper compartment auid a potential 
chemoattractant is added to the lower section separated by a Millipore 
filter with O.65 to 5*1111 pores (too small to allow passive diffusion of 
cells). Chemotaxis can be quantified microscopically by (a) measuring 
the distance that the cells have moved or (b) counting the number of
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cells that have migrated through the filter. Microscopic 
cinematography has allowed the detailed analysis of neutrophils 
in locomotion not only to observe morphological changes but also to 
quantify parameters such as the rate of locomotion, the orientation 
of movement, the frequency and magnitude of turns and to assess 
variations among cells within a population or in a particular cell 
at different times (Zigmond , 1974)* In vivo models of chemotaxis 
have also been reported; for example by making a skin window (a small 
superficial skin lesion) and removing and counting the migrated cells. 
This technique does not distinguish between chemotaxis and chemokinesis, 
hence the information received is difficult to interpret.
Unstimulated neutrophils are usually rounded with' none or very 
few extended pseudopodia or lamellipodia (a thin extrusion of granule 
free cytoplasm) (zigmond & Hirsch, 1973)* A neutrophil when set in 
motion by a given stimulus has a polarized morphology with a 
characteristic extended pseudopodium at the front; a midsection 
containing the nucleus and most of the cytoplasmic granules and 
mitochondria; and a knoblike tail (see results section for micro­
graphs). These techniques have been exploited to show that leucocyte 
motility is influenced by the pH (Bryant et al., 1966) and temperature 
(Nahas et al., 1971). Chemotaxis requires glycolytic energy 
(Carruthers, 1967) but is relatively insensitive to variations in 
the ionic composition of the external milieu; i.e. when cells are 
suspended in medium in the absence of potassium or sodium, although 
there is a notable decrease in locomotion in the absence of calcium 
(Gallin & Rosenthal, 1974; Showell & Becker, 1976; Wilkinson, 1975) - 
Locomotion is inhibited by greater than 10% increases in the osmotic 
strength of the medium whereas a reduction of about 50% oJT the normal 
osmotic levels does not significantly attenuate chemotaxis (Lotz &
Harris , 1956).
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The precise molecular mechanism of chemotaxis is less well 
understood but it has been suggested that micro tubules, actin and 
myosin are probably involved in the overall locomotory process.
(For reviews see Zigmond, 1978; Wilkinson, 1982; Lackie, 1986).
5.2 Adhesion and Aggregation.
In order to function efficiently, neutrophils have a remarkable 
capacity to be selectively adhesive within their life cycle. It is 
presumed that the neutrophil is relatively adherent during its rather 
long developmental phase in the bone marrow. Once the cell has 
entered the blood it foims transient loose adhesions to the capillary 
walls, however, when activated by an appropriate stim'ulus, the cells 
will stop flowing, accumulate and stick to the endothelial wall, 
eventually reaching the site of insult within the tissues. The 
mechanisms that control and produce this calcium and magnesium 
dependent (Allison & Lancaster, 1964) adhesiveness are poorly 
understood.
Adhesion can be examined by a variety of techniques including 
microscopic observation of the adhered neutrophil either by use of 
the scanning electron microscope or by cross-sectional analysis.
By far the most widely used techniques for quantifying neutrophil 
adhesion is by particle-counting, using Coulter counters, or by 
exploiting an in vitro assay similar to the one used for measurement 
of platelet aggregation. Suspensions of neutrophils, in an 
appropriate medium, and upon exposure to an agonist, become sticky 
and form cell-cell aggregates, which can be monitored using a standard 
platelet aggregometer. This technique relies on the fact that the 
extent of light transmission through a suspension of neutrophils will 
be less than through several large clumps of neutrophil aggregates.
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Consequently, aggregation can be monitored as increments in light 
transmission. Although increased neutrophi1-neutrophil aggregation 
may be a rather artificial in vitro index of neutrophil reactivity, 
it may have a parallel in augmented neutrophi1-endothelium 
adhesiveness in vivo and may provide useful information concerning 
the importance of different agonists in neutrophil responsiveness.
5.3 Phagocytosis.
Phagocytosis is the process whereby microorganisms, immune 
complexes and other small particulate matter are ingested by the 
neutrophil. Once the neutrophil has attached itself to the organism, 
pseudopodia are extended and wrapped around .each side of the 
bacterium so that it is interiorized into a pouch (or phagosome) 
of cell membrane. As viewed by transmission electron microscopy 
the cytoplasmic granules seem to fuse with the phagosome and 
releases its repertoire of lytic enzymes which usually destroy the 
invading bacterium. Phagocytosis is an energy requiring process, 
which is mostly derived from glycolysis and, as shown by immuno- 
cytochemical methods, the cytoplasmic contents of the protrusions 
that wrap around the particle are rich in actin and actin-binding 
protein (Stendahl et al., 1980). Nonspecific factors, such as pH, 
ionic strength, calcium concentration, osmotic pressure and 
temperature have profound effects on neutrophil phagocytosis (Murphy, 
1976)• The ability and rate at which neutrophils phagocytose a 
particle partly depends upon the surface characteristics of the 
particle. Although the optimal surface characteristics have not 
been fully investigated, surface charge and hydrophobicity 
profoundly influence digestion. Facilitation of phagocytosis is 
achieved by coating the particles with humoral factors known as
14
opsonins which effectively render the particle ‘primed' for ingestion. 
There are two classes of opsonins, the heat-labile and the heat-stable 
factors. The C3b fragment of serum complement is characteristically 
an example of a heat-labile opsonin. Immunoglobulins particularly 
IgG comprise the heat-stable opsonins and must be intact to promote 
phagocytosis. The IgG antibody is composed of an Fab region which 
binds to specific antigenic sites on the particle and the Fc portion 
binds to specific receptor sites on the neutrophil membrane.
5.4 Degranulation.
Once the neutrophil has engulfed the invading organism the 
storage granules fuse with the membrane of thfe phagosome and release 
their contents. The microbicidal factors and lytic enzymes within 
the phagolysosome (as it is now called) can destroy and digest the 
organism. Although granule contents are usually secreted into the 
phagocytic vacuole (covert secretion) there are certain conditions 
where the enzymes are secreted into the external milieu (overt 
secretion); this process has been linked with various chronic 
inflammatory conditions e.g. rheumatoid arthritis.
When cells are in suspension and activated by an agonist it is 
virtually impossible to detect any enzyme release, however overt 
secretion is promoted by the pharmacological tool, cytochalasin B.
This compound has profound and intriguing biological effects and is 
isolated from fungal moulds such as Helmintosporium dematodium. At 
low concentrations it inhibits hexose and nucleoside transport 
whereas at higher concentrations (1-1QuM) its main effect is on the 
motor apparatus of the cell, inhibiting phagocytosis and chemotaxis 
and enhancing overt secretion. It is widely believed that
cytochalasin B exerts its effects by disruption of microfilaments 
resulting in disorganised contraction instead of controlled local 
effects. Since effects of cytochalasin B are vast and numerous and 
the precise mechanism of action is unknown, caution must be taken when 
using this compound (Tanenbaum, 1978)•
The contents of the storage organelles have been extensively 
examined by differential centrifugation and subcellular fractionation 
followed by biochemical analyses. The azurophil granules contain a 
remarkable armamentarium of lytic enzymes and other constituents with 
antibacterial properties characteristic of lysozomes. They contain a 
variety of acid hydrolases (e.g. B N-acetylglucoasaminidase (NAG) and 
B glucuronidase), neutral proteinases (elastase, cathepsin G and 
proteinase 3) and two microbicidal enzymes (myeloperoxidase & lysozyme). 
The function of the specific granules is more difficult to pin-point. 
However, their contents have been investigated and shown to contain 
lysozyme, collagenase, lactoferrin and various vitamin B12-binding 
proteins. Zonal differential sedimentation experiments performed with 
human neutrophils have shown the existence of a third population of 
smaller subcellular storage particles (C particles and secretory 
vesicles) (Baggiolini et al., 1978). The composition of these small 
organelles are possibly heterogeneous containing some acid hydrolases 
and neutral proteinases which also are found in the azurophil granules. 
Gelatinase, a metallo-proteinase, which was discovered in neutrophils 
by Sopata & Dancewicz (1974)» has been localized exclusively in these 
small structures (Murphy et al., 1980; Dewald et al., 1982).
Therefore, gelatinase has proven to be a useful specific marker for 
these tiny ’granules" . Table 1 shows an up-to-date resume"' of the 
contents of the three storage organelles which presumably is not 
exhaustive (Baggiolini & Dewald, 1985).
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Lysozyme (muramidase).
Since the initial observation of the bacteriolytic activity of 
lysozyme by Fleming in 1922, much progress has been made in under­
standing this powerful lytic enzyme. Lysozyme cleaves the ^-1-4 
bond between N-acetylglucosamine and N-acetylmuramic acid residues of 
murein in bacterial cell walls. Lysozyme is capable of destroying 
some gram-positive organisms that do not have a peptidoglycan 
covering. One such organism is the bacterium Micrococcus lysodeikticus, 
the rapid lysis of which is used as a sensitive assay for lysozyme.
Lactoferrin and Vitamin Bi?-binding proteins.
The iron-binding protein, lactoferrin, found in neutrophilic 
specific granules (Masson et al., 1969; Baggiolini et al., 1970) may 
constitute 10% of the total cell protein but there is no evidence to 
suggest that lactoferrin has any bacteriocidal properties. Due to 
its iron-binding ability, it may retard or block bacterial growth and 
may chelate iron liberated from haemoglobin degradation at inflammatory 
sites. The role of the vitamin B-j2-binding proteins, also present in 
the specific granules, is unknown. However, they may have a 
bacteriostatic action by preventing folic acid production; which 
requires vitamin B12 is necessary for bacterial growth.
Acid Hydrolases.
Comprises the major class of granule enzymes (see table 1) which 
are optimally active in acid conditions (usually below pH 5) and are 
most likely to be secreted into the phagocytic vacuole hence involved 
in intracellular degradation. The two most widely used azurophil 
granule markers are ^-N-acetyl-glucosaminidase and ^-glucuronidase 
which are detected by simple fluorimetric techniques.
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Neutral Proteinases.
There are five main neutral proteinases found in human neutrophils; 
elastase, collagenase, gelatinase, cathepsin G and proteinase 3 which 
are maximally active at physiological pH and probably play a major role 
in extracellular matrix digestion. Interestingly, cathepsin G has 
been identified as the active ingredient of 'neutrophilin', the 
cationic protein released by neutrophils that activates human platelets 
( Selak et al., 1986).
Myeloperoxidase and superoxide generation.
Although phagocytosis is unaffected by anaerobiosis, bacteriocidal 
activity requires oxygen to function optimally hnd neutrophil activation 
is associated with a striking burst of oxidative metabolism. The 
mechanisms involved are not fully understood but it is thought that 
the generation of the extremely reactive and unstable intermediates, 
superoxide and hydrogen peroxide, are involved and that the azurophil 
enzyme, myeloperoxidase, plays an important role.
Hydrogen peroxide is produced from a two step synthesis. The 
superoxide free radical is formed from molecular oxygen and NADPH 
catalysed by the membrane bound enzyme NADPH oxidase (Baboir et al., 
1973).
NADPH + 202 NADPH oxidase_________ v NADP+ + 2-0_2 + H+
Two molecules of the superoxide anion in the presence of protons 
combine either spontaneously or catalysed by the enzyme,superoxide 
dismutase, to form hydrogen peroxide. (McCord & Pridovich, 1969)*
2*0”2 + 2H+ superoxide dismutase  O2 + H2O2
The hydrogen peroxide serves as substrate, in the presence of the
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chloride ion, for myeloperoxidase,
H2O2 + Cl~ ______myeloperoxidase_________ ^ H2O + 0C1”
The resultant hypochlorous acid is not only harmful to bacteria 
but may also produce OH radicals, halogen atoms and singlet oxygen.
These reactive species are extremely important in the destruction 
of invading organisms and are indispensable constituents of the host 
defence system. The above scheme for generating free radicals 
represents only part of the body's capacity for producing these 
toxic molecules; indeed, they are produced by various enzymatic 
lipid peroxidation pathways (e.g. during the formation of prosta­
glandins and leukotrienes). Although the body has a variety of 
efficient measures for removing these reactive species (e.g. 
superoxide dismutase and peroxide-metabolising enzymes; catalase 
and glutathione peroxidase) they are thought to contribute towards 
the pathogenesis of certain chronic inflammatory conditions since 
they not only kill bacteria but can also damage cells belonging to 
the host.
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CHAPTER 2t NEUTROPHIL AGONISTS AND THEIR RECEPTORS.
Neutrophils can be modulated by a variety of different 
compounds which act to promote (stimulatory agents) or retard 
(inhibitory agents) cellular reactivity. However, this section 
is mainly concerned with the role of stimulatory agonists. The 
majority of these agonists exert their effects by interacting with 
specific receptor molecules located on the cell surface membrane. 
Although a number of receptors have been identified and characterised, 
the signal transduction mechanisms that link receptor occupancy to 
neutrophil activation remain largely unknown. This report will 
concentrate primarily on the best characterised agonists and 
receptors, with particular emphasis to PAP and LTB4 , rather than 
presenting a comprehensive list of all neutrophil stimuli.
1. C5a and C5a-des-arg.
The first chemotactic agent to be identified and characterised 
was the cleavage fragment of the complement component of C5 called 
C5a (Shin et al., 1968; Snydexman et al., 1969; Ward & Newman,
1969)* This peptide, as well as being a potent activator of human 
neutrophils, also exhibits anaphalatoxin activity, contracts smooth 
muscle and causes mast cells to degranulate (Jensen et al., 1969; 
Snydexman & Pike, 1984)* C5a has been located in the synovial fluid 
of patients suffering from conditions such as inflammatory arthritis 
(Ward & Zvaifler, 1971) and in the exudates of experimentally-induced 
inflammation (Snydexman et al., 1971)* Human C5a is a glycopoly- 
peptide that contains a complex carbohydrate moiety and a polypeptide 
region of 74 amino acid residues (Fernandez & Hugli, 1976). However,
once formed in human serum, C5a is rapidly metabolised to a C5a-des-arg 
by an endogenous carboypeptidase B enzyme. Using the Boyden chamber 
technique, Fernandez et al., (1978) showed that pure C5a was a potent 
neutrophil chemotactic agent over the concentration range of 0.04 to 
1.7 x 10“®M. In contrast C5a-des-arg, when applied alone, was devoid 
of chemotactic activity. However, C5a-des-arg, if combined with non­
activated normal human serum, the chemotactic activity was restored 
although it was still 10 fold less active than C5a. This serum 
requirement was dependent on the technique employed for chemotactic 
measurement because Chenoweth et al., (1979) > using the agarose 
system, showed that the EC^q for C5a in human neutrophils was between
1-3 x 10-9M and the EC50 ^or C5a-des-arg, in the absence of serum, 
was 6 x 10“% .  Using [^^ij-labelled C5a, Chenoweth & Hugli,
(1978) first demonstrated the presence of specific receptors for 
this ligand on human neutrophils. The dissociation constant (Kd) 
for C5a binding occurred at 3-7nM at 0°C and the number of receptors 
per cell was estimated to be between 100,000-300,000. Subsequently, 
it has been reported by Huey & Hugli, (1985)» using human neutrophils, 
that the C5a receptor complex is actively internalised. With the 
development of better photoaffinity, cross-linking and electro­
phoretic techniques, it is believed that the C5a receptor molecule 
is an oligoprotein with an M.wt. between 40-48K (Huey & Hugli, 1985; 
Johnson & Chenoweth, 1985; Rollins & Springer, 1985)*
2. FOI^L-MEPHIONYLLEUCYLPHENYLAIANINE (EMLP)
Many small synthetic peptides such as N-formylmethionyl- 
leucylphenylalanine (TMLP) are highly potent activators not only of 
neutrophils but also of monocytes, macrophages, basophils and 
eosinophils. There is considerable evidence to show that these 
peptides exert their biological effects by acting on specific
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receptor sites. Many microorganisms, for example; E. Coll, 
initiate protein synthesis with N-foraylmethionine residues which 
eventually may be cleaved from the protein chain (Marasco et al.,
1984). Since eukaryotic cells do not use N-fonnyl peptides in 
protein synthesis, except in the mitochondria, these peptides 
could represent a distinct prokaryotic metabolite that would allow 
these leucocytes to differentiate between foreign microorganisms and 
the host's own cells.
The interaction of N-formylmethionylpeptides with their 
corresponding receptor is probably the best studied agonist-receptor 
interaction in leucocytes. The biochemical nature of the receptor 
was initially determined by covalently linking a radiolabelled 
hexapeptide to the receptor of neutrophil plasma membranes (Niedel 
et al., 1980). The receptor was identified as a polypeptide that 
migrated as a wide band on SDS-polyacrylamide gel electrophoresis 
with an apparent M.wt. between 55 and 70K. It was then shown by 
Schmitt et al., (1983) that the broad band was comprised of two 
distinct entities with a M.wt. of 50K and 60K. The receptor is 
thought to exist as a glycoprotein complex with two N-linked 
oligosaccharide chains bound to a 33 -35K fragment that retains the 
N-formyl peptide binding site and consists of two.distinct proteins 
(Dolmatch & Niedel, 1983; Painter et al., 1982; Malech et al.,
1985)* The protein fragment of the receptor may span the membrane 
phospholipid bilayer and the oligosaccharide chains are probably 
located on the external surface of the plasma membrane. It is 
estimated that there are between 50»000-80,000 receptor sites on 
the human neutrophil surface (Niedel et al., 1979; Sklar et al., 
1984; Zigmond et al., 1982) and approximately an equal number 
expressed intracellularly (Fletcher & Gallin 1983; Jesaitis et 
al., 1984). It is believed that the number of surface receptors for
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IWLP may increase during neutrophil activation and that this raised 
number of receptors may arise from mobilisation of the intracellular 
pool of receptors, synthesis of new receptors or by recycling of 
agonist-mediated internalised receptors (Gallin <fc Seligmann, 1984; 
Omann et ail*, 1987a). The N-formyl peptide receptor in human 
neutrophils was shown by Lane & Snydexman, (1984) to exist in two 
affinity states. They measured a Kd of 0.53 ♦ 0.01nM for the
membrane-bound receptor. An average of 28% of the total receptor 
number was of the high affinity state. It has been shown that 
guanine nucleotides could modulate the conversion of high affinity 
receptors to the low affinity state without affecting the total 
receptpr numbers or the overall receptor affinities (Koo et al., 
1983)* These observations offer some indirect evidence to implicate 
the involvement of guanine nucleotide binding regulatory proteins (G 
proteins) in stimulus-response coupling mechanisms in the neutrophil 
(see Chapter 3)»
3. LEUKOTRIENE B4 (LTB4)
Leukotriene B4 (5-D-(s) ,12-D-(R)-dihydroxy-6,8,10,14- 
eicosatetraenoic acid; 5»12-diHETE: LTB4 ; (figure 3) is the major
product of arachidonic acid metabolism in human neutrophils and is 
one of the most potent chemoattractant agents yet discovered.
Borgeat & Samuelsson, (1979a; b; c) showed that isolated rabbit and 
human neutrophils when stimulated with the calcium ionophore, A23187, 
in the presence of arachidonic acid, were capable of generating 
several dihydroxy fatty acids. Ry using reverse-phase HPLC and 
structural analysis techniques, they revealed that the predominant 
product formed was the 5*12-diHETE with 4 double bonds at carbons 
6,8,10 and 14* This compound was termed LTB4 (Samuelsson et al.,
Figure 3.
Chemical structure of leukotriene B4 (LTB4).
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1979; Samuelsson & Hammarstrom, 1980),
It was subsequently shown that LTB4 is an extremely potent 
neutrophil agonist eliciting a whole series of neutrophil responses 
including chemokinesis, chemotaxis, aggregation and degranulation 
(Ford-Hutchinson et al., 1980; Bray, 1983). Although LTB4 is 
probably the major arachidonic acid metabolite produced in the human 
neutrophil, numerous other products can be derived from arachidonic 
acid. The biosynthetic pathway for the formation and metabolism 
of LTB4 is shown in figure 4*
Arachidonic acid is liberated from membrane phospholipids 
principally via activation of the calcium-dependent phospholipase 
A2 (PI1A2) (o*Flaherty1987 ). Prevention of, arachidonic
acid release or inhibition of arachidonic acid metabolism has 
considerable therapeutic potential since its many biologically 
active products exhibit a plethora of physiological responses which 
have pathological consequences. Although no direct inhibitors of 
PLA2 have yet reached clinical evaluation, some putative inhibitors 
such as p-Bromophenacyl bromide (HPB) and mepacrine have proved 
useful as research tools in various in vitro investigations. It is 
well established that steroids such as hydrocortisone and 
dexamethasone inhibit arachidonic acid release. The mechanism of 
action of these steriodal anti-inflammatory agents is believed to be 
the result of the synthesis of lipocortin, a peptide that inhibits 
PLA2 activity (Flower & Blackwell, 1979). Since neutrophils and 
platelets only have a limited capacity to synthesise proteins, it is 
hardly surprising that these steroids have only a minor effect on 
these cells. Whether all the effects of the steroidal anti­
inflammatory agents can be attributed to lipocortin inhibition of 
PLA2 still remains to be established.
Arachidonic acid can be converted via cycloxygenase and other
Prostaglandins
Thromboxane
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Figure 4»
Arachidonic acid metabolism; demonstrating the biosynthesis and 
deactivation of LTB4.
enzymatic pathways to yield a number of prostaglandins and 
thromboxanes which have extremely powerful and varied biological 
effects (for a review see Johnson et al., 1983)* In neutrophils, 
however, arachidonic acid is predominantly acted upon by the calcium- 
dependent and cytosolic enzyme 5-Iipoxygenase to yield a 5-D-(s)- 
hydroperoxy-6,8,11,14 eicosatetraenoic (5-HPETE) intermediate.
5-HPETE can be further metabolised to the corresponding 5-hydroxy 
acid (5-HETE), which has only modest chemotactic activity in 
comparison to LTB^. Alternatively, 5-HPETE cam be converted by a 
dehydrase enzyme to the highly unstable allylic 5»6-epoxide 
derivative known as leukotriene A4 (LTA4). Although there exists 
a number of different types of lipoxygenases in a wide variety of 
cell systems, including human neutrophils, .the precise function of 
these enzymes and their corresponding products are largely unknown. 
For example, the predominant lipoxygenase in the platelet is the 
12-lipoxygenase (Turner et al., 1975? Nugteren, 1975) which 
catalyses the formation of 12-HPETE/12-HETE (Hamberg & Samuelsson, 
1974; Johnson et al., 1983)*
LTA4 can be non-enzymatically transformed to 6-trans-LTB4,
12-epi-6-trans-LTB4 and 5,6-DiHETEs or can be enzymatically 
hydrolysed to the biologically active LTB4. In human neutrophils 
LTB4 is metabolised by w-oxidation to 2O-OH-LTB4 followed by a 
further transformation to the decarboxylic acid 2O-COOH-LTB4 (Hansson 
et al., 1981).
Other products of LTA4 metabolism are the peptidyl-leukotrienes, 
often referred to as the slow-reacting substances of anaphylaxis 
(SRS-a). Peptidyl-leukotrienes (leukotriene C4 (LTC4), Ifiutotriene 
D4 (LTD4)* I©uk°'fcrien© E4 (LTE4) and leukotriene F4 (LTF4) ) exert a 
number of biological effects such as bronchoconstriction and 
secretion of pulmonary mucus, suggesting a possible role for these
arachidonic acid metabolites in asthma and other inflammatory 
conditions (Piper, 1983* 1984)»
The majority of investigations concerning LTB4 generation have 
been performed using the calcium ionophore, A23187, a potent but 
non-physiological stimulus and such LTB4 biosynthesis has been shown 
to exist in most leucocytic cells. Other more physiological agonists 
such as C5a, fWLP and PAF produce only a fraction of the amount 
generated by the calcium ionophore (Claesson et al., 1981; Salmon 
et al., 1982). LTB4, as well as being a potent activator of neutro­
phils in vitro, also exerts a large number of effects in vivo. Smith 
et al., (1980) demonstrated that administration of LTB4 into the 
peritoneal cavity of guinea pigs stimulates ah accumulation of 
neutrophils and to a lesser extent eosinophils and macrophages, which 
lasts up to five hours after the initial injection. LTB4 also causes 
a profound transient neutropenia and accumulation of neutrophils into 
the dermis and skin chambers of a variety of species (Camp et al.,
1983; Lewis & Austen, 1984; Higgs et al., 1981; Bray, 1983). 
Simultaneously, LTB4 also causes a neutrophil-dependent increase in 
peripheral vascular permeability especially in the presence of a 
vasodilator such as PGE2 (Wedmore & Williams, 1981) • Since LTB4 is 
generated by neutrophils and is a potent stimulatory agonist, this 
lipid may function to amplify neutrophil responses elicited by other 
stimuli both in vivo and in vitro.
Prevention of LTB4 biosynthesis may provide a useful way of 
determining the precise role of LTB4 as an endogenous mediator of 
neutrophil responsiveness. The major problems with studies using 
putative 5-lipoxygenase inhibitors are toxicity and lack of specificity. 
Some investigations using isolated human neutrophils and various 
inhibitors have often produced conflicting and contrasting results
concerning whether products of arachidonic acid metabolism play an 
essential role in cellular activation (Smolen & Weissmann, 1980;
Marone et al., 1983? Smith et al., 1986) or whether agonist-induced 
neutrophil responsiveness is independent of LTB4 synthesis (Palmer 
& Salmon, 1985? Ozaki et al., 1986). With the development of more 
specific 5-lipoxygenase inhibitors, the precise role of LTB4 in 
neutrophil activation may be evaluated.
There is also evidence that products of arachidonic acid may 
act as second messengers in cellular systems (Bevan & Wood, 1987).
It has recently been shown that an eicosanoid, probably 12-HPETE, 
may act as a second messenger at a synapse in the marine mollusc, 
Aplysia califomica. 12-HPETE is thought to be responsible for the 
inhibitory effects of JMEFamide (a neuroactive peptide) on 5HT- 
induced depolarization of Aplysia sensory neurones. (Piomelli et al., 
1987). Whether products of arachidonic acid metabolism in other 
cell types including neutrophils act as second messengers like 
cyclic nucleotides, calcium, inositol phosphates and 1,2-diacylglycerol 
(Chapter 3) remains to be established.
LTB4 is thought to exert its effects by interacting with 
specific HFB4 receptors. O'Flaherty et al., (1981b)provided indirect 
evidence, suggesting that I/FB4 is acting via receptors when they 
demonstrated that neutrophil degranulation elicited by LTB4 was subject 
to homologous desensitisation. Subsequently, specific human 
neutrophil LTB4 receptors were shown independently by Goldman &
Goetzl, (1982) and by Kreisle & Parker, (1983) by quantifying the 
binding of [^hJ-LTB^ Goldman & Goetzl, (1984) showed that human 
neutrophils possess a high affinity receptor with a Kd of 0.39nM and 
4400 sites per cell and a low affinity binding site with a Kd of 60nM 
and 270000 sites per cell. It has been suggested that the high and
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low affinity may be associated with chemotactic and secretagogue 
activity respectively, since higher concentrations are usually 
required for lysosomal enzyme release than for cell locomotion.
Caution must be taken when interpreting LTB^ binding studies because 
LTB4 is rapidly metabolised and other products of arachidonic acid 
metabolism can interact with the same receptor. For example 5-HETE,
6-trans-LTB^ and 12-epi-6-trans-LTB^ can competitively inhibit the 
binding of LTB4. Other compounds at.concentrations which produce a 
chemotactic response such as C5a and FMLP did not interfere with the 
binding of LTB4. There are also marked differences in the radioligand 
binding data between human and rat neutrophils. Rat neutrophils 
exhibited only high affinity binding of LTB4 with a Kd of 4«5nM and 
64OO sites per cell. It was also demonstrated in the same investi­
gation that rat neutrophils did not respond to LTB4 by chemotaxis 
but at high concentration the neutrophils did aggregate (Kreisle et 
al., 1985). These observations indicate that the various effects of 
LTB4 leucocytes may result from interaction with distinct classes 
of receptors.
4. PLATELET-ACTIVATING FACTOR (PAF)
Platelet-activating factor (PAF) also known as PAF-acether or
1-0-alkyl-2-acetyl-sn-glycero-phosphocholine is a collection of ether 
phospholipids derived from membrane phospholipids. The ether lipid 
molecule possesses a long chain 0-alkyl ether residue on the sn-1 
position which may vary in length from (GH2) -j  ^7 and an ester linked 
acetic acid moiety at the sn-2 position. At the sn-3 position, the 
polar head group in all naturally occurring ether lipids is that of an
O-phosphocholine group (Demopoulos et al., 1979? Benveniste et al., 1979) 
(figure 5)• PAF is synthesised by numerous cell types from many 
different species and exerts a wide spectrum of biological responses
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Figure 5*
Chemical structure of platelet-activating factor (PAF).
both in vitro and in vivo (Benveniste & Amoux, 1983)*
Barbaro and Zvaifler, (1966) first reported a leucocyte-dependent 
release of histamine from rabbit platelets but it was not until 1971 
that Siragarian and Osier demonstrated that a soluble intermediate 
was responsible from this reaction. From its biological activity 
this compound was called PAF and shown to be released from rabbit 
basophil sensitised with IgE antibody (Benveniste et al., 1972).
The production of PAF has been shown to exist in many other blood- 
borne cells such as neutrophils, peritoneal macrophages, alveolar 
macrophages, monocytes and platelets. Large amounts of PAF were 
recovered from calcium ionophore stimulated perfused isolated rat 
kidneys in the absence of blood cells (Pirotzky et al., 1980).
Human endothelial cells are probably another source of PAF. A 
recent and interesting observation is that there is a natural 
occurrence of PAF in the protozoan Tetrahymena pyrifoimis. However, 
the significance of its presence in this microorganism is unknown 
(Lekka et al., 1986).
PAF is not stored within the cell but synthesised by the cell 
upon activation. Stimulation of neutrophils by agonists such as 
calcium ionophore, TMLP, C5a» zymosan and LTB^ have been shown to 
generate this ether lipid (Camussi et al., 1981; Betz & Henson,
1980; Mueller et al., 1983). The predominant biosynthetic pathway 
for the production of PAF is thought to be via the combined efforts of 
two enzyme systems; phospholipase A2 and acetyltransferase. It 
is generally agreed that the major precursor of PAF is a resident 
membrane phospholipid called 1-0-alkyl-2-acyl-glycero-phosphocholine 
containing a long chain residue in the sn-2 position (often 
arachidonic acid) (Swendsen et al., 1983)* This precursor molecule 
is thought to be produced by de novo synthesis according to the 
sequence of events outlined in figure 6. Upon stimulation of the
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Figure 6.
The de novo biosynthetic pathway for the formation of
1-alkyl-2-acyl-sn-glycero-3-phosphocholine, the inactive phospholipid 
precursor of platelet-activating factor (PAF).
cell, PLA2 cleaves the pre-existing precursor at the sn-2 position 
to yield lyso-PAP and a free fatty acid. If the free fatty acid 
is arachidonic acid, it can be utilised for eicosanoid (e.g. LTB^) 
production. The lyso-PAP is then acetylated by 1-0-alkyl-2-lyso- 
glycero-phosphocholine acetyltransferase from acetyl-CoA to form 
PAP. Ihis sequence of events is often referred to as the 
deacylation-reacylation pathway. PAP is then rapidly inactivated, 
independently from cell stimulation, by the reverse pathway catalysed 
by acetyl hydrolase and acetyl transferase (figure 7)*
Although I have outlined the major biosynthetic pathway for PAP 
production, one must consider other possible pathways. An alternative 
pathway is by the transfer of a phosphocholine group into the 1-0- 
alkyl-2-acetyl-glycerol catalysed by a specific CDP-cholinephospho- 
transferase. This scheme has been characterised in human neutrophils 
(Alonso et al., 1982), rat platelets (Blank et al.,1984) and in a rat 
spleen preparation (Renooij & Snyder, 1981). The formation and 
availability of the substrate alkylacetylglycerol is not established 
but may be derived from de novo synthesis using dihydroxyacetone and 
fatty alcohol as the starting material. Mueller et al., (1983) using 
rabbit neutrophils showed that this pathway is probably only a minor 
source of PAP and that most is derived via the deacylation-reacylation 
pathway. It is also possible that PAP formation could be initiated 
by activation of phospholipase C which could attack the parent 
phosphoglycerides to yield a 1-0-alky 1-2-acyl glycerol; the long 
chain acyl residue from this molecule could then be replaced by an 
acetyl residue and the choline moiety could be added by the CUP- 
cholinephosphotransferase system.
PAP is one of the most potent activators of platelets and 
neutrophils so far described. PAP-induced neutrophil activation was
AcyltransferasePhosDholipase A.
AcylCoA
Fatty acid
AcetylCoA Acetate
AcetylhydrolaseAcetyl transferase
LYSO-PAF
HO - CH
15-17
R- C - 0 - CH
AtKYl-ACYL-PAF PRECURSOR
15-17
PAF
15-17
Figure 7.
The deacylation-reacylation pathway for platelet-activating factor (PAF). 
PC - phosphorylcholine and R - a long chain hydrocarbon.
first reported by Henson, (1981) who demonstrated that intravenous 
injection of PAF causes a neutropenia with the founation of neutrophil 
aggregates. It has subsequently been shown that this ether lipid, at 
concentrations varying between 0.1-1juM, induces neutrophil aggregation, 
degranulation, chemotaxis and the release of superoxide anions (0'Flaherty 
et al., 1981a; Czametzi & Benveniste, 1981; Pirotzky et al., 1985). 
Intravenous injection of PAF leads to a number of systematic effects, 
which are sometimes species-dependent, including vasoconstriction, a 
particularly powerful bronchoconstriction, hypotension, pulmonary 
hypertension, increased vascular permeability, thrombocytopenia, 
neutropenia and death. Intradermal administration of PAF causes 
oedema and hyperalgesia with accumulation of both neutrophils and 
mononuclear cells (Benveniste & Vargaftig, 1983)* With its wide 
spectrum of biological effects it is hardly surprising that this lipid 
has been implicated in a variety of pathological conditions. There is 
abundant literature indicating that PAF may be causally involved in 
thrombosis, acute inflammation, asthma and systemic anaphylaxis, 
cardiac anaphylaxis, endotoxic shock and in gastrointestinal ulcerations. 
The vast majority of these conditions are thought to be mediated partly 
by platelets or leucocytes but the precise role and participation of 
these cells still remains to be elucidated. PAF, like LTB^, has the 
potential to act as an endogenous mediator or amplifier of neutrophil 
activation elicited by other agonists. Due to the lack of specific 
PAF biosynthesis inhibitors, the exact role of PAF awaits clarification. 
However, with the development of specific PAF antagonists such as 
kadsurenone and BN 52021, sane light may be shone on this matter.
It is widely believed that PAF exerts its repertoire of biological 
effects by interacting with specific PAF receptors located on the 
plasma membrane. The involvement of specific PAF receptors was first 
demonstrated independently by Wykle et al., (1981) and by Heymans et al.,
(1981). They showed that the naturally occurring stereoisomer 
(R-PAF), hut not S-PAF, was effective in stimulating the various 
responses associated with platelets and neutrophils both in vivo and 
in vitro. Radioligand binding analyses have revealed high affinity 
receptors in human neutrophils (Valone & Goetzl, 1983; O'Flaherty et 
al., 1986), human platelets (Valone et al., 1982), rabbit platelets 
(Hwang et al., 1983)> guinea pig smooth muscle (Hwang et al., 1983) 
and human lung membranes (Hwang et al., 1986a).
Valone & Goetzl, (1983) showed that the binding of PAF in human 
neutrophils was maximal within 20-30 mins at 37°C, exhibiting a high 
affinity site (Kd of 0.11nM) with approximately 5*2 x 10^ PAF binding 
sites per cell. A lower affinity binding site was also observed which 
the authors attributed to a non-specific uptake into cellular compart­
ments. O'Flaherty et al., (1986b)demonstrated using human neutrophils 
that PAF binding fits a two receptor model; with Kd values for high 
and low affinity sites of 0.2nM and 500nM respectively. Lambrecht & 
Parnham, (1986) using the specific PAF receptor antagonist, kadsurenone, 
have shown that this agent can discriminate between PAF receptors in 
leucocytes and macrophages. These PAF receptors have provisionally 
been designated PAF-j and PAF2 receptors respectively.
5. OTHERS.
There are numerous other agents that cause the activation of 
human neutrophils that probably produce their effects by interacting 
with specific receptors. For example, crystal-induced chemotactic 
factor, various immune complexes, C3b opsonised and Ig coated particles, 
interleukin 1 and concanavalin A.
Non-physiological activators of human neutrophils such as phorbol
38
esters (e.g. FMA) and calcium ionophores (e.g. A23187 and ionomycin) 
have been used as pharmacological tools to probe the mechanisms 
underlying neutrophil reactivity. These compounds are thought to 
bypass ligand-receptor interactions; the phorbol esters directly 
stimulate protein kinase C and the ionophores cause an increase in 
cytosolic-free calcium ions, I Ca^+Ji (Chapter 3)*
CHAPTER 3. STIMULUS-RESPONSE COUPLING.
1• General Introduction.
Neutrophils, in common with other cells, are able to 
respond to changes in their environment; a process which is 
usually achieved by external chemical stimuli acting upon membrane 
associated specific recognition sites known as "receptors"•
These external stimuli (or agonists) are diverse in nature and 
may be soluble or particulate. Consequently, the receptor types 
are also numerous and equally diverse in their recognition 
capacity. Agonist-receptor combination can stimulate, inhibit 
or modulate cellular activity but the mechanisms linking the 
receptors to the cellular response, a phenomenon often referred to 
as stimulus-response coupling, are less well understood. The 
generalised concept of stimulus-response coupling is depicted 
schematically in Figure 8.
Receptors have been the focus of intense investigation within 
the last few decades and, as a result, some receptors have been 
identified, partially or completely purified, sequenced, cloned 
and classified. Receptors are usually proteins consisting of 
monomeric or oligomeric subunits located on the external surface 
of the plasma membrane or integrated into the phospholipid 
bilayer. The agonists combine with specific ligand binding sites 
in the receptor and information is transmitted through the plasma 
membrane via a particular transduction mechanism. These 
transducers are thought to be a family of heterotrimer proteins 
known as guanine nucleotide binding regulatory proteins or "G
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Schematic representation of the general mechanism of stimulus- 
response coupling*
See text for explanation.
proteins” because they require guanosine triphosphate (GTP) to 
function. The G protein-GTP complex stimulates an effector, 
usually an enzyme, which amplifies the signal by converting pre­
cursor molecules into intracellular second messengers. Second 
messenger molecules convey information by combining with specific 
intracellular target entities or acceptors. These target sites 
are often proteins which undergo a conformational change or 
kinases which catalyse the phosphorylation of other target proteins. 
Collectively these events result in alteration of the rates of 
key biochemical reactions that govern the cellular responses. 
Although numerous agents have been proposed to be second messengers, 
remarkably few agents satisfy the criteria necessary to be 
formally categorised as such. These criteria are:
a) The putative second messenger and the enzymes responsible 
for its formation should be present within the cell.
b) The time-course for the formation of the second messenger 
should be consistent with agonist effect.
c) Addition of the putative second messenger or structural 
analogues should mimic the effect of the agonist 
response.
d) A mechanism for the inactivation of the second messenger 
should be present.
e) An intracellular target entity for the second messenger 
should be identified.
2. Cyclic AMP
Since the discovery of cyclic AMP by Sutherland and Rail
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(1960), and the proposal that this nucleotide may be the intra­
cellular mediator of the effects of glucagon and adrenaline in 
the liver, cyclic AMP has been the subject of much research.
The foimation of intracellular cyclic AMP through stimulation of 
the enzyme, adenylate cyclase, is the second messenger pathway 
currently best understood and thought to play an important role 
in many biological systems ranging from prokaryotes to complex 
eukaryotes. The pathway is schematically represented in Figure 
9* Agonists combine with the specific stimulatory (Rg) or 
inhibitory (Rj) receptors to either cause an increase or decrease 
in cyclic AMP via stimulation or inhibition of adenylate cyclase 
which enzymatically converts ATP to cyclic AMP in the presence of
m  2+ •Mg ions.
Extensive research on the transduction process mediating 
adenylate cyclase activity has shown that two G proteins (Ng and 
Nj) are intimately involved (Ross & Gilman, 1980; Jakobs et 
al., 1984). Ng is associated with agonist-induced stimulation 
of adenylate cyclase and Ni mediates agonist-induced inhibition 
of the enzyme. Ng and Nj are oligomeric proteins comprising of 
three non-identical subunits termed as alpha (41-45K M.wt.), 
beta (35K M.wt.) and gamma (10K M.wt.). The beta and gamma 
subunits of these regulatory proteins appear to be similar, 
whereas the alpha subunits, which provide the GTP binding site, 
vary in molecular size (Codina et al., 1984; Hildebrandt et al., 
1985; Housley, 1984).
The existence of the stimulatory G protein, Ng, was first 
shown in avian erythrocyte membranes using GTP photoaffinity 
analogues and shown to be a heat stable protein of 42K M.wt. 
(Pfeuffer, 1977; 1979). Stimulation of Ng facilitates binding
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of GTP to the alpha subunit, which then dissociates from its 
beta and gamma subunits, thereby activating the catalytic unit 
(Gilman, 1984» Schramm & Selinger, 1984? Taylor & Merrit,
1986). The subunits remain dissociated for as long as GTP is 
bound to the alpha subunit; it is the alphag that activates 
adenylate cyclase activity and thereby elevating intracellular 
levels of cyclic AMP. The activity of the Ng complex is 
terminated by the hydrolysis of the GTP to GDP by a GTPase 
inherent in the alpha subunit (Cassel & Selinger, 1978; Jakobs 
et al., 1984). GTPase activity has been shown to be present 
in the human neutrophil (Hyslop et al., 1984) as well as many 
other systems. This GTPase activity is a'target for the toxin 
produced by the Cholera bacillus. Cholera toxin causes the 
NAD-dependent ADP ribosylation of the alpha subunit of the Ng 
which subsequently inhibits the inherent GTPase activity. This, 
in turn, prevents the hydrolysis of GTP, hence the Ng complex 
is permanently activated so that the cell continually produces 
cyclic AMP.
The presence of an inhibitory G protein, Nj, was first 
proposed in the late 60's from the ability of GTP to inhibit 
adenylate cyclase in rat adipocytes membranes (Creyer et al.,
1989)* The interaction of agonists with distinct receptors 
that exhibit a reduction of cyclic AMP accumulation stimulate 
Nj in a similar GTP-dependent manner as Ng. When GTP binds to 
the alpha subunit of Nj, the alpha subunit dissociates; however, 
the mechanisms by which adenylate cyclase activity is inhibited 
are not understood. It has been suggested that the beta-gamma 
subunits of N^ may mediate the inhibition of adenylate cyclase 
indirectly by favouring the reassociation of the Ng complex (Gilman,
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1984; Snigel et al., 1984). This G protein too can be 
influenced by a naturally occurring toxin isolated from the 
bacterium Bordetella pertussis (Sekura et al., 1985)* Pertussis 
toxin or Islet-activating protein ADP-ribosylates, and hence 
inhibits, the alpha subunit of Nj. This inhibition of the 
inhibitory G protein will thus cause a net increase in cyclic 
AMP (Gilman, 1984; Ui, 1984). Stable (non-hydrolysable) 
analogues of GTP (GppNHp and GTPj^ S) can also modulate G protein 
function causing persistent activation whereas analogues of GDP 
(GDPjgS) result in inhibition (Jakobs & Aktories, 1983).
Adenylate cyclase has recently been purified from rabbit 
myocardium and shown to be a glycoprotein (150K M.wt.) located 
in the plasma membrane (Pfeuffer et al., 1985)* The catalytic 
subunit of adenylate cyclase can be activated directly, hence by­
passing the receptors and the G proteins, by using the diterpene 
forskolin (isolated from the roots of Coleus forskolii). Forskolin 
has proven to be an extremely useful compound in examining the 
adenylate cyclase system in numerous cell types.
Other important enzymes controlling the levels of cyclic AMP 
metabolism is cyclic AMP phosphodiesterases which hydrolyses 
cyclic AMP to the inactive nucleotide 5’-AMP. Cyclic nucleotide 
phosphodiesterases have been shown to exist in multiple forms in 
a variety of mammalian cells which are structurally distinct and 
have different substrate affinity and specificity (Wells &
Hardman, 1977; Appleman et al., 1982). Most cyclic AMP phospho­
diesterase isoenzymes so far described have been categorised 
according to their substrate specificity: cyclic nucleotide
phosphodiesterase with low affinity for both cyclic AMP and cyclic 
GMP, a high affinity cyclic AMP phosphodiesterase and a high affinity
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cyclic GMP phosphodiesterase. The former two enzymes have 
been shown to exist in human neutrophils (Smith & Peters, 1980; 
1981) whilst the latter enzyme could not be detected (Grady and 
Thomas, 1986).
Many cellular responses consequent upon receptor stimulation 
by hormones or agonists in numerous biological systems are 
regulated or modulated by changes in intracellular cyclic AMP 
concentrations. However, the precise role of cyclic AMP in 
neutrophils is somewhat controversial and confusing. Agents 
that cause a sustained rise in the levels of cyclic AMP in human 
neutrophils cause an inhibition of cellular activation. The E- 
type prostaglandin receptor or the ^-adrenergic receptor when 
stimulated by PGE1 or isoprenaline respectively,which activate 
adenylate cyclase and increase cyclic AMP content, attenuate 
agonist-induced chemotaxis, superoxide production and lysosomal 
enzyme secretion (Stephens & Snyderman, 1982; Bergman et al., 
1978; Rivkin et al., 1975; Simchowitz et al., 1980). 
Paradoxically, however, agents that cause neutrophil activation 
also cause a small transient rise in cyclic AMP. Such agents 
include latex particles, EMLP, C5a, immune complexes, zymosan- 
treated serum, opsonized zymosan, calcium ionophores such as 
A23187, PAP and LTB^ (Herlin et al., 1978; Simchowitz et al., 
1980; Smolen & Weissmann, 1981; Pryzwansky et al., 1981; 
Claesson, 1982; Hopkins et al., 1983)* Indeed, this transient 
rise in cyclic AMP led several workers to postulate that cyclic 
AMP elevation constituted a fundamental requirement for neutro­
phil activation (Simchowitz et al., 1980). On the other hand, 
Smolen et al., (1980) observed that sub-threshold concentrations 
of PMLP incapable of inducing cellular activation could still 
elicit normal rise in cyclic AMP. They also reported that
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superoxide generation and lysosomal enzyme release were markedly
4* 24sinhibited in the presence of low extracellular Na or Ca or in 
high K+ concentrations whereas cyclic AMP elevation was unaffected. 
From these observations they concluded that rises in cyclic AMP 
were not responsible for neutrophil responsiveness. Much 
evidence has emerged, using specific phosphodiesterase inhibitors 
(e.g. 1-isobutyl 3-methyl xanthine) or agents that act directly on 
the adenylate cyclase complex, indicating the latter conclusion to 
be correct, suggesting that cyclic AMP has an inhibitory effect 
or only a modulatory role in leucocytes (simchowitz et al., 1983» 
Marone et al., 1980; Lad et al., 1985c). The rise, in cyclic AMP 
associated with neutrophil agonists may not be directly coupled to 
adenylate cyclase. Indeed, Verghese et al., (1985) have 
demonstrated that chemoattractants raise intracellular cyclic AMP 
in human polymorphonuclear cells by a unique Ca^+-dependent 
mechanism which may involve transient inhibition of phospho­
diesterase activity.
Many actions of cyclic AMP are thought to be mediated through 
activation of a cyclic AMP-dependent protein kinases, which 
subsequently cause phosphorylation of a number of different 
proteins. (Flockhart & Corbin, 1982; Krebs, 1984? Berridge,
1985). The precise site of cyclic AMP-dependent reduction or 
modulation of neutrophil activation remains largely unknown. One 
possible mechanism, that has been suggested, for cyclic AMP- 
induced inhibitory effects is by interfering with the production, 
metabolism and effect of other second messenger molecules 
(Berridge, 1985). Strong evidence has been presented, using 
platelets, suggesting that cyclic AMP may interfere with phospho- 
lipase C activity (Lapetina et al., 1977) or with the consequent
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Many actions of cyclic AMP are thought to be mediated through 
activation of a cyclic AMP-dependent protein kinases, which 
subsequently cause phosphorylation of a number of different 
proteins. (Plockhart & Corbin, 1982; Krebs, 1984? Berridge,
1985)* The precise site of cyclic AMP-dependent reduction or 
modulation of neutrophil activation remains largely unknown. One 
possible mechanism, that has been suggested, for cyclic AMP- 
induced inhibitory effects is by interfering with the production, 
metabolism and effect of other second messenger molecules 
(Berridge, 1985). Strong evidence has been presented, using 
platelets, suggesting that cyclic AMP may interfere with phospho- 
lipase C activity (Lapetina et al., 1977) or with the consequent
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production of inositol phosphates (Watson et al., 1984) and 
elevation of [ca2+]i (Peinstein et al., 1983; Zavoico & Peinstein, 
1984; MacIntyre et al., 1985b; Bushfield et al., 1985). There 
is some evidence in human neutrophils showing a relationship 
between cyclic AMP and [ca2+]i elevation (DeTogni et al., 1984;
Kato et al., 1986). These authors showed that, although cyclic
r 2+iAMP did affect agonist-induced |_ Ca Ji transients, this could not 
fully explain cyclic AMP inhibition. Increased levels of cyclic 
AMP produced by PGE1 or by the cyclic AMP stable analogue; 
dibutyryl cyclic AMP and the phosphodiesterase inhibitor; 
theophylline, caused an inhibition of IMLP-induced phosphatidyl- 
inositide metabolism in human neutrophils (DellaBianca et al.,
1986; Kato et al., 1986). Similar observations were made using 
guinea pig neutrophils where elevated levels of cyclic AMP induced 
by PGE2, dibutyryl cyclic AMP and forskolin inhibited arachidonic 
acid release and inositol phospholipid hydrolysis elicited by the 
chemotactic tripeptide (Takenawa et al., 1986).
Although there are potentially many other mechanisms whereby 
cyclic AMP could exert its inhibitory effect in human neutrophils, 
the precise biochemical consequence of elevated cytoplasmic cyclic 
AMP remains to be elucidated.
3. Calcium.
It was over 100 years ago that Sydney Ringer first systematically
investigated the effects of removal of particular ions from the
bathing medium surrounding various tissues. His experiments
2+demonstrated the requirement for extracellular Ca for the 
normal continued beating of an isolated frog heart (Ringer, 1883).
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Many elegant studies followed showing that removal of external
calcium affected various physiological processes which led to 
2+proposal that Ca ions play a critical role in excitation-
contraction coupling of muscle tissue (Heilbrunn, 1940; Sandow,
1952; Katz, 1969)* It was subsequently shown that this
ubiquitous ion was necessary for acetylcholine-induced secretion
of catecholamines in the perfused adrenal medulla of the cat
(Douglas & Rubin, 1961). From their studies they proposed 
2+
that Ca might act as a general effector of agonist stimulated
secretion and thus coined the term stimulus secretion-coupling.
With the knowledge that calcium plays a crqcial role in
contractile tissue and secretory cells, it soon became apparent
that this divalent cation was an important coupling agent in
neutrophil movement and secretion. Calcium is thought to act
either by direct combination with a target enzyme, e.g. phospho-
2+
lipase A2 (PLA2), or by interaction with a Ca acceptor protein, 
calmodulin, which can modulate enzyme activity (Fecheimer & 
Zigmond, 1985) and modulate cellular activation.
2+The proposal that intracellular Ca is involved in neutro­
phil activation was originally made from circumstantial or 
indirect evidence by analogy with other cell types. It was 
shown that removal of external Ca^+ by suspending neutrophils in 
calcium-free buffer and/or in the presence of the calcium chelator 
EGTA reduced, but did not abolish, agonist-induced neutrophil 
activation. Numerous reports showed that the presence of 
external calcium is required for maximal agonist-induced adhesion 
and aggregation (O'Flaherty et al., 1978), chemokinesis and 
chemotaxis (Becker & Showell, 1972; Boucek & Snyderman, 1978; 
Estensen et al., 1978), lysosomal enzyme release (Goldstein et al.,
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1975? Showell et al., 1977) and superoxide production (Hallett 
et al., 1981). Further indirect evidence implicating calcium 
as an important second messenger came from the observations that 
calcium ionophores, A23187 and ionomycin, could stimulate 
(Goldstein et al., 1974; Koza et al., 1975; Cockcroft et al., 
1980a)and that the calcium antagonist TMB-8 or the inhibitor of 
calmodulin, trifluoperizine, could inhibit (Smolen et al., 1981; 
Naccache et al., 1980) neutrophil responsiveness.
ir 2 +
The use of radiolabel Ca has proved useful in 
2+demonstrating Ca fluxes in a variety of cells including neutro­
phils. Activation of neutrophils with chemotactic agents 
resulted in large uptake of ^Ca^+ and in cells previously loaded 
with this radiolabel a net efflux of ^Ca^+ was observed (Boucek 
& Snyderman, 1976; Naccache et al., 1977; Bennett et al.,
1980). Caution must be taken when interpreting these results 
because neutrophils, when exposed to such stimuli, will undergo 
conformational and morphological changes such as cell movement, 
extrusion of pseudopods and degranulation. Such changes alter 
the cell surface area and increase calcium binding sites. 
Consequently, this prevents simple conclusions to be drawn 
concerning calcium fluxes across cell membranes (Sha'afi & 
Naccache, 1983; Foreman et al., 1977)*
The fluorescent probe chiortetracycline (CTC) has been 
employed to investigate the possible involvement of calcium in 
a variety of cells including neutrophils. This hydrophobic 
molecule partitions into cell membranes, interacts with divalent 
cations and the resultant complex fluoresces. Several workers 
have shown that chemotactic agents (e.g. FMLP, C5a) cause a 
decrease in CTC fluorescence which has been attributed, perhaps
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optimistically, to release of membrane associated calcium
(Naccache et al., 1979a, 1979b; Takeshinge et al., 1980; Smolen
& Weissmann, 1982). Current evidence, however, suggests that
this is a misleading concept and that CTC does not only measure
2+plasma membrane bound Ca (Millman et al., 1980) but also measures 
2+Ca located in other membrane bound organelles. Although CTC
can be readily incorporated in neutrophils, for various reasons
2+including lack of specificity (CTC also binds Mg ions), lack 
of sensitivity (Caswell, 1979), the autofluorescence of neutro­
phils (Cross et al., 1982; Gabig, 1983), interference of oxygen 
metabolites with the dye (Whitin et al., 1981), pH dependence 
and difficulty in quantifying the fluorescence (Gains, 1980), it 
is inadequate as an indicator of [ca^+Ji.
The direct measurement of cytosolic-free calcium concentrations,
[ca^+Ji, would be a better way of demonstrating the involvement 
2+of Ca in neutrophil activation. This has been made possible 
only within the last few years by the introduction of various 
chemical [ca^+]i indicators which include photoproteins (e.g. 
aequorin and obelin), organic dyes (e.g. arsenazo III) and 
fluorescent indicators (e.g. Quin2, Fura-2, Indo-1).
The photoproteins, especially aequorin, have a number of 
characteristics that make them good indicators of [ca^+]i (Hallett 
& Campbell, 1982a; 1983; Cobbold et al., 1983)* They do not 
cause any calcium buffering, they are sensitive enough to resolve
T 2+1small agonist-induced changes in I Ca Ji and not toxic to the 
cell. However, one particular problem is that the proteins are 
consumed with repeated £ Ca^+]i measurements because Ca^+ binding 
is not reversible. The main disadvantage of this technique
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appears to be the technical difficulties of introducing the protein 
into the cytosol. A number of procedures have been developed in 
order to overcome this access problem including microinjection of 
the indicator directly to the cytosol (Morgan & Morgan, 1982) or 
by cell permeabilisation (Sutherland et al., 1980; Johnson et al., 
1985)• A particular technique adopted for measuring £ Ca2+Ji in 
neutrophils is to conceal the photoprotein in human erythrocytes 
,ghosts, and induce them to fuse with the cells using Sendai virus 
(Hallett & Campbell, 1982b). These hybrids have shown rises in 
[ca2+Ji induced by fTtLP and concanavalin A but no elevation could 
be detected using unopsonised particles (Campbell & Hallett, 1983)*
r 2+1By far the most widely used indicator of neutrophil [Ca Ji
is the fluorescent probe quin2 (Taien, 1980; 1981; Tsien et al.,
1982a;b). This calcium-sensitive dye is introduced into the cells
in the fomi of the non-polar derivative, quin2-acetoxymethyl ester
(quin2-AM). This ester can readily penneate the plasma membrane
and, once located in the cytoplasm, it is hydrolysed into quin2
by cytoplasmic esterases. Quin2 is water-soluble, cannot pass
the membrane and so remains within the cell. It will avidly bind
intracellular calcium ions with a 1:1 stochiometry and undergoes
fluorescence changes in response to calcium binding. This tetra-
2+carboxylic acid is relatively indifferent to Mg ions and changes 
in pH within the physiological range; and is thought to be 
distributed evenly throughout the cytosol.
White and colleagues first reported changes in using
quin2 loaded rabbit neutrophils. They showed that resting [ca2+Ji 
varied between 100-200nM in different experiments and that BMLP,
C5a and LTB4 all caused a rapid increase in [ca2+]i reaching maximal 
values by 15 seconds (White et al., 1983b). Chemotactic tripeptide
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-induced changes in [Ca Ji were subsequently shown in human 
neutrophils (Pozzan et al.» 1983)* The resting [ca^+]i in 
unstiraulated human neutrophils reported by various workers is 
maintained between 100-140nM depending on the experimental 
conditions used. Rapid concentration-dependent increases in 
[ca^+]i in human neutrophils can be induced by many agonists 
including 3<MLP, C5a> LTB^, PAP and ionomycin (for a review, see 
Westwick & Poll, 1986). In contrast, the phorbol ester, PMA, 
was found to cause neutrophil activation without elevating [ca^+Ji 
(Sha'afi et al., 1983).
Although quin2 has been extensively used in a wide variety 
of cell systems and a wealth of useful information can be credited 
to this fluorescent indicator, it does possess certain weaknesses 
and pitfalls. Quin2 has a poor quantum yield. Consequently, 
the dye has a poor fluorescent intensity resulting in only a two 
fold increase in fluorescence. The dye is excited by ultraviolet 
light irradiation which also generates considerable autofluorescence 
of the cells. This background autofluorescence has to be over­
come by high concentrations of quin2 (0.1-mM) which causes signifi­
cant increases in calcium buffering and blunting of agonist-induced 
elevation of [ca^+]i (Tsien et al., 1982a). Indeed, under certain 
loading conditions and with a high concentration of cytosolic 
quin2, the indicator has been shown to inhibit neutrophil chemo- 
taxis (Elferink & Deierkauf, 1985)> exocytosis and superoxide 
production (Lew et al., 1984a). With large increases in [ca^+]i 
(J>1aiM) quantification of accurate [ca^+]i levels becomes difficult 
because quin2 becomes almost saturated. The fluorescence 
intensity is also dependent on a number of variables including 
illumination intensity, emission collection efficiency and tissue
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thickness. In order to obtain accurate measurements, all
these factors have to be taken into account and minimised or 
standardised for each particular cell system (Tsien et al., 1985;
Rink & Pozzan, 1985)•
With the development of newer fluorescent indicators such as 
fura-2 or indo-1, some of the problems associated with quin2 can 
be largely overcome (Grynkiewicz et al., 1985)* Fura-2 displays 
a 50 fold greater fluorescence intensity in comparison with quin2; 
therefore it can be used at lower cytosolic loading concentrations. 
These lower concentrations (10-10Q«M) offer less calcium buffering
T 2+1. 2+enabling more accurate measurement of I Ca li transients. Ca -
dye interaction not only increases the fluorescence intensity but
also shifts the excitation and emission wavelengths. Thus, by
2+measuring the ratio of free dye to Ca -bound dye, a more precise
measure of [ca^+Ji can be attained that is independent of dye
concentration, illumination intensity and the amount of tissue in
the light path. Fura-2 also has a larger dissociation constant 
2+(Kd) for Ca than its predecessor, quin2, thus allowing measurements
[ 2+1 2+Ca Ji. A better selectivity for Ca than
2+
for Mg and other heavy metals is also associated with these new 
indicators (Grynkiewicz et al., 1985). The observations made in 
human neutrophils using quin2 still await investigation and 
confirmation with fura-2.
The neutrophil is surrounded by an external calcium concentration
approximately 10000-fold greater than its resting [ca^+Ji.
Consequently, the cell has adopted various homeostatic mechanisms
in order to maintain this low £ca^+Ji. This is achieved by a
number of calcium extrusion and sequestration mechanisms. Most
2+ 2+cells possess two main mechanisms, a Ca , Mg -ATPase pump and an
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Na+/Ca^+ exchange system.
2+ 2+
Ca , Mg -ATPase pumps have been reported to be present
in the plasma membrane (Ochs & Reed, 1983; Volpi et al., 1983;
Lagast et al., 1984) and in lysosomal membranes (Klempner, 1985)
of neutrophils. This pump has been shown to be activated by
calmodulin-dependent kinase and cyclic AMP-dependent kinase.
Recently, Lagast et al., (1984) and Rickard & Sheterline, (1985)
have shown that PMA-stimulated guinea pig neutrophils activate 
2+this Ca transporter, suggesting that protein kinase C may also 
regulate [ca^+]i levels. Since the pump can be found on intra­
cellular membranes such as lysosomal, mitochondrial knd sarco­
plasmic reticulum membranes, this mechanism may also be involved 
in Ca^+ sequestration.
Another mechanism by which cells have the potential to maintain 
low £ca^+Ji is by the extrusion of Ca^+ from the cell via an Na+/Ca^+ 
electrogenic exchange system (Cauvin et al., 1983). The presence 
of this antiporter in human neutrophils has not been reported yet. 
However, Sha'afi & Naccache, (1983) failed to demonstrate the 
presence of an Na /Ca exchanger in rabbit neutrophils. The
development of amiloride analogues with increased specificity 
towards this antiporter (Kaczorowski et al., 1985) may help 
determine the precise function of this electrogenic exchange, if 
indeed present, in human neutrophils.
The mechanism and nature underlying agonist-induced elevation 
of £ca^+Ji has been the subject of intense research not only in 
the neutrophil but also in numerous other cell systems. It is 
thought that the increase in neutrophil [ca^+Ji is derived partly 
from the external milieu and partly from mobilisation of internal
56
stores. Quantification of the amount resulting from both sources
has been attempted using quin2 loaded neutrophils suspended in the
2+presence and absence of external Ca . For example, White et al.,
(1983b)showed that in rabbit neutrophils IMLP-induced elevation of 
[ca^+]i occurred independently of external Ca^+. However, in human 
neutrophils, it is thought that the majority (> 75%) of the agonist- 
induced rise in £ca2+]i derives mainly from influx of extracellular 
Ca^+ (Pozzan et al., 1985)•
2+
The translocation of extracellular Ca into the cytosol is
thought to occur through the opening of specific calcium channels
located in the plasma membrane. There exist voltage-operated
channels (VOCs) found in electrically excitable cells (Bolton, 1979)*
In tissues such as cardiac and smooth muscle cells, membrane
depolarization results in the opening of VOCs which results in a net
2+influx of external Ca leading to activation, i.e. contraction. 
Although neutrophils can undergo membrane depolarization (Korchak 
& Weissmann, 1980) it is insufficient to cause activation and 
elevation of [ca^+]i. Membrane depolarization caused by elevation 
of the extracellular K + concentration or hyperpolarization produced 
by K + ionophores (e.g. valinomycin and nigericin) fails to cause 
chemotaxis, degranulation or an increase in [ca^+]i (Showell et al., 
1977? Romeo et al., 1975). In addition, classical calcium 
antagonists (e.g. diltiazem and nifedipine) which inhibit agonist- 
induced responses in depolarization activated tissue by allegedly 
blocking VOCs (Triggle, 1982) fail to attenuate agonist-induced 
activation of neutrophils. Therefore, it is highly unlikely that 
increases in [ca^+]i occur via VOC in human neutrophils.
The other main type of calcium channel, which opens as a direct 
consequence of receptor occupation and are consequently termed receptor
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operated calcium channels (ROCs), are thought to be involved in
human neutrophil activation. The precise way that these ROCs
open remains largely unknown. However, three reports have
recently been published which might account for receptor operated 
2+Ca entry. Kuno & Gardner, (1987) working with T-lymphocytes 
have shown that Ins(l,4»5)P^» a product of phosphoinositide meta­
bolism and mainly thought to be involved with the mobilisation of
2+ 2+ intracellular Ca stores, produces influx of external Ca
through a specific channel in the plasma membrane. Irvine & Moor,
(1986) have demonstrated that I n s ( l d e r i v e d  from Ins(l,4»5)P^
phosphorylation may be involved in the translocation of external 
2+Ca to the cytosol in sea urchin eggs. Another mechanism has 
been proposedby V-Tscharner et al., (1986) using quin2 and fura-2 
loaded human neutrophils, suggesting ROCs may be opened by calcium 
itself. They have reported that an initial PMLP or PAP-induced 
rise in £ca^+Ji induces the opening of other calcium, or more 
accurately divalent cations, channels on the neutrophil membrane.
These channels are not opened by Ins(l,4»5)P^ or by the agonist 
directly but only by the elevation of £ Ca^+Ji. It also remains
possible that rises of [ca^+]i may result from other yet unidentified
[ 2+1 2+Ca i due to mobilisation of Ca
from internal stores has been mainly attributed to a product of
inositol phospholipid metabolism, Ins(l,4»5)l>3*
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4. Inositol Phospholipid Metabolism.
4-1- General
Since the original observations made by Hokin & Hokin in 
1953 that neurotransmitters and hormones cause a turnover of 
membrane phosphoinositide lipids, our knowledge has vastly 
expanded within the last few years, suggesting that the ’phospho­
inositide cycle' is much more complex than was previously 
believed (for reviews see Berridge, 1985; Hokin, 1985; Abdel- 
Latif, 1986). Figure 10 shows the pathways and proposed path­
ways involved in the phosphoinositide cycle thought to occur in 
a wide variety of cell systems including human neutrophils.
Inositol-containing lipids are relatively minor phospho­
lipid constituents of mammalian cells, comprising less than 10% 
of the total phospholipid content (Marcus et al., 1969)* 
'Phosphoinositides' is the collective term used for three lipids; 
phosphatidylinositol (Ptdlns), the major inositol phospholipid 
comprising about 90% of total, and the phosphorylated derivatives 
phosphatidylinositol 4 phosphate (PIP) and phosphatidylinositol 
4»5 bisphosphate (PIP2) (Figure 11).
The interconversion of the phosphoinositides is achieved by 
the presence of specific kinases and phosphatases. Ptdlns 
kinase phosphorylates Ptdlns at position 4 on the sugar inositol 
ring to yield PIP which is further phosphorylated at position 5 
via PIP kinase to produce PIP2» The reverse reaction can also 
occur enzymatically via PIP and PIP2 phosphatases.
These inositol phospholipids, especially PIP2» have a high
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Figure 10.
The Complex Nature of the Phosphoinositide Cycle.
Agonistic-receptor combination results in the activation of 
phospholipase C presumably via a transducer (GTP binding protein) 
mechanism to yield a number of inositol phosphates and 1,2-diacylglycerol 
(LAG)• These products may then be incorporated into cycles leading 
to the resynthesis of the phosphoinositides.
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Structures of the Phosphoinositides.
Phosphatidyl inositol (Ptd Ins), phosphatidyl inositol 4-phosphate 
(PIP) and phosphatidyl inositol 4»5-bisphosphate
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2+
affinity for Ca (Hirasawa & Nishizuka, 1985) and much of the 
2+
membrane-bound Ca is probably associated with these lipids 
(Buckley & Hawthorn, 1972). Indeed, it has been suggested that 
hydrolysis of PIP2 could represent a receptor-linked mechanism 
whereby membrane-bound calcium might be released into the cytosol
(Broekman, 1984). However, PIP2 also exhibits a slightly lower
2+ 2+ 2+ 
affinity for Mg where the cellular Mg : Ca ratio is 1000 t 1,
2+suggesting that a substantial amount of PIP2 is likely to bind Mg
2+(Fain, 1982). Bearing this in mind, the precise contribution Ca 
released during the hydrolysis of PIP2 has in agonist-induced 
elevation of £ca^+Ji still remains to be established.
There is considerable evidence suggesting that the principle 
phosphoinositide which is acted upon by the phosphodiesterase, 
phospholipase C, is PIP2 (Berridge, 1983; Martin, 1983? Drummond 
et al., 1984). Consequently, the initial reaction resulting from 
agonist receptor combination appears to be the hydrolysis of PIP2 
via phospholipase C to form inositol 1,4»5 triphosphate (lns(l,4»5)P^) 
and 1,2-diacylglycerol (BAG) (Berridge, 1985). It has also been 
shown that minor pathways exist for the conversion of Ptdlns and 
PIP to inositol 1 phosphate (ins 1P) and inositol 1,4 bisphosphate 
(lns(l,4)P2) respectively, although these inositol phosphates are 
thought to be less important than the formation of Ins(l,4»5)Pj 
(Figure 12). These inositol phosphates can be sequentially 
dephosphorylated to form inositol; the enzymes responsible are 
believed to be inhibited by lithium and such blockade has been useful 
in monitoring phosphoinositide turnover in a number of cell systems 
(Hallicher & Sherman, 1980; Huang & Detwiter, 1986; Drummond,
1987). The other product of PIP2 hydrolysis, DAG, can be 
enzymatically converted by DAG kinase to yield phosphatidic acid
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Figure 12.
Structures of the Inositol Phosphates.
Inositol 1 phosphate (ins 1P),
Inositol 1,4 bisphosphate (ins (1,4) P2)>
Inositol 1,4*5 trisphosphate (ins (1,4*5) ^3)*
Inositol 4 phosphate (ins 4P),
Inositol 1,3*4 trisphosphate (ins (1,3* 4P)3)»
Inositol 1,3*4*5 tetrakisphosphate (ins (1,3*4*5)^4)»
Inositol 1,2-(cyclic) phosphate (ins (l,2-cyc)P),
Inositol 1,2-(cyclic) 4 bisphosphate (ins (1,2-cyc,4)P2) 
Inositol 1,2-(cyclic) 4*5 trisphosphate (ins (1,2-cyc,4>5)P3)•
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(PtdA) which is then acted upon by CTP-PtdA-cytidyl transferase to 
form CBP-MG (Figure 13) • This latter product can combine with free 
inositol to resynthesise the phosphoinositides, thereby completing the 
cycle.
Recent reports have further complicated this cycle with the 
discovery of an isomer of Ins(l,4»5)P3 known as inositol (1,3»4) 
trisphosphate (lns(l,3»4)f>3) (Irvine et al., 1985? Burgess et al., 
1985). Ins(l,4»5)P^ is thought to be rapidly phosphorylated by the
activity of an ATP-dependent kinase (lns(l,4,5)P^-5-kinase) to 
inositol 1,3»4»5 tetrakisphosphate (lns(1,3>4>5)P4) which is then 
converted to Ins(l,3>4)P^ (Batty et al., 1985? Irvine et al., 1986). 
It has been suggested that Ins(l ,3*4*5)P4 niay be formdd by receptor- 
linked PLC catalysed hydrolysis of an appropriate phospholipid, 
phosphatidylinositol 3»4*5-'trisphosphate (PIP^) (Batty et al., 1985). 
It has also been shown that under special experimental procedures 
Ins(l,3t4»5)1*4 can be further phosphorylated to InsP^ and InsP^
(Heslop et al., 1985)* There is also evidence for the existence 
of cyclic inositol phosphates produced from the inositol phospho­
lipids (Wilson et al., 1985a,b.). It is conceivable that inositol
1,2-(cyclic) phosphate (lns(l,2-cyc)P), inositol 1,2-(cyclic) 4- 
bisphosphate, (lns(l,2-cyc4)P2) 311(1 inositol 1,2-(cyclic) 4*5- 
trisphosphate, (lns(l,2-cyc,4*5)^3) could be produced from Ptdlns,
PIP and PIP2 respectively.
Many of the above pathways have been studied using a variety of 
techniques including measurement of the mass, or, more recently, 
analysis by HPLC, of the intermediates, but by far the most widely 
used technique is by prelabelling the cells with radioactive species. 
For example p^pj-orthophosphate prelabelling, which is incorporated 
into the cellular ATP pool and labels the phosphoinositides and
PtdA. Other prelabelling procedures include P h I- or P^cl-
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Structures of the Diglycerides.
1,2-diacylglycerol (LAG), phosphatidic acid (Ptd a ) and cytidine 
diphosphate diacylglycerol (CLP-DAG).
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arachidonic acid or glycerol or [^HJ-inositol. However, depending
on the cell system under investigation, there are different problems
associated with each of these prelabelling procedures. Ever since
Kamovsky and Wallach in 1961 first demonstrated phosphoinositide
metabolism in stimulated neutrophils undergoing phagocytosis, there
have been a number of investigations showing receptor-activated
phosphoinositide metabolism in human neutrophils, the majority of
which have been centred on M L P  as agonist. Whether phosphoinositide
turnover in neutrophils is dependent on the presence of external
calcium has been a matter of controversy. Early studies in
Cockcroft's laboratory suggested that MLP-induced breakdown of
Ptdlns and the formation of PtdA were dependent on the presence of
calcium in the medium (Cockcroft et al., 1980b; 1981; Cockcroft,
1984). However, Dougherty et al., (1984) showed that, although
2+Ptdlns metabolism and PtdA formation are indeed Ca -dependent,
agonist-induced PIP and PIP2 metabolism was independent of the
2+
presence of external Ca • Rossi et al., (1985) have shown that 
M L P  causes rises in [ca^+]i in quin2-loaded cells at concentrations 
significantly lower than MLP-induced PtdA formation and superoxide 
production suggesting that phosphoinositide hydrolysis is not 
involved in the rise of [ca^+Ji. On the other hand, DiVirgilio 
et al., (1985) have shown that M L P  stimulates Ins(1,4»5)^ 
production in human neutrophils under conditions where calcium 
levels, as monitored by quin2, do not rise.
Examination of phosphoinositide hydrolysis induced by other 
ligands in neutrophils has proven to be equally as difficult and 
confusing. LTB^ can cause an elevation of jca^+J^ in neutrophils to 
much the same extent as MLP. However, Volpi et al., (1984) could 
not detect significant stimulation of phosphoinositide hydrolysis
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in rabbit neutrophils by this arachidonic acid metabolite even 
although the chemotactic tripeptide could elicit phosphoinositide 
metabolism. The ether lipid, PAF, has been shown to cause a 
phosphoinositide turnover in rabbit neutrophils. However, Naccache 
et al., (1986) have also shown that higher concentrations of PAF 
are required to cause phosphoinositide turnover than are required to 
cause an elevation of £ca^+]i. These observations along with others 
(discussed later) have led to the hypothesis that there may exist 
at least two distinct receptors for PAF. Clearly then, phospho­
inositide hydrolysis plays a role in neutrophil activation but for 
each particular agonist the precise functional significance still 
awaits elucidation.
4*2. Inositol Phosphates.
The gap between inositol lipid metabolism and mobilisation of
intracellular stores of calcium is thought to be bridged by the
formation of the second messenger molecule, Ins(l,4i5)F^, the
water-soluble product of PIP2 hydrolysis. The first indirect
evidence was put forward by Berridge, (1983) who demonstrated the
early (within 5 seconds) liberation of Ins(l,4»5)F^ in insect
salivary glands. More direct evidence came from Streb et al.,
(1983) who demonstrated that the addition of exogenous Ins(l,4»5)F^
2+
to permeabilised pancreatic acinar cells could release Ca from
an intracellular non-mitochondrial store. Prentki et al., (1984)
showed that the addition of Ins(l,4»5)F^ to digitonin permeabilised
2+
human neutrophils also caused the release of Ca from non- 
mi tochondrial stores. This has subsequently been shown in a 
variety of other cell types including hepatocytes (Burgess et al.,
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1984a)i peritoneal macrophages (Hirata et al., 1984)» Swiss 3T3 
cells (Irvine et al., 1984)» vascular smooth muscle (Somlyo et 
al., 1985)» skeletal muscle (Vergara et al., 1985) and platelets 
(O'Rourke et al., 1985)* It is thought that Ins(1,4*5)Pj releases 
intracellular calcium from the smooth endoplasmic reticulum by 
acting upon specific acceptor sites. Indeed, Spat et al., (1986) 
have demonstrated, in permeabilised guinea pig neutrophils and 
hepatocytes, that Ins(l,4»5)P^ binds to specific saturable sites.
In addition, Wilson et al., (1985b) have reported that addition of 
the cyclic phosphate Ins(l,2-cyc,4 »5)P^ causes release of calcium 
from intracellular stores in permeabilised platelets' and Limulus 
photoreceptor cells.
The role of the many other inositol phosphates (Figure 12) in 
agonist-induced cellular activation remains unknown. However, as
already mentioned, Ins(l,5*4*5)P^ may be involved in the trans-
2+location of external Ca across the plasma membrane (Irvine &
Moor, 1986).
4.3* 1,2-Diacylglycerol (MG)
The production of another primary product of inositol 
phospholipid hydrolysis is MG. This neutral lipid has been 
proposed to act as a second messenger molecule by stimulating a 
Ca^+-dependent and phospholipid (particularly phosphatidylserine)- 
dependent protein kinase C (Nishizuka, 1984; 1986).
M G  is foxmed at the plasma membrane only transiently and 
disappears within a few seconds due to its phosphorylation to PtdA.
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Indeed, this derivative of M G  was once believed to be a prime
candidate for causing the elevation of [ca^+]i. It was reported
that PtdA could act like a calcium ionophore, thereby elevating
[ca^+]i (streb et al., 1983). However, others have subsequently
shown convincing evidence disputing these observations (Holmes &
Toss, 1983; Putney, 1986) hence it is unlikely that PtdA is a
2+second messenger molecule, at least in terms of Ca signalling.
2+
Protein kinase C affinity for Ca is increased by 
kinetically small quantities of MG, hence this kinase can be 
fully activated at resting [ Ca^+] i without a net increase in 
[ca^*]i (Kishimoto et al., 1980). Protein kinase C activation 
can be mimicked by either synthetic M G  (e.g. 1 oleoyl 2 acetyl 
glycerol, OAG) or by the tumour promoters known as phorbol esters 
(e.g. phorbol 12 myristate 13 acetate, PMA) (Castagna et al.,
1982). It is thought that protein kinase C activation plays an 
important role in neutrophil responsiveness. PMA can stimulate 
a variety of neutrophil responses including superoxide production 
and degranulation (McPhail & Snydenman, 1983). Addition of sub­
threshold concentrations of PMA or OAG with subthreshold calcium 
ionophore can cause a marked activation of human neutrophils 
(Robinson et al., 1984» Penfield & Dale, 1984). These 
observations suggest that stimulation of protein kinase C can 
activate human neutrophils either independently or synergistically 
with an elevation of £ Ca^+Ji (Michell, 1983).
More recently there is evidence to suggest that protein 
kinase activation may have a regulatory effect on agonist-induced 
activation in a number of cell systems (MacIntyre et al., 1985a; 
Vicentini et al., 1985). Preincubation of neutrophils with 
increasing concentration of PMA prior to the addition of an agonist,
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e.g. 5MLP, PAF and LTB4, can inhibit neutrophil activation 
produced by these agonists (Naccache et al., 1985a;b). The 
precise mechanism and role of this negative feedback system is 
not fully understood although there is some evidence to suggest 
that protein kinase C is inhibiting the possible transduction 
processes involved in neutrophil activation.
Stimulation of protein kinase C is believed to cause the 
phosphorylation of a number of proteins usually with an M.wt. 
greater than 40K. However, the precise number of proteins or 
function of this phosphorylation remains to be determined.
Ohtsuka et al., (1986) showed, using intact guinea pig neutrophils, 
the involvement of protein kinase C in the phosphorylation of a 
46K protein which parallels the activation of NABPH oxidase.
This observation may explain why PMA seems to be a good stimulator 
of superoxide production in neutrophils. Another interesting 
observation made by Touqui et al., (1986) is that protein kinase 
C may be phosphorylating a 4OK anti-phospholipase A2 protein 
indistinguishable from lipocortin (DiRosa et al., 1984). Other 
proteins believed to be phosphorylated by protein kinase C include 
Ins(l,4»5)P^ phosphatase (Connolly & Majerus, 1986), glucose 
transporter (Witters et al., 1985) and. tyrosine hydroxylase 
(Vulliet et al., 1985) to name only a few.
4«4» Involvement of G Proteins in Phosphoinositide Metabolism.
There is evidence to suggest that G proteins play a role 
either directly or indirectly in receptor coupled phosphoinositide 
metabolism by regulating phospholipase C activity (for a review,
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see Litosch & Pain, 1986).
The first clues to the involvement of G proteins in this 
case came from observations that guanine nucleotides modulate 
the binding of agonists linked to stimulation of phosphoinositide 
turnover. This phenomenon was shown with muscarinic cholinergic 
agonists (Florio & Stemweiss, 1985), vasopressin (Cantau et al.,
1980) and a1-adrenergic amines (Goodhardt et al., 1982). This 
was also shown with FMLP activated neutrophil plasma membranes 
where a high affinity form of the receptor can be converted to a 
low affinity foim by guanine nucleotides (Koo et al., 1983; 
Snydenman et al., 1984). More convincing evidence came from 
studies by Gomperts, (1983) where non-hydrolyseable analogues of 
GTP caused the Ca2+-dependent release of histamine from 
permeabilised mast cells. Further work by Cockcroft & Gomperts, 
(1985) and others (Smith et al., 1985) have shown that GTP 
analogues could stimulate phosphoinositide hydrolysis in 
neutrophil plasma membranes. Similar observations have been 
made in numerous other cell systems including permeabilised 
platelets (Haslam & Davidson, 1984), hepatocyte membranes 
(Wallace & Fain, 1985), blowfly salivary gland membranes (Litosch 
et al., 1985), smooth muscle membranes (Sasaguri et al., 1985) 
and permeabilised GH3 cells (Martin et al., 1986). These 
results suggest that GTP binding protein participates in the 
coupling of receptor activation to phospholipase C activity.
There probably exist numerous G proteins involved in signal 
transduction mechanisms, the best characterised being N§ and Ni 
which function in the adenylate cyclase system and transducin 
which transduces the effect of light activation on rhodopsin
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stimulation of cyclic GMP phosphodiesterase activity on rod 
outer segments. The identity of the G protein (often referred 
to as Np) coupled to PLC has not yet been identified but may 
resemble these other better studied G proteins.
Pertussis toxin which causes the NAD-dependent ADP 
ribosylation of the 41K M.vt. alpha-subunit of Nj and inhibits 
its action in the adenylate cyclase system can also be utilised 
to probe G protein involvement in PLC activation. Pretreatment 
of neutrophils with pertussis toxin inhibited MLP-induced 
phosphoinositide turnover, [ Ca^+]i elevation and cellular 
activation, including arachidonic acid release, degraniilation 
and superoxide generation in neutrophils isolated from a variety 
of species (for review, see Omann et al., 1987q)* These reports 
suggest that the G protein involved in neutrophil activation may 
be Nj or a related protein. Indeed, Bokoch & Gilman, (1984) 
have shown that the effect of this bacterial toxin on neutrophils 
could be correlated with ALP ribosylation of a 41K membrane 
protein that comigrated on SLS poly-acrylamide gels with purified 
rat liver Njalpha subunit. These workers also showed that sodium 
fluoride, a stimulator of G proteins that causes the dissociation 
of the alpha from the beta/gamma subunits, was able to cause a 
pertussis toxin sensitive release of arachidonic acid from 
neutrophils. This evidence strongly suggests that G proteins are 
involved in MLP-induced neutrophil activation; whether they are 
involved in neutrophil responsiveness induced by other receptor 
agonist still remains to be fully established.
5. Changes in Membrane Potential.
It is worth mentioning that human neutrophils, in common with
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other cells, possess a resting membrane potential which changes
with the addition of certain agonists. The transmembrane
potential can be measured in small cells such as neutrophils by
preloading with the fluorescent dye 3-3 '-dipentyloxacarbocyanine
(di-O-C^) or with the lipophilic dye triphenylmethylphosphonium
ion (TFMP+). The resting potential of human neutrophils
measured by such dyes ranges from between -25mV to -75mV. This
variation in the resting potential may depend on the age of the
neutrophil (Seligmann et al,, 1981a) or on the particular dye
used, Korchak & Weissmann, (1978) have shown that the resting
membrane potential is dependent on the K+ concentration across
the membrane since elevating the external concentration of this
cation causes a marked depolarization. These workers also showed
that stimulation of neutrophils with immune complexes or
concanavilin A causes a rapid hyperpolarization which is not
2+dependent on the presence of external Ca but requires the 
presence of extracellular Na+ for an optimal membrane potential 
response. It has also been shown by Korchak and Weissmann,
(1978) that IMLP causes a triphasic response consisting of a 
transient increase in cell associated TPMP+ followed by a decrease 
and finally a prolonged increase interpreted as a hyperpolarization, 
depolarization and a hyperpolarization respectively. Seligmann 
et al., (1980) using di-O-C^ reported that IMLP stimulated a 
biphasic response; an apparent depolarization followed by a 
hyperpolarization. These discrepancies between the two groups 
may have resulted from differences in dye incubation periods 
(Seligmann et al . , 1981aj). Using di-O-C^ Seligmann & Gallin, 
(1980) observed that low concentrations of PMA and A23187 cause 
a transient hyperpolarization. However, they also demonstrated 
that intermediate concentrations of these agonists produced a
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similar hyperpolarization followed by a depolarization and that 
high concentrations of either secretagogue caused a large 
depolarization. An interesting observation made by Seligmann et 
al.t (19811?) using di-O-C^ is that neutrophils respond hetero­
geneously to IMLP. They showed that the majority (65%) of cells 
respond to JMLP by depolarization and the remaining cells either 
do not respond at all or cause a hyperpolarization of the membrane 
potential. Although these changes in membrane potential occur 
rapidly and precede superoxide generation and degranulation, 
(Korchak & Weissmann, 1980; Cohen & Chovaniec, 1978a;b) their 
significance in stimulus-response coupling is unknown. It is 
unlikely that alterations in the membrane potential play a major 
role in neutrophil activation but movement of ions across the 
plasma membrane may have a modulatory role in neutrophil acti­
vation by altering, for example, intracellular pH (for review, 
see Simchowitz & Roos, 1985)*
DAG has been shown to induce an Na+/H+ exchange via acti­
vation of protein kinase C and the resultant increase in intra­
cellular pH appears to be intimately linked with stimulus-response 
coupling. Brass & Joseph, (1985) have shown that increasing the
extracellular pH lowered the apparent Km of Ins(l,4»5)P^ towards 
2+
the Ca stores by around 40% in penneabilised platelets. More 
recently, Siffert & Akkerman, (1987) demonstrated that suppression 
of Na+/H+ counter transport by ethylisopropyl-amilioride or by 
lowering extracellular Na+ reduces or even completely abolishes 
thrombin-induced elevation of [ca^+]i in human platelets. They 
concluded that an increase in intracellular pH evoked by activation 
of Na*/ll+ exchange is an important signal in stimulus-response 
coupling and forms an essential step in the cascade of events
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required to increase [ca^+Ji in platelets. They have also 
reported that thrombin-induced cleavage of PIP2 was unaffected 
by treatments that blocked Na+/E+ exchange for increased 
intracellular pH and concluded that, although Na+/H+ exchange 
is a prerequisite for[ca^+]i mobilisation, it is not necessary 
for the stimulus-induced hydrolysis of PIP2 (Siffert et al., 
1987)* Whether pH changes are modulating agonist-induced 
changes in [ca^+]i and phosphoinositide hydrolysis in the human 
neutrophil is currently the focus of much attention.
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OBJECTIVES.
The major objectives of this study were to investigate the 
mechanisms of action and interaction of the arachidonic acid 
metabolite, LTB4 , and the ether lipid, PAP, as mediators of human 
neutrophil activation.
The parameters examined were:
(a) Ultrastructural changes.
(b) Aggregation.
(c) Degranulation by measuring (i) NAG release
(ii) Lysozyme release.
(d) LTB4 generation.
(e) Changes in ^Ca^+Ji.
(f) Phosphoinositide hydrolysis.
This was attempted by:
(1) Comparing the various neutrophil responses induced by 
LTB4 and PAP with those elicited by the chemotactic 
tripeptide, MLP, the phorbol ester, PMA and the calcium 
ionophore, ionomycin.
(2) Examining the possible involvement of "G proteins" in 
neutrophil activation by utilising pertussis toxin.
(3) Investigating the role of protein kinase C activation in 
agonist-induced elevation of |ca^+Ji and phosphatidic acid 
production (an indirect index of phosphoinositide 
hydrolysis)
(4) Exploring the role of LTB4 and PAF as endogenous mediators 
or amplifiers of neutrophil responsiveness by employing a 
selective 5-lipoxygenase inhibitor and a specific PAP 
receptor antagonist.
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METHODS AND MATERIALS
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CHAPTER 4: METHODS AND MATERIALS.
1. PREPARATION OF HUMAN NEUTROPHILS,
Blood was obtained by ante-cubital venepuncture from healthy 
adult volunteers who denied taking any drugs known to affect 
neutrophil function. The blood samples were immediately mixed 
with 3*8% trisodium citrate (9 parts blood to 1 part anticoagulant) 
and then centrifuged (850g; 5 min; room temperature) in a bench 
minor centrifuge. The platelet rich plasma was discarded and the 
erythrocyte / leucocyte ("buffy coat") layer was mixed with 1-2 
volumes gelatin solution (2.5% gelatin in 154®M saline) and 
incubated at 37°C for 50-45 min. The supernatant was removed and 
centrifuged (l,000g; 5 min; room temperature) and the resultant 
cell pellet was resuspended in lysis buffer (C) to remove 
contaminating erythrocytes (Henson, 1971)• This cell suspension 
was then centrifuged (850g; 3 min; room temperature) and the
resultant cell pellet resuspended in Hanks Balanced Salt Solution. 
This procedure was repeated and the cells were finally resuspended 
in appropriate buffer at the desired neutrophil concentration.
The cells were stored on ice until use.
2. COUNTING OF NEUTROPHILS.
The cells were counted and their viability assessed by*
(a) Trypan blue exclusion, using a standard haemocy tome ter 
under a Leitz labovert light microscope.
(b) Coulter counter; where 2Qul aliquots of cell suspensions 
were added to 20ml of Isoton and counted at predetermined 
settings (amplitude 8 ; aperture current 0.354) for human 
neutrophils.
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The cells were approximately 95-98% viable, 90-98% pure and 
were free from any neutrophil aggregates.
5. BUFFERS.
BUFFER A
NaCl 124mM
KC1 4mM
NalfyPOa 0.64mM
K2HPO4 0.66mM
NaHCO^ 5.2mM
Hepes 10mM
Glucose 5*6mM
CaCl2 1.6mM
The above were dissolved in glass-distilled water and the pH 
was adjusted to 7*4 using NaOH (1N).
BUFFER B (phosphate free buffer)
NaCl 140mM
KC1
NaHCO} 2.8mM
MgCl2 1mM
MgSO4 0.06mM
Hepes 15raM
Glucose
CaCl2 1.6mM
The above were dissolved in glass-distilled water and the pH 
was adjusted to 7»4 using NaOH (1N).
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BUFFER C (lyais buffer)
NH4CI 150mM
KHCO3 10mM
EDTA 1mM
The above were dissolved in glass-distilled water.
BUFFER D (LTB4 radioimmunoassay dilution buffer)
NaH2P04 40mM
NaCl 0.9% (w/v)
Bovine gamma globulin 0.1% (w/v)
The above were dissolved in glass-distilled water and the pH 
was adjusted to 7*4 using NaOH (1N).
BUFFER E (LTB4 stopping "cocktail”)
BW755C 1mM
Indomethacin 1mM
EGTA 100mM
Sodium azide 1% (w/v)
The above were dissolved in glass-distilled water and the pH 
was adjusted to 7*4 using NaOH (1N)*
4. ELECTRON MICROSCOPY STUDIES.
Neutrophils were dispersed into aliquots of 0.5ml (containing
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10 cells) and challenged with an agonist. At a desired time the 
reaction was stopped and fixed by addition of 0.5ml aliquots of 
prewarmed (37°C) 2.5% glutaraldehyde (0.25ml) and 0.1M sodium 
cacodylate buffer (0.25ml), pH 7*4» which were mixed together 
immediately before use to give a final glutaraldehyde concentration 
of 1.25%. The cells were allowed to fix in suspension for 1 hour 
and then centrifuged gently (300g; 2 min; room temperature). The
resultant supernatant: was decanted and 0.5ml of fresh human serum 
was added to the cells, which were resuspended and then centrifuged 
(850g; 3 min; room temperature). The serum was removed and 
carefully replaced by" 0.5ml fresh fixative (2.5% glutaraldehyde) 
and left for 2 hours (Payne & Satterfield, 1980). The samples were 
washed, at room temperature, in 0.1M sodium cacodylate containing 
3mM CaCl2 three times over a period of 24 hours.
Much of the following procedure was performed with the assistance 
of Dr. Caroline Jones from the Pathology Department of the University 
of Manchester. The samples were diced into 1mm cubes then post­
fixed in 1% osmium tetroxide in 0.1M sodium cacodylate at 4°C for 1 
hour, washed in buffer, and dehydrated in an ascending series of 
alcohols. Two changes of propylene oxide were then given and samples 
transferred to equal parts of propylene oxide and Taab epoxy resin for 
1 hour at room temperature. They were then left in 1 part propylene 
oxide to 3 parts resin overnight, given three changes of fresh resin 
at 48°C and polymerised in gelatin capsules at 60°C for 72 hours.
Ultrathin sections were cut on a Reichert OMuIII ultramicrotone, 
picked up on copper grids (300 mesh), and double stained with uranyl 
acetate and lead citrate prior to examination in a Philips 301 electron 
microscope at an accelerating voltage of 60 KV.
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5. AGGREGATION.
Neutrophil aggregation was measured photometrically in a 
standard Malin Clinical Aggregometer. To a cuvette containing a 
teflon-coated stirring bar revolving at 600 r.p.m., was added 0.6ml
7
of neutrophil suspension (2.5 x 10 cells/ml) in buffer A. After a 
2 min delay, to allow warming of cells to 37°C, the neutrophils 
were challenged with an agonist and the resultant changes in light 
transmission recorded on a Linseis recorder.
6. DEGRANULATIQN.
(a) Sample Generation.
7
Neutrophil suspensions (0.6ml of 10 cells/ml) in buffer A, in
the presence or absence of cytochalasin B (^ug/ml; 10 min), were
o
challenged with an agonist for 10 min at 57 C. The reactions 
were terminated by centrifugation (9*000g; 20 sec) in a micro- 
centrifuge. The supernatant was removed and stored at ~20°C.
(b) NAG Measurement.
NAG activity was measured fluorimetrically as the formation of 
4-methylumbelliferone by a modification of the technique of Gordon, 
(1975) for measuring platelet lysosomal enzymes. The reaction 
mixture contained 10Qul of cell supernatant or cell pellet, 100yiul 
of citrate buffer (0.3M; pH 4*8) and 100ul of 4-niethylumbelliferyl- 
N-acetyl B-D-glucosaminide (3mM)« The reaction mixture was 
incubated for 60 min at 57°C and then stopped by boiling for 2-5 
min. The mixture was then diluted with 0.7ml glass-distilled 
water and centrifuged (9»000g» 20 sec.) to remove any remaining
cell fragments. A sample (100/i1) was added to 1.9ml glycine-NaOH
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buffer (50mM glycine in 39mM NaOH; pH 10.4). Fluorescence was 
monitored in a Perkin-Elmer LS3 Fluorescence Spectrometer using 
excitation and emission wavelengths of 370 and 450nm respectively.
(c) Lysozyme Measurement.
Lysozyme was determined as the rate of lysis of the bacterium 
Micrococcus lysodeikticus. The rate at which the bacterial 
suspension (substrate) clears is thus a measure of the lysozyme 
content within a sample. An aliquot (2C)ul) of sample was added to 
1ml of substrate and the decrease in absorbance at 550nm was 
determined in a Shimadzu recording spectrophotometer. The change 
in absorbance was determined between 1-3 ^in of the reaction at a 
constant temperature of 25°C.
The cell pellets, in both enzyme assays, were digested with
0.2% Triton X-100 and the results were expressed as a percentage of 
the total enzyme activity.
7. LTB4 MEASUREMENT.
(a) Sample generation.
7
Neutrophil suspensions(0.6ml of 1 x 10 cells/ml) in buffer A, in 
the presence or absence of cytochalasin B (^ug/ml; 10 min) were 
challenged with agonist for 10 min. The reactions were terminated 
by addition of 10% stopping "cocktail" (buffer E) and immediately 
centrifuged (9»000g; 2 min) to remove any cell fragments. The 
samples were stored at “20°C prior to assay for LTB4 by specific 
radioimmunoassay (RIA) or for authentication by reverse phase 
HPLC.
(b) Radioimmunoassay.
The LTB4 concentration was estimated by RIA essentially as 
described by Carey & Forder, (1986). Authentic LTB4 standard
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concentrations (0.1-10ng/ml) were prepared in buffer D. To each 
assay tube was added 20Qul of 1/1000 dilution (in 0.1% bovine 
gamma globulin, d) of anti-LTB^ antiserum (raised in New Zealand 
white rabbits) and 10Qful of 1/666 dilution of [^hJ-LTB^ (approximately 
2000cpm/sample). Samples (lOQul) or standard (lOQul) were mixed
and incubated for 18-24 hours at 4°C. After the incubation period, 
20QwI of dextran-coated charcoal (0.5% w/v dextran T70 and 1% w/v 
charcoal in buffer D) was added. The samples were mixed and the 
charcoal sedimented by centrifugation (2,000g; 15 min; 4°C).
Aliquots (45Qul) of the supernatant were taken to assess antibody 
bound ^hJ-LTB^ which was counted (1 min) in an LKB Wallac 1218 
Rackbeta scintillation counter. The results were processed and 
the standard calibration curves in each experiment were plotted as 
radioactivity bound (cpm) against LTB4 (pg/lOQul)(Figure 14) using 
an IBM personal computer.
(c) Reverse phase HPLC
Extraction Procedure.
In order to remove contaminants from the samples (1ml of
7
10 cells/ml) they were purified by extraction through Bond Elut 
1ml C-j0 mini-extraction columns. The solvent/sample addition was 
gently forced through the columns by vacuum suction. The 
extraction procedure is summarised as follows:
a) 1ml ethylacetate (100%)
■> discard eluate
b) 1ml methanol (100%)
>  discard eluate
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c) 1ml methanol (1%)
NK
d) 0.5ml sample mixed with 
0#125ml citric acid (1%)
e) 1ml methanol (1%)
f) 2 x 0.5ml methylformate
discard eluate
discard eluate
discard eluate
collect eluate
The collected extract was dried under N2 and reconstituted in 
methanol (60%) and stored overnight in a glass vial at -20°C. The 
vial was placed in a WISP prior to HPLC separation.
HPLC Separation.
An internal standard containing a mixture of cold LTB4, Ph]-LTB4 , 
[3h]-5HETE, arachidonic acid andj^&|-LTB4 metabolites or test sample 
were eluted using a gradient from 60% to 95% methanol at a flow rate 
of 1.5ml/min on a Spherisorb 25cm x 4*9cm column.
The internal standard (8Qul) was applied to the column and a 
total of 60 fractions, one every 0.5 rain, were collected for liquid 
scintillation counting. This procedure was repeated for 20Qul of 
test sample and the resultant separation identified by Ultraviolet 
detection and by comigration with the authentic standards. The 
collected fractions were evaporated to dryness using a Savant Aquavac
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and redissolved in 0.5ml buffer D and volumes removed for 
quantitative analysis by RIA.
8* p h o s p h o l i p i d STUDIES.
(a) Measurement of p^pj-PtdA and [^p]-PtdIns
n
Neutrophils (5 x 10 cells/ml) suspended in a phosphate free 
buffer B were incubated (37°C, 90 min) with carrier-free M -  
orthophosphate (3Qu.Ci/ml) and 0.025% bovine serum albumin.
n
Neutrophils were then pelleted and resuspended (2.5 x 10 cells/ml) 
in fresh albumin free buffer and 0.4ml aliquots were dispensed into 
plastic tubes at 37°C. The cells were allowed to equilibrate for 
10 min before being challenged with an agonist. At'the appropriate 
time, reactions were terminated and lipids extracted essentially by 
method B of Lloyd et al., (1972).
Briefly, the neutrophil sample was transferred into a glass 
test-tube containing 2ml of chloroformjraethanol:10N HCl (25:50:4» 
v/v/v) at room temperature. Neutrophil lipids were extracted by 
partitioning of the aqueous and organic phases following the addition 
of 625jul chloroform and 62'yal water, vortexing and then centrifuging 
at 1,000g for 3-5 min. The lower organic phase was removed into a 
glass vial, dried at 40°C under N2 using a Techne Dri-Block, and 
stored at -20°C until use.
The lipids were redissolved in 10Qul of chloroform/methanol 
9:1 v/v) and spotted on silica-gel t.l.c. plates (10cm x 10cm) for 
two dimensional separation of phospholipids (Yavin & Zutra, 1977) - 
This t.l.c. system employs three basic solvents; in the first 
dimension- chloroform:methanol:40% aqueous methylamine (13:6:1.5»
v/v/v) and in the second dimension- diethylether:glacial acetic 
acid (19s1» v/v) and chlorofoiro:acetone:methanol:glacial acetic 
acidswater (10j4:2:3:1, v/v/v/v/v ). Phospholipid samples were 
applied to the lower left hand comer of the t.l.c. plates, using 
a 10ml disposable micropipette. They were then placed in pre­
equilibrated chromatographic chambers containing Whatman I filter 
paper at both ends. The solvent front was allowed to run to 
within 1cm from the edge of the plate; they were then removed 
and dried in warm air. Each plate was then exposed to concentrated 
HCl fumes followed by sequential drying in warm and cool air. The 
plates were then placed in the second solvent running in the second 
dimension (origin at the lower right comer). Following this, the 
plates were removed, dried in cool air and placed in the third 
solvent in the same dimension as the second solvent. After the 
solvent front had run to 1cm from the edge of the plates, they were 
dried thoroughly in a stream of cool air. The major phospholipids 
separated by this method are shown in figure 15* Individual spots 
were detected visually by exposure to I2 vapour for 5 min and/or 
by autoradiography on X-Omat S X-ray film (Kodak) for 16-24 hours. 
Spots corresponding to Ptdlns and PtdA were identified by 
comparison with reference standards, scraped into vials and 
counted for radioactivity in a liquid-scintillation spectrometer.
(b) Measurement of [^p]-PIP and [^p]-PIP2
Neutrophils (5 x 10 cells/ml) suspended in phosphate-free 
buffer B with 0.025% bovine serum albumin were incubated (37°C;
45 min) with carrier-free [^p]-orthophosphate (3QiiCi/ml). In 
order to enhance the possibility of observing agonist-induced 
changes in PIP and PIP2 it was necessary to prevent the specific 
activity of the phosphoinositides from increasing. This was 
achieved by adopting a pulse chase protocol, in which the ^  pJ-
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(i)
Chloroform 
Methanol 
40% Methylamine 
(13:6:1.5 v /v /v )
(2) Diethyl Ether (3) Chloroform 
Acetic Acid Acetone
(19:1 v /v ) Methanol
Acetic Acid
Water
(10:4:2:3:1 v / v / v /v /v )
Figure 15.
Diagrammatic representation of phospholipid separation by two- 
dimensional thin layer chromatography by method of Yavin and 
Zutra (1977TT
Phospholipids identified by iodine staining are indicated and the 
hatched spots represent those phospholipids which are significantly 
labelled following preincubation with [ *^]-orthophosphate. 
0-origin; Pl-phosphatidylinositol; PS-phosphatidylserine; 
PA-phosphatidic acid; LPE-lyso phosphatidylethanolamine; 
SPM-sphingomyelin; PC-phosphatidylcholine; 
PE-phosphatidylethanolamine; P-LPE-plasmalogen lyso 
phosphatidylethanolamine; NL-neutral lipids.
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labelled cells were pelleted by centrifugation (850g; 3 min; 20°c),
resuspended in fresh buffer B containing KH2PO4 (100jiM) and incubated 
for 45 min at 37°C. This had the effect of ’chasing* the label from 
the ATP pool, effectively diminishing the specific activity of 
neutrophil j^*p]-ATP, with a resultant decrease in specific activity 
of Ptdlns (Pollock et al., 1984).
The cells were then pelleted and resuspended (2,5 x 10 cells/ml) 
in fresh, albumin-free, buffer B and 0.4ml aliquots were dispersed 
and allowed to equilibrate for 10 min before being challenged with 
agonists. At the appropriate time the reactions were terminated 
by transferring the entire sample to 1.2ml of chloroformjmethanol 
(1:2, v/v) and thoroughly vortexed. The phospholipids were 
extracted by the addition of 2.4 N HC1 (0.4ml) and chloroform (0.4ml) 
and then vortexed. The sample was partitioned into two distinct 
phases separated by a cell fragment interface by centrifugation 
(l,000g; 3 min). The lower organic phase was removed and stored 
at 4°C. The remaining aqueous phase was washed by mixing with 
chloroform (0.8ml) and centrifuged (l,000g; 3 min) to separate the
phases. The aqueous phase was discarded and the two organic phases 
combined. The organic phases were washed by addition of 1.6ml 
methanol:1 N HC1 (1:1)» centrifuged (l,000g; 3 min), and the lower 
phase removed, dried at 40°C under N2 and stored at -20°C (Schacht,
1981).
The phospholipids were resuspended in 100ul of chloroform: 
methanol:water (75s25:2, v/v/v) and spotted as 1.5cm bands (1.5cm 
from the bottom edge) on high perfonnance t.l.c. plates for one 
dimensional separation of Ptdlns, PIP and PIP2 (Jolles et al., 1981). 
Prior to spotting, the plates were impregnated with potassium oxalate 
(1% in methanol:water; 2:3, v/v) and ’activated' by placing in an
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Figure 16.
Diagrammatic representation of phospholipid separation by 
one-dimensional thin layer chromatography by method of Jolles 
et al. (1981).
Phospholipids identified by iodine staining are indicated.
0 -origin; PIP2 -phosphatidylinositol-4#5 bisphosphate, PIP 
-phosphatidylinositol-4 phosphate; Ptdlns -phosphatidylinositol; PtdA 
-phosphatidic acid; NL -neutral lipids; SF -solvent front.
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oven for 15 min at 110°C« The plates were developed in chloroform: 
acetone:methanol:glacial acetic acid:water (40:15*13*12:8, v/v/v/v/v) 
until the solvent front had reached 1cm from the top.
The individual phospholipids were visualised by iodine staining 
and autoradiography (figure 16) and identified by comparison with 
reference standards. Spots corresponding to the relevant phospho­
lipids were scraped into vials and counted for radioactivity in a 
liquid scintillation counter.
9. [ca2*] i MEASUREMENT.
Neutrophil ^Ca2+]i was monitored using the fluorescent
2+quinoline dye, quin2, which displays high affinity for Ca and
2+
undergoes fluorescent changes as a result of Ca binding (Tsien
D
et al., 1982a; Rink & Pozzan, 1985)* Neutrophils (10 cells/ml) 
in buffer A were incubated (37°C; 10 min) with quin2 acetoxymethyl
ester (lOQuM final concentration), which is membrane permeant and 
crosses the plasma membrane where it is rapidly hydrolysed by 
cytosolic esterases to form the hydrophilic polycarboxylate anion 
that is quin2. Samples were then diluted ten fold with thermally 
equilibrated buffer and incubated for a further 20 min at 37°C.
At the end of the incubation period the cells were centrifuged 
(850g: 3 min) to remove extraneous dye and resuspended in the buffer 
at 10^cell/ml (White et al., 1983b). Quin2 is thus trapped within 
the cytosol of the neutrophil and consequently the resting [ca2+Ji 
and the changes in £ca2+Ji which result from exposure to agonists 
can be determined. Neutrophils (2ml) were placed in 1cm square 
quartz cuvettes and changes in fluorescence were monitored in a 
Perkin LS3 Fluorescence Spectrometer at 37°C with standard mono­
chromator settings of excitation at 339nm and emission at 492nm.
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The [ca2*]* was calculated according to the following equation:
[ca^+Ji = Kd x (F - Enin)
(Emax - F)
Where Kd represents the apparent dissociation constant of quin2
for calcium (Kd=115nM under these conditions); F is the fluorescence
signal in arbitrary units and Enax and Enin are fluorescence at very
high and low calcium respectively (Tsien et al., 1982 a; b). Enax was
obtained by the addition of 5Q«M digitonin to lyse the cell and
2+expose all of the quin2 to the extracellular Ca and to liberated 
2+intracellular Ca and Enin was obtained by the later- addition of
2+
EGTA (20mM) to chelate all of the Ca (Rink & Pozzan, 1985).
1°. QUANTIFICATION OF RADIOACTIVITY.
All radioactive samples to be analysed were added to 5-10ml of 
either Scintillator-299 (Packard) or Ecoscint (National Diagnostics) 
in polythene vials and counted (1-5 min) for their radioactive 
content in a liquid scintillation counter (Packard Tri Carb or an 
LKB Wallac 1218 Rackbeta).
11. CALCULATION OF RESULTS.
Results are expressed as mean values + standard error of mean 
(SM) where individual points in each experiment were normally 
performed in triplicate. Data were compared statistically using the 
student's t-test and only values of probability (P) which were less 
than 0.05 were taken to indicate significance. The precise level of 
significance is indicated at each experiment where probability (P) 
values * = P <  0.05; ** = P<0.01; *** = P < 0.001.
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In the phospholipid experiments; vehicle controls were carried 
out at the beginning and the end of each experiment and the test 
values were expressed as the percentage of these controls.
The term EC^q represents the concentration of agonist that 
elicits 50% of the maximum response of that agonist. The term 
IC50 represents the concentration of antagonist (inhibitor) that 
inhibits the response to an agonist by 50%* Both parameters were 
calculated by extrapolation from either the stimulatory or the 
inhibitory concentration response curves.
12. MATERIALS.
(a) Drugs and Reagents.
The drugs and reagents used in the course of this project are 
listed below and the sources indicated. Unless otherwise stated, 
all drugs were dissolved in glass-distilled water with subsequent 
dilutions in 0.9% saline.
LeukotrieneB4 (LTB4) was synthesised by Dr. Y. K. Yee (Stuart 
Pharmaceuticals, Division of ICI Americas, Wilmington, Delaware, 
U.S.A.) and dissolved in methanol.
The stock (l.8mM) platelet-activating factor (PAP, Bachem, 
Babbendorf, Switzerland) was dissolved in iso-osmotic saline 
containing bovine serum albumin (0.25%). Subsequent dilutions of 
this stock were made up in saline.
Eormylmethionylleucylphenylalanine (IMLP, Sigma U.K.) was 
dissolved in dimethylsulphoxide (IMSO, Sigma).
Quin2-acetoxymethylester (quin2-AM) was obtained from Lancaster 
Synthesis (Morecambe, England) and was dissolved in LMSO.
Lysozyme Reagent Set was purchased from Worthington Diagnostics,
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Freehold, New Jersey, U.S.A.
Ionomycin, purchased from Calbiochem, U.K., was initially 
dissolved in DMSO.
Phorbol myristate acetate dissolved in DMSO, cytochalasin B 
dissolved in IMSO, Bovine gamma globulins, Bovine serum albumin, 
HEPES, EDTA, EGTA, gelatin, TritonX-100, glutaraldehyde, sodium 
cacodylate, osmium tetroxide, indomethacin dissolved in UMSO, 
nordihydroguaiaretic acid, NDGA dissolved in DMSO; were all 
purchased from Sigma, U.K.
Pertussis toxin was a generous gift from Dr. Rodger Parton, 
Department Microbiology, Glasgow University.
LTB^-antisera was prepared by Mr. R. Forder (ICI, U.K.)
Kadsurenone (2-(3,4-dimethoxyphenyl)-2,3-dihydro-3a-methoxy- 
3-methyl-5-(allyl)-6-2H-oxobenzofuran) was purchased from Merck, 
Sharpe & Dohme, New Jersey, U.S.A. and was dissolved in DMSO.
Revlon 5901 («< -pentyl-3-(2-quinolinylmethoxy)-benzene-methanol) 
was purchased from Revlon Health Care Group, New York, U.S.A. and 
dissolved in DMSO.
AA861 (2-(l2-hydroxydodeca-5*10-dinyl)-3»5»6-trimethyl-1,4- 
benzoquinone), BW755C (3-amino-i- m-trifluoromethyl)-phenyl -2- 
pyrazoline HCl) and Nafazatrom (2,4-dihydro-5-methyl-2- 2- 
(napthyloxy ethyl-3H-pyrazol-3-one) were synthesized in the 
Chemistry Department at ICI Pharmaceuticals Divisions, U.K. (all 
dissolved in IMSO).
(b) Phospholipid Standards.
Phosphatidic acid (Sigma) was dissolved in chlorofoimimethanol 
(2s1), phosphatidylinositol (sigma), phosphatidylinositol 4 phosphate 
(Sigma) and phosphatidylinositol 4*5 bisphosphate (Sigma) were 
dissolved in chloroformjmethanol (1s1) and phosphatidylcholine
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(Sigma) vas dissolved in chloroform,
(c) T.L.C, Plates,
Merck Silica Gel 60' high performance t.l.c. plates (1Gc* x 20cm) 
and Mecherey-Hagel precoated t.l.c. plates SIL G-25 (20ca x 20c*) were 
purchased from MaeEarlane Robson Ltd., Glasgow. The latter were cut 
into 4 smaller plates (10cm x 10cm) prior to use,
(d) Badiochemicals.
Carrier—free orthophosphate was provided by the Regional
Isotopes Bispensary (Western Infirmary, Glasgow),
[ % ] - L T ^ t p n ] —583ffi!fS and [1^c]-aiachidonic acid were purchased f x m  
Amersham totenoational and p^-LTB^ metabolites were prepared by Br.
1. M. McMillan (ICX, Ehgland),
RESULTS AND DISCUSSION
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CHAPTER 5: AGONIST-INDUCED HUMAN NEUTROPHIL ACTIVATION.
1. Electron Microscopy Studies.
The general morphology of the unstimulated human neutrophil is 
described in Chapter 1. They are usually rounded, with little plasma 
membrane ruffling and with the occasional extrusion of fine projections 
which may or may not make cell to cell contact (figures 1 and 17a). 
Exposure of neutrophils to a variety of stimuli produce a number of 
cellular and biochemical responses which can vary depending on the 
type of agonist used. In this investigation I compared the 
morphological changes produced by the arachidonic acid metabolite,
LTB4; the ether lipid, PAP; and the chemotactic tripeptide, IMLP, 
using transmission electron microscopy.
1.1. Effect of LTB4
Ultrastructural changes consistent with migrating activity 
(Schiffmann & Gallin, 1979) were observed after exposure of the cells 
to LTB4 . Unlike that seen in control preparations, after 10 seconds 
exposure to LTB4 (30nM), there was marked plasma membrane ruffling 
affecting the whole surface with a strongly crenated or stellate 
profile (figure 17b)« ?y 30 seconds the cells had become polarized 
with the foimation of large lamellipodium (figure 18a) or in many 
cases knob-like, frilly uropodia or ,ftails" could be seen, which 
persisted for at least 5 minutes. These structures contained skeins 
of microfilaments and clusters of ribosomes but from which granules 
were excluded. No microtubules were detected in this area of the 
cell.
Stirring of the cells in the presence of an appropriate agonist
Figure 17.
(a) Control suspension of neutrophils. Generally rounded with 
smooth contours and the occasional extension of fine projections 
(EM x 3,800).
(b) Unstirred neutrophils exposed to LTB4 (30nM) for 10 seconds 
showing marked plasma membrane ruffling over their entire surface 
(EM x 3,800).
ab
Figure 18,
(a) Unstirred neutrophils exposed to LTB4 (30nM) for 30 seconds 
showing well developed lamellipodia (EM x 2,850).
(b) Aggregated neutrophils after 25 seconds exposure to LTB4 
(30nMT^in stirred suspensions, with well developed lamellipodia. 
Sub-plasmalemmal microfilaments can be observed (arrows) (EM
^ 8,750).
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causes cell to cell contact and aggregation. Figure 18b shows 
the effect of LTB4 (30nM) at 30 seconds at which time the cells had 
aggregated into small clumps. Many of the neutrophils within the 
aggregate were polarized with the foimation of a large, agranular 
lamellipodium extending outward from the aggregate. Plasma membranes 
were often closely aligned and bands of microfilaments could be seen 
parallel to, and just subjacent to, the cell surface, especially 
where the contours were smooth and round. In all cases individual 
cells could be distinguished; cell fusion had not occurred.
1.2. Effect of PAF
A similar ultrastructural profile was observed when PAF was 
examined. By 10 seconds (figure 19a) there was a generalised 
plasma membrane ruffling and by 30 seconds (figure 19b) the polar­
ization of the cell and extension of the lamellipodium had occurred 
on exposure to 180nM PAF.
1.3. Effect of FMLP
The chemotactic tripeptide was not dissimilar to LTB4 or PAF.
In the presence of 100nM IMLP the neutrophils looked extremely 
"agitated" with pronounced membrane ruffling by 10 seconds (figure 
20a) and the characteristic polarization and lamellipodium formation 
was evident by 30 seconds (figure 20b).
1.4* Effect of Cytochalasin B
The fungal metabolite, cytochalasin B, is extensively used as a 
pharmacological agent to promote overt secretion of granular contents 
thereby rendering the contents detectable in the external medium (see
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Figure 19.
(a) Unstirred neutrophils exposed to PAF (l80nM) for 10 seconds 
showing marked plasma membrane ruffling over their entire surface
( m  x 4 ,3 7 5).
(b) Unstirred neutrophils exposed to PAF (l80nM) for 30 seconds 
showing well developed lamellipodia (EM x 6 ,1 2 5).
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Figure 20.
(a) Unstirred neutrophils exposed to M L P  (lOOnM) for 10 seconds 
showing marked plasma membrane ruffling over their entire surface 
(EM x 4,375).
(b) Unstirred neutrophils exposed to JMLP (lOOnM) for 30 seconds 
showing well developed lamellipodia (EM x 6,125).
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Chapter 1). However, caution must be taken when using this agent 
because it produces many other biochemical and physical effects 
within the cell. Pretreatment of human neutrophil suspensions with 
5Mg/ml for 10 min cytochalasin B produced dramatic alterations in 
cell ultrastructure (figure 21). The cells did not appear 
activated since no membrane ruffling was evident however there were 
large vacuoles present in the cytoplasm not usually found in 
untreated control cells. Addition of the agonists after cytochalasin 
B pretreatment (^g/ml; 10 min) resulted in the loss of the cell's
spherical appearance exhibiting marked blebbing and forming 
grotesque profiles. Figure 22 shows the effect of’l80nM PAF (a) 
and 100nM M L P  (b) after 60 seconds in the presence of cytochalasin 
B. There was little polarization of the granules and they were not 
restricted to the inner regions of the cell but were present in the 
blebs and extrusions. Marked vacuolation was still evident 
especially beneath the uropod which frequently showed bleb formation 
with or without the presence of granules. The formation of clumps 
was not especially evident in the electron microscope, although 
some instances of cell to cell contact were observed.
2. Agonist-induced neutrophil aggregation.
Suspensions of stirred human neutrophils when exposed to a 
variety of stimuli become adhesive and foim cell-cell aggregates 
(O'Flaherty et al., 1979; Ford-Hutchinson, 1983* Rossi et al., 
1987b). Such neutrophil aggregation can be monitored as changes 
in light transmission through a stirred suspension of neutrophils 
using a standard platelet aggregometer as described in Chapter 4*
The aim of this particular study was to investigate the nature and 
extent of the aggregatory response and to compare the cumulated
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Figure 21.
Neutrophils pretreated with cytochalasin B (^jig/ml; 10 minutes) 
showing cytoplasm containing many vacuoles (EM x 5»250).
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Figure 22.
(a) Neutrophils pretreated with cytochalasin B (5/ig/ml; 10 
minutes) followed by exposure of PAF (l80nM) for 60 seconds 
showing vacuolation and bleb formation (0! x 5>250).
(b) Neutrophils pretreated with cytochalasin B 10 
minutes) followed by exposure of FMLP (lOOnM) for 60 seconds 
showing vacuolation and bleb formation (01 x 5 >000)
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concentration-response curves induced by the various agonists*
2.1. Typical Aggregation Traces.
Aggregation traces induced by LTB^, PAF and IMLP are shown in 
figure 23. These receptor directed agonists all caused a 
concentration-dependent aggregation; the effects observed were rapid 
in onset, maximal within two minutes of agonist addition, and 
reversible.
Aggregation when monitored photometrically is quantified in 
arbitrary units of light transmission, consequently it is difficult 
to compare the extent of aggregation evoked by different agonists 
when tested in different experiments. However, when examined in the 
same experiment, the extent of aggregation induced by RiLP and PAF 
was similar whereas LTB4 was much less efficacious. Indeed it is 
not uncommon that the response elicited by LTB4 is even less than 
that shown in figure 23» the maximum response induced by LTB4 may 
only reach one-third or less than the responses elicited by PMLP and 
PAF.
When examining the aggregation traces induced by the phorbol 
ester, FMA, and the calcium ionophore, ionomycin, a different picture 
emerged (figure 24). Although the responses were concentration- 
dependent, they were irreversible, up to at least 10 min, and maximal 
aggregation was usually slower in onset, especially with lower 
concentrations of these stimuli, when compared to FMLP, PAF and
ltb4.
2.2. Concentration-Response Curves for Agonist-Induced Aggregation.
The next five figures show the cumulated concentration-response 
curves for the various agonists. IMLP induced aggregation in the
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Figure 23.
Aggregation traces induced by LTIfy, PAF & FMLP in human 
neutrophils.
0.6 ml samples of neutrophils (2.5 x 10 cells/ml) were added to a 
cuvette containing a teflon-coated stirring bar revolving at 600rpm. 
The cells were exposed to an agonist at the concentrations shown and 
the changes in light transmission recorded.
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Figure 24.
Aggregation traces induced by PMA & ionomycin in human 
neutrophils.
7
0.6ml samples of neutrophils (2.5 x 10 cells/ml) were added to a 
cuvette containing a teflon-coated stirring bar revolving at 600rpm. 
The cells were exposed to an agonist at the concentrations shown 
and the changes in light transmission recorded.
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concentration range of 0.1nM— "tyuM with an EC^q value, i.e. concentration 
producing 50% of the maximum response elicited by each particular 
agonist, of«; 50nM (figure 25)• Similarly, the other stimuli produced 
concentration-dependent aggregation; PAP in the range of 1nM-1QuM; 
estimated EC^o^ (figure 26), LTB4 in the range of 0.25nM-2.5;uM;
EC50 ~ 50nM (figure 27)» PMA in the range of 0.01nM-0.1/iM; EC^q^ 1nM 
(figure 28) and ionomycin in the range of 50nM-1QuM; EC^o^lA^
(figure 29).
An overall comparison for each agonist is shown in figure 50*
The rank order of potency of the five agonists in terms of induction 
of neutrophil aggregation is PMA> FMLP^LTB^> PAP^ionomycin.
5. Agonist-induced neutrophil degranulation.
In order for neutrophils to efficiently perform their function of 
destroying invading organisms and digestion of particulate matter, they 
have to be capable of releasing their battery of stored enzymes into 
the phagocytic vacuole or into the surrounding medium (Weissmann ,
1982; Baggiolini & Dewald, 1985). The release of two enzymes was 
examined; B-N acetyl-glucosaminidase (NAG), found in the azurophil 
granules, and lysozyme located in the azurophil and specific granules.
5.1. Requirement of Cytochalasin B
Initial studies were performed to examine the dependence of each 
agonist, to release both enzymes, in the presence or absence of 
cytochalasin B. Neutrophils were pretreated, for 10 minutes, with 
either 5jig/nil cytochalasin B or with BMS0 (vehicle) and then challenged
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Figure 25•
Concentration-response relationship for EMLP-induced aggregation 
of human neutrophils.
0.6ml samples of neutrophils (2.5 x 10 cells/ml) were added to a 
cuvette containing a teflon-coated stirring bar revolving at 600rpm 
The cells were exposed to TMLP at the concentrations shown and the 
changes in light transmission recorded. The results are expressed 
as a percentage of the maximum response and are mean values + SEW 
for six experiments, each performed in triplicate.
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Figure 26.
Concentration-response relationship for PAF-induced aggregation 
of human neutrophils.
0.6ml samples of neutrophils (2.5 x 10^cells/ml) were added to a 
cuvette containing a teflon-coated stirring bar revolving at 600rpm. 
The cells were exposed to PAF at the concentrations shown and the 
changes in light transmission recorded. The results are expressed 
as a percentage of the maximum response and are mean values ± SEM 
for three experiments, each performed in triplicate.
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Figure 27.
Concentration-response relationship for LTB/i-induced 
aggregation of human neutrophils.
y
0.6ml samples of neutrophils (2.5 x 10 cells/ml) were added to a 
cuvette containing a teflon-coated stirring bar revolving at 600rpm. 
The cells were exposed to LTB4 at the concentrations shown and 
the changes in light transmission recorded. The results are 
expressed as a percentage of the maximum response and are mean 
values ± S01 for three experiments, each performed in triplicate.
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Figure 28.
Concentration-response relationship for PMA-induced aggregation 
of human neutrophils.
n
0.6ml samples of neutrophils (2.5 x 10 cells/ml) were added to a 
cuvette containing a teflon-coated stirring bar revolving at 600rpm 
The cells were exposed to PMA at the concentrations shown and the 
changes in light transmission recorded. The results are expressed 
as a percentage of the maximum response and are mean values + SEM 
for four experiments, each performed in triplicate.
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Figure 29.
Concentration-response relationship for ionomycin-induced aggregation 
of human neutrophils.
7
0.6ml samples of neutrophils (2.5 x 10 cells/ml) were added to a 
cuvette containing a teflon-coated stirring bar revolving at 600rpm.
The cells were exposed to ionomycin at the concentrations shown and 
the changes in light transmission recorded. The results are expressed 
as a percentage of the maximum response and are mean values + SEM for 
five experiments, each performed in triplicate. ”
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Figure 30.
Cumulated concentration-response curves for agoni3t-induced 
aggregation of human neutrophils.
n
0.6ml samples of neutrophils (2.5 x 10 cells/ml) were added to a 
cuvette containing a teflon-coated stirring bar revolving at 600rpm. 
The cells were exposed to the agonists at the concentrations shown 
and the changes in light transmission recorded. The results are 
expressed as a percentage of the maximum response and are mean 
values + SEM for between three and six experiments, each performed 
in triplicate.
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with high concentrations of agonists for a further 10 minutes and the 
enzyme release determined.
Figure 31 shows the effect of cytochalasin B on agonist-induced 
NAG release expressed as a percentage of the total enzyme content.
The histogram clearly shows that cytochalasin B alone produces no 
significant release of NAG and that IMLP, PAF, LTB4 and PMA all require 
the presence of cytochalasin B to release this enzyme into the external 
milieu. The calcium ionophore could release NAG both in the presence 
and absence of this compound.
The effect of cytochalasin B on agonist induced release of 
lysozyme is depicted by the histogram in figure 32. Again FMLP, PAF 
and LTB4 require the presence of cytochalasin B, however PMA, as well 
as ionomycin, can release lysozyme in the absence of the fungal meta­
bolite.
3.2. Agonist-Induced Enzyme Release.
The next Istage of the investigations was to construct concentration- 
response curves for the release of both enzymes for all five agonists. 
Preincubation for 10 minutes with 5*ig/ml cytochalasin B was used for 
all subsequent measurements of enzyme release.
a) NAG Release.
The next five graphs show the concentration-response curves for 
agonist-induced release of NAG (expressed as a percentage of the total 
NAG content). NAG release induced by all agonists was within the 
approximate concentration range of 1nM-1Q;uM. PMLP (EC^o^ 50nM; figure 
33), PAF (EC5o~70nM; figure 34)» LTB4 (EC^o^ 50nM; figure 35), PMA 
(EC5QS*60nM; figure 36) and ionomycin (EC5Q ^ 500nM; figure 37) induced
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Figure 31•
The effect of cytochalasin B on agonist-induced NAG release from 
human neutrophils.
Neutrophils (1 x 10^cells/ml) were pretreated with cytochalasin B 
(5^/ml), or vehicle control, for 10 minutes. The neutrophils were 
then challenged with agonist for a further 10 minutes at the 
concentrations indicated and the release of NAG determined. The 
results are mean values + SEM for between three and four experiments, 
each performed in triplicate.
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Figure 32.
The effect of cytochalasin B on agonist-induced lysozyme release 
from human neutrophils.
Neutrophils (1 x 10^cells/ml) were pretreated with cytochalasin B 
(5/ig/ml), or vehicle control, for 1 0  minutes. The neutrophils were 
then challenged with agonist for a further 10 minutes at the 
concentrations indicated and the release of lysozyme determined. The 
results are mean values + SUM for between three and four experiments, 
each performed in triplicate.
119
2 5 -
20 -
4->
O
o
i  15
O)a:
1 0 -
5-
J
1—
0 10~10 1 0 " 9
T
10 °  10 
[FMLP] M
-7 “ l! ---10 b 10 b
Figure 33*
Concentration-response relationship for MLP-induced NAG release 
from human neutrophils.
n
0.6 ml samples of neutrophils (1 x 10 cells/ml) were pretreated, 
for 10 minutes, with cytochalasin B (5/ig/ml) and then challenged 
with FMLP for a further 10 minutes at the concentrations indicated 
and the release of NAG determined. The results are expressed as 
the percentage release of the total enzyme content and are mean 
values + SEM for five experiments, each performed in triplicate.
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Figure 34-
Concentration-response relationship for PAF-induced NAG release 
from human neutrophils.
0.6ml samples of neutrophils (1 x 10 cells/ml) were pretreated, 
for 10 minutes, with cytochalasin B (^Lig/ml) and then challenged 
with PAF for a further 10 minutes at the concentrations indicated 
and the release of NAG detezmined. The results are expressed as 
the percentage release of the total enzyme content and are mean 
values + SEM for six experiments, each performed in triplicate.
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Figure 35*
Concentration-response relationship for LTB^-induced NAG release 
from human neutrophils.
7
0.6ml samples of neutrophils (1 x 10 cells/ml) were pretreated, 
for 10 minutes, with cytochalasin B (^ig/ml) and then challenged 
with LTB4 for a further 10 minutes at the concentrations indicated 
and the release of NAG determined. The results are expressed as 
the percentage release of the total enzyme content and are mean'values 
+ S M  for four experiments, each performed in triplicate.
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Figure 36.
Concentration-response relationship for PMA-induced NAG release 
from human neutrophils.
n
0.6 ml samples of neutrophils (1 x 10 cells/ml) were pretreated, 
for 10 minutes, with cytochalasin B (^ug/ml) and then challenged 
with PMA for a further 10 minutes at the concentrations indicated 
and the release of NAG determined. The results are expressed as 
the percentage release of the total enzyme content and are mean 
values + SEM for four experiments, each performed in triplicate.
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Figure 37.
Concentration-response relationship for ionomycin-induced NAG 
release from human neutrophils.
1
0.6ml samples of neutrophils (1 x 10 cells/ml) were pretreated, 
for 10 minutes, with cytochalasin B (^/ug/ml) and then challenged 
with ionomycin for a further 10 minutes at the concentrations 
indicated and the release of NAG determined. The results are 
expressed as the percentage release of the total enzyme content 
and are mean values + SIM for between three and six experiments, 
each performed in triplicate.
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maximal release (basal subtracted) of approximately 20%, 14%, 11%, 7% 
and 37% respectively.
b) Lysozyme Release.
The concentration-response curves for agonist-induced lysozyme 
release (expressed as a percentage of the total lysozyme content) are 
shown in the five following figures. Again the agonists stimulated 
lysozyme release within the approximate concentration range of 1nM- 
1QuM. M L P  (EC5o ~ 50nM; figure 38), PAF (EC^SOnM; figure 39), 
LTB4 (EC50^ 30^ ;  figure 40), PMA (EC5q ~ 90nM; figure 41) and iono­
mycin (EC50^ 400nM; figure 4 2) induced maximal release (basal sub­
tracted) of approximately 30%, 20%, 18%, 16% and 55% respectively.
4« Agonist-Induced LTB4 Generation.
When human neutrophils become activated they have the capacity to 
hydrolyse membrane phospholipids by a number of enzymatic pathways to 
mobilise arachidonic acid; the precursor for the biosynthesis of 
leukotrienes, including LTB4 (O'Flaherty, 1987)* Most previous 
studies have examined the effects of the calcium ionophore, A23187, 
on LTB4 biosynthesis in polymorphonuclear leucocytes. Reports on 
LTB4 formation in response to more physiological stimuli, e.g. C5a, 
MLP, PAF and immune complexes, are fewer, often conflicting, and 
the levels of LTB4 produced are much lower than those produced by the 
calcium ionophore (Ham et al., 1983; Palmer & Salmon, 1983, McMillan 
et al., 1985? Haines et al., 1987)*
4.1. Measurement by Specific Radioimmunoassay (RIA).
The aim of the following experiments was to examine and compare 
agonist-induced generation of LTB4 , monitored by specific RIA.
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Figure 38.
Concentration-response relationship for IfrlLP-induced lysozyme 
release from human neutrophils.
n
0.6ml samples of neutrophils (1 x 10 cells/ml) were pretreated, 
for 10 minutes, with cytochalasin B (^ug/ml) and then challenged 
with M L P  for a further 10 minutes at the concentrations indicated 
and the release of lysozyme determined. The results are expressed 
as the percentage release of the total enzyme content and are mean 
values + SEM for five experiments, each performed in triplicate.
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Figure 39•
Concentration--response relationship for PAF-induced lysozyme 
release from human neutrophils.
n
0 .6ml samples of neutrophils (1 x 10 cells/ml) were pretreated, 
for 10 minutes, with cytochalasin B (^ug/ml) and then challenged 
with PAF for a further 10 minutes at the concentrations indicated 
and the release of lysozyme determined. The results are expressed 
as the percentage release of the total enzyme content and are mean 
values + SEM for six experiments, each performed in triplicate.
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Figure 40*
Concentration-response relationship for LTB^induced lysozyme 
release from human neutrophils.
n
0.6ml samples of neutrophils (1 x 10 cells/ml) were pretreated, 
for 10 minutes, with cytochalasin B (^|ug/ml) and then challenged 
with LTB4 for a further 10 minutes at the concentrations indicated 
and the release of lysozyme determined. The results are 
expressed as the percentage release of the total enzyme content 
and are mean values + SEU for four experiments, each performed 
in triplicate. ”
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Figure 41 •
Concentration-response relationship for PMA-induced lysozyme 
release from human neutrophils.
7
0.6ml samples of neutrophils (1 x 10 cells/ml) were pretreated, 
for 10 minutes, with cytochalasin B (^ug/ml) and then challenged 
with PMA for a further *10 minutes at the concentrations indicated 
and the release of lysozyme determined. The results are expressed 
as the percentage release of the total enzyme content and are mean 
values + SIM for four experiments, each performed in triplicate.
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Figure 42.
Concentration-response relationship for ionomycin-induced lysozyme 
release from human neutrophils.
7
0.6ml samples of neutrophils (1 x 10 cells/ml) were pretreated, 
for 10 minutes, with cytochalasin B (5/ig/ml) and then challenged 
with ionomycin for a further 10 minutes at the concentrations 
indicated and the release of lysozyme determined. The results- 
are expressed as the percentage release of the total enzyme content 
and are mean values + SEM for between three and six experiments, 
each performed in triplicate.
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Initially, I examined the effect of ionomycin (figure 43) on LTB4 
generation; neutrophils were challenged with the calcium ionophore 
for 10 minutes, the reaction stopped and the levels of LTB4 determined. 
The 10 minute time point was chosen since preliminary time course 
experiments established that at this time LTB4 formation was maximal. 
Ionomycin induced a concentration-dependent generation of LTB4 with 
an EC50 value of approximately 30nM. Maximal levels of LTB4 were 
produced at concentrations of ionomycin above 100nM, reaching values 
of between 50-70ng/l0^cells.
The effects of FMLP and PAF on LTB4 generation were next 
examined (figure 44)* Both receptor directed agonists evoked 
significant production of LTB4 at high concentrations. However, in
comparison to ionomycin, the extents of LTB4 formation were greatly
n
reduced. Maximal levels produced by FMLP at 10/zM were 3«5ng/lO
n
cells and PAF at 18uM was only just significant at lng/10 cells. No 
significant production of LTB4 was produced by the phorbol ester,
PMA (data not shown).
4*2. Authentication of Immuno-reactive LTB4 by Reverse Phase HPLC.
When determining LTB4 levels by RIA, it is best to check the 
authenticity of the stimulated LTB4 by making sure that there is no 
cross-reactivity with other possible arachidonic acid derived 
products. The internal standard after separation by reverse phase 
HPLC and collection of fractions at various time points showed four 
major peaks occurring at elution times of 6.5» 15» 19*5 and. 23 
minutes corresponding to LTB4 metabolites, LTB4 , 5HETE and 
arachidonic acid respectively (figure 45? upper panel).
An ionomycin (1uM) stimulated test sample was processed by HPLC 
and the fractions collected at all time points. When the fractions
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Figure 43*
Concentration-response relationship for ionomycin-induced 
LTB4 generation by human neutrophils,
0 ,6ml samples of neutrophils (1 x 10 cells/ml) were pretreated 
for 10 minutes with cytochalasin B (5jug/ml) and then challenged 
with ionomycin for a further 10 minutes at the concentrations 
indicated and the production of LTB4 determined. The results
are expressed as the amount of LTB4 produced (ng/ml) above 
basal and are mean values + SEM for between three and five 
experiments, each performe3 in triplicate. Analysis of data: 
* P < 0,05; ***P < 0 .001.
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Figure 44*
Concentration-response relationship for agonist-induced LTB4 
generation by human neutrophils.
0.6ml samples of neutrophils (1 x 10 cells/ml) were pretreated 
for 10 minutes with cytochalasin B (5M£/ml) then challenged 
with an agonist for a further 10 minutes at the concentrations 
indicated and the production of LTB4 determined. The results 
are expressed as the amount of LTB4 produced (ng/ml) above basal 
and are mean values + SEM for between three and five experiments, 
each performed in triplicate. Analysis of data: *P 0.05}
***P <  0.001.
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Figure 45*
Authentication of Immuno-reactive LTB4 by Reverse Phase HPLC.
The upper panel shows radiolabelled internal standard, following 
fractionation using reverse phase HPLC and liquid scintillation 
counting.
The lower panel shows the I/TBa immuno-reactivity of a fractionated 
human neutrophil sample stimulated with ionomycin (ljuM) for 10 minutes.
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(60 in total) were tested with RIA only one fraction, which eluted 
after 15 minutes, had significant immuno-reactivity. This fraction 
co-chromatographs with authentic LTB4, suggesting that the eicosanoid 
generated by the ionophore is indeed LTB4 (figure 45; lower panel).
5. Agonist-Induced Changes in [ca2+Ji.
I next examined the correlation between agonist-induced 
aggregation and degranulation with changes in cytosolic-free calcium 
in quin2-loaded cells. When certain agonists are added to neutro­
phils preincubated with quin2 they elicit a concentration-dependent 
increase in fluorescence which can be calibrated to report £ca2+Ji 
and increases in [ca^+Ji (White et al«, 1983b; Westwick & Poll, 1986).
5*1. Typical Fluorescence Records in Quin2-loaded Cells.
Recordings from a single experiment showing the effect of the 
receptor directed agonist are depicted in figure 48. The resting 
£ca^*Ji in human neutrophils is 155 + 3nM (mean + SIM) calculated
from at least 50 determinations. The agonists all caused a rapid 
concentration-dependent elevation of fluorescence (and so £ca2+Ji) 
until a maximal value (300-500nM in different experiments) was 
attained. Thereafter the fluorescence declined towards the resting 
value. Figure 47 shows the effect of ionomycin and PMA on 
neutrophil [ca2+]i. Ionomycin elicits a similar trace as IMLP,
PAF and LTB4 however the extent of elevation of [ca2+]i reaches a 
greater ma.Yinrnm of between 1200—1500nM. In accordance with other 
workers (sha'afi et al., 1985) PMA, at all concentrations tested, 
failed to elicit Ca2 |i elevation.
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Figure 46.
Representative experimental traces of fluorescence changes in 
quin2 labelled neutrophils.
n
2,0ml samples of quin2 labelled neutrophils (1 x 10 cells/ml), 
in the presence of 1.6mM external Ca^+, were exposed to agonist 
at the concentrations indicated. Fluorescence response|+were 
monitored after agonist addition and the appropriate [Ca ] i 
calibration scale is shown on the right of the fluorescence record.
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Figure 47*
Representative experimental traces of fluorescence changes in 
quin2 labelled neutrophils.
*7
2.0ml samples of quin 2 labelled neutrophils (1 x 10 cells/ml), 
in the presence of 1.6mM external Ca +, were exposed to agonist 
at the concentrations indicated. Fluorescence responses were 
monitored after agonist addition and the appropriate [Ca *] i' 
calibration scale is shown on the right of the fluorescence record.
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5*2. Concentration-Response Curves for Agonist-Induced Elevation 
of [ca2+]i.
The extent of the elevation of £ca2+]i induced by the different 
stimuli varied between experiments using cells isolated from different 
donors. The cumulated concentration-response curves for BMLP(EC^q 
value ^  1nM), PAF (EC^q value ^ 5nM)» BTB4 (EC^q valued 0,6nM) and 
ionomycin (EC^q value ^ SOnM) are shown in figures 4 8 , 49, 50 and 51 
respectively.
The three receptor directed agonists were active in the concen­
tration range of 0.1-100nM and the ionophore was active in the range 
of 1nM-1;uM. The maximal increment in £ca^+J]i above ’basal was 
comparable for 1MLP, PAF and LTB4 (between 150-250nM) whereas 
ionomycin was more effective (maximum increment approximately 
1400nM).
5.3. The effect of External Calcium on Agonist-induced £ca2+Ji 
Elevation.
In order to examine the possible sources of this agonist-induced 
elevation of [ca2+]i, I compared the rise in [ca^+]i in cells suspended 
in the presence and absence of external calcium. Figure 52 depicts
one such experiment; cells were either suspended in buffer containing
2+ 2+1.6mM Ca or in the absence of Ca but in the presence of the
calcium chelator, EGTA (20mM) • When the cells were challenged with
2+
agonists in the absence of external Ca the response was dramatically
reduced. Over several experiments using different concentrations of
agonists it was estimated that approximately 80% of the signal arises
via influx of external Ca2+ and that the remaining 20% presumably
2+
arises via mobilisation of internal Ca •
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Figure 48*
Concentration-response relationship for IMLP-induced changes
in ICa^+ji in human neutrophils,
n
2,0ml samples of quin2 labelled neutrophils (1 x 10 cells/ml), 
in the presence of 1.6mM external Ca^+ , were exposed to IMLP 
at the concentrations indicated. The ordinate shows the 
change in [Ca^+]i in nM above resting value (135 + 3nM: n=50)
and the results are mean values + SIM from nine separate 
experiments using neutrophils isolated from different donors.
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Figure 49*
Concentration-response relationship for PAF-induced changes in 
fCa^+li in human neutrophils.'
*7
2.0ml samples of quin2 labelled neutrophils (1 x 10 cells/ml), 
in the presence of 1.6mM external Ca^*, were exposed to PAF at 
the concentrations indicated. The ordinate shows the changes in 
[Ca^+ JL in nM above resting value (135 + 3nM: n=50) and the
results are mean values + SEM from five separate experiments using 
neutrophils isolated from different donors.
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Figure 50.
Concentration-response relationship for LTIfy-induced changes in 
fCa^+li in human neutrophils."
2.0ml samples of quin2 labelled neutrophils (1 x 10 cells/ml), in 
the presence of 1.6mM external Ca^+, were exposed to LTB4 at the 
concentrations indicated. The ordinate shows the change in 
[Ca^+]i in nM above resting value (135 + n=50) and the results
are mean values + SEM from five separate experiments using 
neutrophils isolated from different donors.
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Figure 51•
Concentration-response relationship for ionomycin-induced 
changes in f Ca^+Ti in human neutrophils.
j
2.0ml samples of quin2 labelled neutrophils (1 x 10 cells/ml), in 
the presence of 1.6mM external Ca2+, were exposed to ionomycin at 
the concentrations indicated. The ordinate shows the change in 
[ Ca^+]i in nM above resting value (155 + 3nM: n=50) and the
results are mean values + SIM from four separate experiments 
using neutrophils isolated from different donors. Analysis 
of data: *P <  0.05; **P <  0.01; ***P <^0.001.
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Figure 52.
Representative traces of fluorescence changes in quin2 labelled 
neutrophils demonstrating the effect of external calcium on 
agonist-induced [~Ca^+1i elevation.
n
2.0ml samples of quin2 labelled neutrophils (1 x 10 cells/ml), 
were suspended in medium containing either 1.6mM or 0 (in the 
presence of 20mM EGTA) external calcium. The cells were th6n 
exposed to agonists at the concentrations indicated and changes 
in fluorescence were monitored. The Cca ]i calibration scale 
is shown on the right of the fluorescence record.
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6. Agonist-Induced Phosphoinositide Hydrolysis.
Although previous studies have examined the effects of various 
agonists, especially PMLP, on phosphoinositide metabolism in 
neutrophils of other species (Rubin et al., 1981), characterisation 
of these effects on human neutrophils (Dougherty et al., 1984) is by 
no means complete. Whilst there is sane evidence that receptors for 
PAP and LTB4 on neutrophils are coupled to a similar transduction
O i
process (namely phosphoinositide hydrolysis and Ca flux) this 
matter remains to be fully established (Bradford & Rubin, 1985; 
Naccache et al., 1985a). Indeed Volpi et al., (1984) reported that 
LTB4 could mobilise calcium without the breakdown of phosphoinositides 
and the production of PtdA in rabbit neutrophils.
Accordingly, this section is concerned with investigating the 
effects of IMLP, PAP, LTB4, ionomycin and PMA on PtdA, Ptdlns, PIP 
and PIP2 turnover to ascertain whether phosphoinositide hydrolysis 
serves as a/the transduction process by which these agonists generate 
second messenger molecules to influence human neutrophil function.
I began by examining the time course of PtdA formation using 
[^^p]-orthophosphate prelabelled neutrophils and concentrations of 
agonists that were maximally effective at eliciting aggregation, 
degranulation and elevation of [ca^+]i.
Preliminary studies established that neutrophils prepared under 
conditions of the radio-labelling procedures retained responsiveness 
in terms of agonist-induced cellular responsiveness. PtdA is the 
phosphorylated product of 1,2-diacylglycerol (DAG) hence this lipid 
acts as an indirect measure of phosphoinositide metabolism. After 
having established the optimal time for [^pJ-PtdA production, I 
examined the concentration-response curves for each agonist. For,
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perhaps, a more direct index of phosphoinositide hydrolysis, I 
looked at the effects of various agonists on £^pj-PtdIns, [^p]-PIP 
and ^ ^pj-PIP2 levels, again in neutrophils prelabelled with [^^]“ 
orthophosphate.
6.1* Effect of IMLP on neutrophil phosphoinositide metabolism.
Figure 53 depicts the time course of 5MLP (ljuM)-induced [ ^ p]- 
PtdA formation in human neutrophils. In all cases the levels of 
[^p]-PtdA did not change significantly over the duration of the 
experiment in unstimulated neutrophils. FMLP (1juM) produced peak 
stimulation of ^^pJ-PtdA formation within 2 minutes of agonist 
addition, reaching approximately a 2 fold increase aboye basal, 
which then begins to decrease towards unstimulated levels. Having 
established that peak stimulation of [^pJ-PtdA formation occurs at 
2 minutes, I began examining the concentration-response curve for 
the chemotactic tripeptide at this time point (figure 54)* 
Stimulation of ^^pJ-PtdA formation was observed at a threshold 
concentration of 1-1 OnM, with maximum stimulation at 100nM-1juM.
Prom the cumulated data maximum stimulation of ^ ^pJ-PtdA formation 
was approximately 200% of vehicle control with an EC50 value of
~50nM*
The final index of FMLP-induced phosphoinositide metabolism 
monitored, was the effect of the agonist (ljuM) on [^^pJ-Ptdlns, 
[^^pJ-PIP and £^pj-PIP2 levels; the results are shown on figure 
55* There was a transient decrease in J^^pJ-Ptdlns (between 0-120 
seconds) and [^pJ-PIP (between 0-60 seconds) levels and a more 
persistent decrease in ^^pJ-PIPg (the time course for £^pJ-PtdA 
is included for comparison).
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Figure 53* f
Time course of FMLP -induced L^^J-PtdA formation in human
neutrophils.
0.4ml samples of -orthophosphate prelabelled neutrophils r, ■
(2.5 x 10'cells/ml) were exposed to 1aiM ITCLP and the levels of |_ 
PtdA measured at the times indicated. The results are the mean 
values + SEM for three experiments, each performed in triplicate. 
Analysis of data: *P <  0.05; **P <^0.01.
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Figure 54. _
Concentration-response curve for MLP-induced L^^J- formation in 
human neutrophils.
[32PlJ-orthophosphate prelabelled neutrophils (2.5 x 10^cells/ml) were exposed to JMLP at the concentrations 
indicated. D2P] -PtdA levels were measured 120 seconds after 
agonist addition. The results are mean values + SEM for between 
three and eight experiments, each performed in triplicate. 
Analysis of data: *P <  0.05; <  0.01; *-**P < 0.001.
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Figure 55.
Time course of FMLP (luM)-induced changes in the levels of l 
phospholipids in human neutrophils.
0.4ml samples of -orthophosphate prelabelled neutrophils r,pp"|
(2.5 x 10'cells/ml) were exposed to IMLP and the levels of {/ J- 
PtdA (■), [52P]_ptdIns (•), [32P]^PIp (A) and [32P]_pip2 (Q ) 
measured at the times indicated. The results are the mean values + 
SEM for between two and five experiments, each performed in 
triplicate.
6.2. Effect of PAP on neutrophil phosphoinositide metabolism.
The time course for £^pJ-PtdA formation induced by PAP (l.QuM) 
(figure 56) is similar to the one observed with JMLP, in that maximal 
P^J-PtdA was reached at 2 minutes although it was only about a 60% 
increase above basal.
Looking at the concentration-response curve (figure 57)» stimu­
lation of p^pj-PtdA formation was observed at a threshold concentration 
of 1.8-18nMf with maximum stimulation (160% of saline control) at 
1 .Q-1QuM with an EC^q value of~?500nM.
Finally, there was a transient but non-significant decrease in 
£^pJ-PIP and £^pj-PIp2 levels (both at 15 seconds) with no change in 
£^pJ-PtdIns levels using a PAP concentration of I.QuM (figure 58) •
6.3* Effect of LTB4 on neutrophil phosphoinositide metabolism.
When investigating the effect of LTB4 on phosphoinositide 
hydrolysis a completely different picture was observed. I began by 
examining the time course for [^pJ-PtdA formation using a high 
concentration of LTB4 (2.^uM) and could not observe any change in the 
levels of |^p]-PtdA (figure 59* lower panel). I then looked at the 
lower concentration of 1.25nM and still no significant change in [^p]~ 
PtdA levels were detected (figure 59* upper panel). In order to 
check the viability of the cells, when examining LTB4 , I used PMLP to 
prove that the neutrophils were indeed responsive.
This phenomenon was investigated further by examining the 
concentration-response curve for this arachidonic acid metabolite 
(figure 60). I/PB4 was ineffective at eliciting £^pJ-PtdA at any 
concentration up to 2.5hM. Likewise, LTB4 (1.5uM) failed to evoke
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Figure 56. . -
Time course of PAF (1.fouM)-induced |_^*J-»PtdA formation m
human neutrophils.
r32Pl0 .4ml samples of I  J-orthophosphate prelabelled neutrophils r ,  -i 
(2.5 x 10'cells/ml) were exposed to 1.8/uM PAF and the levels of |_ J
PtdA measured at the times indicated. The results are the mean 
values + SEM for four experiments, each performed in triplicate. 
Analysis of data: *P <0.05; ***p <0.001.
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Figure 57*
Concentration-response curve for PAF-induced 
human neutrophils.
0.4ml samples of -orthophosphate prelabelled neutrophils
(2.5 x 10'cells/ml) were exposed to PAF at the concentrations 
indicated. [32r]_ptdA levels were measured 120 seconds after 
agonist addition. The results are mean values + SEM for between 
three and five experiments, each performed in triplicate. Analysis 
of data: **P <  0.01; ***P <  0.001.
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Figure 58. j.
Time course of PAF (1.8uM)-induced changes in the levels of j- 
phospholipids in human neutrophils.
0.4ml samples of -orthophosphate prelabelled neutrophils f32p'
(2.5 x 10'cells/ml) were exposed to 1.8uM PAF and the levels of (_ 
PtdA (■), [32P]_ptdIns (•), [32p]-PIP and [32F]-p i p2 (Q ) 
measured at the times indicated. The results are the mean values + 
SEM for between two and five experiments, each performed in 
triplicate.
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Figure 59* r
Time course of LTB>pinduced j-PtdA foimation in human 
neutrophils*
0,4ml samples of ['^J-orthophosphate prelabelled neutrophils 
(2.5 x 10'cells/ml) were exposed to 1.25nM or 2.5uM LTB4 and the 
levels of L32Pj_p-tdA measured at the times indicated. The 
results are the mean values + SEM of triplicate determinations. 
The experiment shown is typical of three similar experiments.
All experiments examining the effect of LTB4 were responsive 
to EMLP (1/jM).
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Figure 60.
I 32P IConcentrateon-response curve for LTB^-induced L J-formation in 
human neutrophils.
0.4ml samples of [^^^J-orthophosphate prelabelled neutrophils 
(2.5 x 10'cells/ml) were exposed to LTB4 at the concentrations 
indicated. [32P]_ptdA levels were measured 120 seconds after 
agonist addition. The results are mean values + SEM for three 
experiments, each performed in triplicate. All experiments 
examining the effect of LTB4 were responsive to TWLP (ljuM).
—
in
os
ito
l 
ph
os
ph
ol
ip
id
s: 
fol
d 
st
im
ul
at
io
n
154
2.0-1
1.5 -
1.0 -
Q»
CM
CO
0.8-
0.6-I
i— i— r
0 30 60 120 300 
Time (s)
600
Figure 61.
Time course of LTB4 (1 .^uM)-induced changes in the levels of 
phospholipids in human neutrophils.
0,4ml samples of [^^]-orthophosphate prelabelled neutrophils 
(2,5 x 10'cells/ml) were exposed to l.^ fuM LTB4 and the levels of 
[32P]_ptdA (■), [32P]_ptdIns (•), [32P]-PIP (z^ and [32Pj_pip2 (Q ) 
measured at the times indicated. The results are the mean values + 
SEM for between two and five experiments, each performed in 
triplicate.
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changes in the levels of [^j-PtdA, [^J-Ptdlns, p 2pJ-PIP and 
p 2p]-PIP2 when examined up to 10 minutes following agonist addition 
(figure 61)•
6,4* Effect of ionomycin on neutrophil phosphoinositide metabolism.
The literature is somewhat confusing and contradictory as to 
whether or not calcium ionophores can elicit phosphoinositide 
metabolism in neutrophilic leucocytes (Cockcroft et al., 1980).
However when I examined the time course for ionomycin (1;uM)-induced 
PtdA formation (figure 62) the ionophore did augment p 2pJ-PtdA levels, 
although the pattern is different from that observed with FKLP and 
PAF. Maximal levels of PtdA formation (600% of control) was reached 
at later time points of 5-10 minutes. In order to make a direct 
comparison with the other agonist, a time point of 2 minutes was 
chosen to perform the concentration-response curve (figure 63) for 
ionomycin-induced [^2p]-PtdA formation. Maximal production of 
P^pj-PtdA (approximately 380% of control) at 2 minutes was induced 
by 10-5QuM ionomycin with an EC^q of^ 1pM. There was a transient 
reduction in [*,] -PIP (not significant) and a more prolonged decrease 
in the levels of [^^pj-Ptdlns (not significant) and [^2pJ-PIP2 (only 
significant at later time points) (figure 64)*
6.5* Effect of PMA on neutrophil phosphoinositide metabolism.
The phorbol ester class of compound has been shown to stimulate 
human neutrophils by direct activation of protein kinase C and 
therefore should bypass receptor mediated phosphoinositide hydrolysis. 
The phorbol ester, PMA, when examined (l;aM) had no significant 
effect, at all time points, on p 2pJ-PtdA, p^pJ-Ptdlns, and p 2?]- 
PIP2 levels (figure 65). This suggests that, as expected, PMA does
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Figure 62. P
Time course of ionomycin (1juM)-induced j-PtdA formation in
human neutrophils.
0 .4ml samples of [^^J-orthophosphate prelabelled neutrophils 
(2.5 x 10'cells/ml) were exposed to 1;uM ionomycin and the levels 
of [32P]_ptdA measured at the times indicated. The results are 
the mean values + SEM for three experiments, each perfoimed in 
triplicate. Analysis of datas **P<0.01; ***p <  0.001.
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Figure 63. 1“ 1
Concentration-response curve for ionomycin-induced J-formation
in human neutrophila.
r32Pl0.4ml samples of |_ J-orthophosphate prelabelled neutrophils
(2.5 x 107cells/ml) were exposed to ionomycin at the concentrations 
indicated. [32P-j-ptdA levels were measured 120 seconds after 
agonist addition. The results are mean values + SEM for three 
experiments, each perfonned in triplicate. Analysis of data:
*P <  0.05; **P <  0.01; ***P <  0.001.
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Figure 64. _
Time course of ionomycin (1;uM)-induced changes in the levels of L^*j- 
phospholipids in human neutrophils.
0 .4ml samples ofio r -orthophosphate prelabelled neutrophils
(2.5 x 10'cells/ml) were exposed to 1ajM ionomycin and the levels of 
[ 32P ]_ptdA (■), [32P]_ptdIns (•), [32P]_pip (A) and [ 32PLpip2 (o) 
measured at the times indicated. The results are the mean values + 
SEM for between two and five experiments, each performed in 
triplicate.
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Figure 65. r
Time course of PMA (ljuM)-induced changes in the levels of 
phospholipids in human neutrophils.
0 .4ml samples of -orthophosphate prelabelled neutrophils
(2.5 x 10'cells/ml) were exposed to 1aoM PMA and the levels of 
L32P]_ptdA (■), C32P]_ptdIns (•), I?2P]-PIP (£) and [32PJ -pip2 
(o) measured at the times indicated. The results are the mean 
values + SEM for between two and five experiments, each performed 
in triplicate.
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not stimulate phospholipase C activity, however, since PMA does cause 
a small rise in p 2p]-PIP, this may be indicative of some effect by 
PMA. on phosphoinositide metabolism.
6.6. Effect of External Calcium on Agonist-Induced [^pJ-PtdA 
formation.
All my previous studies on [^^pJ-PtdA formation have been performed
2+
with cells suspended in buffer containing 1.6mM Ca . It was therefore
interesting to examine the role this external calcium had on agonist-
induced p 2pJ-PtdA formation. The histogram (figure 66) shows the
effect of 1>iM PMLP, 1.8pM PAP and 1juM ionomycin on PtdA formation in
the presence (l.6mM [ca2+]o) and absence (no and in the presence
of 20mM EGTA) of external calcium. There was no significant
difference in levels of [^^pJ-PtdA formation elicited by PMLP (160-
180% of control) and PAP (160-180% of control) in the presence and
absence of external calcium. [^2pJ-PtdA production induced by
2+ionomycin in 1.6mM Ca was almost reduced to basal level in the 
presence of the calcium chelator.
This therefore suggests that receptor directed phospholipase C 
activation occurs independently of the presence of external calcium. 
However, the data from ionomycin suggests that PtdA formation induced 
by the calcium ionophore requires external calcium possibly via
A ,
activation of a Ca -dependent phospholipase C (Cockcroft et al.,
1981) or perhaps indicative of another molecular mechanism for PtdA 
production.
7. Cumulated Concentration-Eesponse Curves.
When the data for each agonist are scaled to the same maximum 
response, a comparison of the concentration-dependence of the agonist
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Figure 66.
The effect of external calcium on agonist-induced 
formation.
M - PtdA
0 .4ml samples of -orthophosphate prelabelled neutrophils
(2.5 x 10'cells/ml) were suspended in medium containing either 
1.6mM or 0 (in the presence of 20mM EGTA) external calcium. The 
cells were then exposed to an agonist for 120 seconds, at which 
time [32P]-ptdA levels were measured. The results are mean values 
+ SEM for between three and four experiments, each performed in 
triplicate. Analysis of data: **P <0.01.
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-Induced, transduction processes and functional responses can yield 
useful information on possible cause and effect relationships between 
the events.
7.1. FMLP.
Figure 67 gives the cumulated data for MLP-induced human 
neutrophil activation. Each neutrophil function is expressed as a 
percentage of the maximal response induced by the chemotactic 
tripeptide plotted against increasing concentrations of agonist.
The BC50 values for EMLP-induced elevation of [ca^+]i, aggregation, 
NAG release, lysozyme release and £^pJ-PtdA formation were 
approximately 1nM, 30nM, 50nM> 50nM and 50bM respectively.
JMLP evoked an elevation of neutrophil cytoplasmic-free 
calcium at concentrations significantly lower than were required 
to elicit aggregation, enzyme release and p^pJ-PtdA formation.
7.2. PAF.
A similar pattern was observed when PAF was examined (figure
68). The E C 5 0  values for PAF-induced elevation of £ca^*Ji,
aggregation, NAG release, lysozyme release and [^pJ-PtdA formation 
were approximately 5nM, 1;uM, 70nM, 80nM and 500nM respectively.
All PAF-induced responses, including j^^pj-PtdA formation, lie to
the right of the curve for PAF-induced elevation of [ca^+]i* Once
again, J^^pJ-PtdA formation is produced in a similar concentration 
range as the cellular responses, although aggregation seems to lie 
marginally further to the right.
7.3. LTB4.
Figure 69 shows the concentration-dependence of LTB4-induced
163
100-i
CD
CO
c
o
Q.
CO
CD
1_
X
CD
e
cz
CD
CJ
I—
CD
Q_
5 0 -
I— / /
-1010"
[FMLP] M
Figure 67.
Cumulated concentration-response curves for MLP-induced human 
neutrophil activation.
Each neutrophil function; [Ca ]i elevation (#)t aggregation (A), 
NAG release (■), lysozyme release (o) and P^]-PtdA formation (A) 
is expressed as a percentage of the maximal response elicited by 
5TCLP.
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Figure 68.
Cumulated concentration-response curves for PAF-induced human 
neutrophil activation.
2+Each neutrophil function; [Ca ]i elevation (•)> aggregation (A), 
NAG release (■), lysozyme release (o) and [32P]_ptdA formation (A) 
is expressed as a percentage of the maximal response elicited by 
PAF.
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Cumulated concentration-response curves for LTIfy-induced human 
neutrophil activation.
Each neutrophil function; [ Ca^+ ]i elevation (#), aggregation (A),
NAG release (■) and lysozyme release (o) is expressed as a percentage 
of the maximal response elicited by LTB4.
[32P]-PtdA formation (A) is expressed as the fold stimulation above 
basal.
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neutrophil responsiveness. Again, each neutrophil function is 
expressed as a percentage of the maximal response elicited by bTB^. 
However, since it is impossible to express [^p]-PtdA formation, in 
this case as a percentage of the maximum, £ ^ pJ-PtdA formation is 
expressed as the fold stimulation above basal. The EC50 values for 
LTB^-induced elevation of [ca^+]i, aggregation, NAG release and lysozyme 
release were approximately 0.6nM, 20nM, 50nM and 30nM respectively.
LTB^ is similar to IMLP and PAP in relation to the fact that LTB^ 
caused an elevation of [ca^+Ji at concentrations lower than were required 
to elicit aggregation and enzyme release. It is also clear that in 
contrast to IMLP and PAP, LTB^ caused no significant change in [^ - 
PtdA levels.
7*4. Ionomycin.
The cumulated effect of ionomycin on human neutrophil activation is 
depicted in figure 70. The results are expressed as a percentage of the 
maximum response elicited by the ionophore and the EC50 values for 
elevation of £ca^+Ji, LTB^ generation, aggregation, NAG release, lysozyme 
release and p^pj-PtdA formation were approximately 80nM, 20nM, 'UiM,
500nM, 400nM and "UiM respectively.
Also included on the right of the graph are the actual levels of 
[ca^+]i elevation elicited by the ionophore. This enables the 
estimation of the approximate [ca^+Ji threshold, defined as the 
concentration at which a significant increase in cellular/biochemical 
response was evident. The [ca^+]i thresholds were calculated to be 
^600nM for aggregation,^ 500nM for NAG release,^600nM for lysozyme 
release,^SOOnM for p 2PJ-PtdA formation and^200nM for LTB4 biosynthesis.
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Figure 70.
Cumulated concentration-response curves for ionomycin-induced 
human neutrophil activation.
2+Each neutrophil function; [Ca ]i elevation (#), LTB4 generation 
(□)» aggregation (A), NAG release (■), lysozyme release (o) and 
l?2r1-PtdA foimation (A) is expressed as a percentage of the maximal 
response elicited by ionomycin. In addition, the right axis gives 
the Cca^+]i elevation (•) in nM above basal.
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8. Discussion
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The major objective of this particular section was to investigate 
the relationship between the ultrastructural, functional (aggregation, 
degranulation and LTB4 generation) and the more biochemical ( [ca^*]i 
elevation and phosphoinositide hydrolysis) responses induced by LTB4 
and PAP in comparison with other neutrophil stimuli. Such an 
investigation may help elucidate the mechanism(s) of action of LTB4 
and PAP and assist in the understanding of the molecular transduction 
mechanisms involved in human neutrophil activation.
LTB4 and PAP are potent lipid activators of human neutrophils 
and produce a similar but not identical array of responses to those 
produced by the chemotactic tripeptide, JMLP; the calcium ionophore, 
ionomycin, and the phorbol ester, PMA. The ultrastructural changes 
induced by LTB4 and PAF are broadly similar to those produced by JKLP, 
with an initial period of general ruffling followed by polarization 
and lamellipodia formation. There is evidence of increased actin 
polymerization after neutrophils are exposed to FMLP with skeins of 
fine filaments traversing lamellipodia and forming sub-plasma bands 
(Rao & Varani, 1982; V/hite et al., 1982; Howard & Meyer, 1984)* 
Microtubule quantity has variously been described as increased 
(Goldstein et al., 1973; Boxer et al., 1979; Hoffstein, 1980) or 
unchanged but with alterations in their length and distribution 
(Anderson et al., 1982). The absence of microtubules in the 
lamellipodia is in agreement with previous observations (Davis et 
al., 1982; Oliver & Berlin, 1982). ltoe polarization seen in response 
to LTB4, PAP and IMLP is characteristic of migrating cells and, since 
the neutrophils were randomly orientated and the cells were not in a 
chemotactic gradient, the ultrastructural changes observed in 
unstirred samples probably reflects chemokinesis. A similar pattern
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of morphological changes was observed in stirred suspensions of activated 
neutrophils except that small clumps containing aggregated neutrophils were 
evident. The clumps contained polarized cells with large agranular 
lamellipodia generally extending outward from the aggregate. Hoff stein
et al., (1982) have reported similar ultrastructural changes with IMLP- 
induced aggregation of human neutrophils. The remarkable similarity in 
response in unstirred and stirred neutrophils may indicate that chemokinesis 
and aggregation are mediated by the same contractile mechanism.
A rapid, reversible and concentration-dependent aggregation of human 
neutrophils was observed with LTB4, PAF and MLP. The arachidonic acid 
metabolite was by far the least efficacious agonist. However, it was 
approximately equi-potent with 5MLP and both were almost 10 fold more 
potent than the ether lipid. These data are in accordance with previous 
investigations (Ford-Hutchinson, 1983* 0 'Flaherty et al., 1981aj)* The
aggregatory responses elicited by PMA and ionomycin were also concentration- 
dependent but not reversible. This probably reflects the fact that these 
agents are not acting upon specific cell surface receptors but causing 
neutrophil activation by stimulating protein kinase C and directly 
elevating £ca^+]i respectively.
The concentration-dependent release of both NAG (an azurophil granule 
marker) and lysozyme (an azurophil and specific granule marker) induced by 
the receptor directed agonists all required the presence of cytochalasin 
B. Although all three agonists have a similar potency, PMLP releases 
greater amounts of both enzymes. The degranulation response of ionomycin 
and PMA are somewhat different from the other stimuli. Ionomycin 
stimulates the release of both enzymes in the absence of cytochalasin B.
PMA is extremely weak at releasing NAG from the azurophil granules and any 
release is cytochalasin B dependent. However, the phorbol ester is 
capable of inducing lysozyme secretion in the presence or absence of this 
fungal metabolite. Other workers have found similar results demonstrating
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that PMA is capable of releasing lysozyme but not /^-glucuronidase, 
another azurophil enzyme, from human neutrophils (Estensen et al.,
1974; Wright et al., 1977). The reason for this apparent selective 
release and differential mobilisation of human azurophil and specific 
granules remains unclear.
Caution, however, must be taken whilst interpreting data using 
cytochalasin B treated neutrophils. Ultrastructural studies reveal 
that cytochalasin B causes a distinctive vacuolation within the 
cytoplasm that is not present in untreated control cells. The 
addition of agonist to cytochalasin B treated neutrophils causes the 
formation of a bizarre profile with marked blebbing and little polar­
ization of the granules. Thus, despite claims to the contrary 
(Chandler et al«, 1983; Showell et al., 1982), cytochalasin B has been 
shown both here and in previous investigations to have a dramatic 
effect on cell ultrastructure (Zigmond & Hirsch, 1972; Hoffstein, 
1981). It should also be recognised that this pharmacological tool 
produces a wide spectrum of other biological responses which may 
interfere with the normal functioning of the neutrophil (Chapter 1).
The release of arachidonic acid from membrane phospholipids, 
principally via activation of phospholipase A2» is a phenomenon common 
to a variety of cell types. In human neutrophils arachidonic acid is 
predominantly acted upon by a calcium-dependent enzyme located in the 
cytoplasm known as 5-lipoxygenase. The resultant 5HPKTE intermediate 
is sequentially acted upon by a dehydrase followed by a hydrolase 
enzyme to yield the biologically active LTB4 (chapter 2 ; figure 4 ) •
My results show that LTB4 generation is produced in a concentration- 
dependent manner by ionomycin and that EMLP and PAF only produced a 
fraction of the amount of LTB4 generated by the calcium ionophore.
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Indeed, very high concentrations of PAF (1§oM) are required for 
significant production of the arachidonic metabolite. Similar 
observations have been made by other workers using the calcium 
ionophore, A23187 (Palmer & Salmon, 1983; McMillan et al., 1985)* 
However, data with more physiological agents are fewer and often 
contradictory.
Palmer & Salmon, (1983) using human neutrophils reported that 
serum-treated zymosan or IMLP produced low or barely detectable amounts 
of LTB4 which could be potentiated by simultaneous addition of arachi­
donic acid or only marginally increased by pretreatment of cells with 
cytochalasin B. Haines et al., (1987) demonstrated that 5MLP, heat- 
aggregated IgG and serum-treated zymosan produce low levels of LTB4.
This arachidonic acid metabolite was only produced in significant 
amounts when cells are loaded with arachidonic acid in quantities 
(50uM) that stimulate superoxide production and activate protein kinase 
C (Badwey et al., 1981; McPhail et al., 1984)* Other workers have 
reported LTB4 biosynthesis by neutrophils exposed to JMLP, serum- 
treated zymosan, C5a and monosodium urate (Jubiz et al., 1982;
Claesson et al., 1981; Clancy et al., 1983; Ham et al., 1983;
Serhan et al., 1984; Williams et al., 1985)* Some of these studies, 
including this investigation, have many different factors or variables 
which may confuse interpretation of data. For example: contamination
of neutrophil preparations with monocytes and other cells; use of high 
concentrations of neutrophils, arachidonic acid or agonists; reliability 
of detection techniques, etcetera.
One common feature that all the above studies share is that 
neutrophils produce large amounts of LTB4 in response to calcium 
ionophores and that other inflammatory ligands produce low or barely 
detectable levels of this arachidonic acid metabolite. An interesting
172
observation made by Williams et al., (1985) Is that there is an 
intracellular retention of LTB^ by human neutrophils activated with 
unopsonized zymosan suggesting that the release of 5-lipoxygenase 
metabolites may be an event that is regulated separately from their 
generation. Whether there is a similar intracellular retention of 
5 lipoxygenase products by neutrophils produced by other agents is 
unknown. Therefore, the precise reason for the differences between 
stimuli remains to be established.
a
All the receptor directed agonists caused^rapid concentration- 
dependent elevation of neutrophil [ca2+]i. The calcium ionophore 
was much more effective than PMLP, PAP and LTB^ at elevating £ca2+Ji. 
This may explain why ionomycin can elicit a, massive production of 
LTB4 whereas IMLP and PAP produce only barely detectable levels.
The notable exception was PMA which did not cause a rise in £ca2+Ji 
at all concentrations tested; this is in agreement with previous 
findings (Sha'afi et al., 1983) and consistent with the hypothesis 
that phorbol esters cause the activation of cells by directly 
stimulating protein kinase C (Castagna et al., 1982). Studies 
with the calcium chelator, EGTA, demonstrated that the elevation of 
[ca2+]i induced by PMLP, PAP and LTB4 derives predominantly, but not 
exclusively, via influx of external calcium through channels that 
open as a consequence of receptor occupancy (white et al., 1983b\
Naccache et al., 1985b)*
The chemotactic tripeptide caused the formation of PtdA and the 
transient breakdown of Ptdlns, PIP and PIP2* These observed effects 
of PMLP are most readily explained via receptor linked hydrolysis of 
phosphoinositides catalysed by phospholipase C. Indeed, that this 
is so, has been shown both in intact cells (Dougherty et al., 1984) 
and membrane preparations (anith et al., 1985)* I11 the case of
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PAP, only changes in PtdA are easily demonstrable. This may reflect
the action of phospholipase C on phosphoinositides, but equally could
be explained either by phospholipase D action on these phospholipids
to yield PtdA directly (Kater et al., 1976) or by triglyceride lipase
action on triglyceride to yield DAG (Allan & Michell, 1977) which
subsequently would be phosphorylated by DAG kinase to produce PtdA.
The present studies do not allow us to discriminate between these
possibilities. Other investigations have shown that PAP causes
phosphoinositide hydrolysis in a number of cell systems including
rabbit neutrophil (Naccache et al., 1986) and human platelets
(MacIntyre & Pollock, 1983). The breakdown of phosphoinositides and
production of PtdA that occurs in neutrophils with calcium ionophores
is somewhat confusing (this investigation; Cockcroft et al., 1981;
Rubin et al., 1981; Cockcroft, 1984). Such an observation may be
2+
explained by the possibility that there exists a Ca -dependent
phospholipase C in the neutrophil which is activated by calcium
ionophores. The fact that JMLP- and PAF-induced PtdA formation is
2+
not attenuated in the absence of external Ca whereas the same 
response elicited by ionomycin was almost abolished may
suggest that the calcium ionophore is doing something additional in 
neutrophils. Since the time course for PtdA formation is much slower 
to peak than JfflLP and PAP, it cannot be ruled out that ionomycin could 
be producing an additional endogenous mediator of neutrophil activation 
that may stimulate phosphoinositide hydrolysis; for example PAP. PMA 
did not cause an elevation of PtdA, an observation consistent with the 
fact that phorbol esters bypass phosphoinositide hydrolysis by 
substituting for endogenous DA.G to activate protein kinase C. The 
phorbol ester, however, did cause a late and small increase in PIP. 
Similar observations have been made in human platelets (McNicol,
1986; Halenda & Feinstein, 1984) and in lymphocytes (Boon et al., 1985)
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where PMA stimulates the incorporation into PIP and PIP2. Human 
neutrophils have been reported to ’'remodel’1 membrane phospholipids 
upon stimulation with PMA. Serhan et al., (1982) showed early (15 
seconds) changes in phosphatidylcholine, phosphatidyl serine and 
phosphatidylethanolamine and later (60 seconds) changes in Ptdlns 
in response to the phorbol ester.
At the start of my investigations very little information
concerning the possible stimulus-response coupling mechanisms for
LTB4 was available in the literature. Serhan et al., (1984) had
2+proposed that LTB4 may exert its effect by acting as a Ca ionophore
and Volpi et al., (1984) had published the first evidence to suggest
2+that LTB4 could mobilise Ca without the breakdown o,f polyphospho­
inositides and the formation of PtdA in rabbit neutrophils. The 
latter group demonstrated that the addition of IMLP and LTB4 caused a 
concentration-dependent rise in [ca2+]i as measured by quin2. In 
addition, they showed that [^p]-prelabelled rabbit neutrophils 
exposed to the arachidonic acid metabolite at concentrations up to 
70nM did not cause any significant breakdown of any of the phospho- 
inositides or generation of PtdA, arachidonic acid or DAG. Further­
more, the concentration-response curves for IMLP-induced generation of 
PtdA is shifted to the right when compared with that for calcium 
mobilisation. They concluded that there was an important qualitative 
difference between the mechanism of these two chemotactic agents. 
Bearing in mind these findings, we repeated these investigations using 
human neutrophils. Our results show that there is a lack of effect of 
LTB4, up to concentrations of 2«5»M, on PtdA formation and on the 
levels of the phosphoinositides. This could indicate, as is the 
case in rabbit neutrophil, that receptors for this eicosanoid in the 
human neutrophil are not coupled to inositol lipid hydrolysis.
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Two recent reports have demonstrated that LTB4 can evoke
phosphoinositide hydrolysis in guinea pig alveolar macrophages (Holian, 
1986) and in human leukaemic HL60 cells differentiated with retinoic 
acid but not with IMSO (Andersson et al., 1986). This may indicate 
the existence of sub-types of LTB4 receptors that could be 
differentiated according to the transduction process to which they are 
coupled. It should be noted that a.^ and a^ adrenoreceptors can be 
differentiated by such criteria (Berridge, 1985)* Alternatively, the 
ineffectiveness of LTB4 on the various aspects of phosphoinositide 
hydrolysis in human (this study) and rabbit (Volpi et al., 1984;
Sha’afi et al., 1985) may merely reflect the insensitivity of the 
assays involved. Indeed, various workers using rabbit neutrophils 
(Bradford & Rubin, 1985)> rat peritoneal polymorphonuclear leucocytes 
(Mong et al., 1986) and, more recently, human neutrophils (Lew et al., 
1987; Smith et al., 1987) prelabelled with pli]-inositol showed that 
LTB4 promotes a rapid accumulation of Ins(l ,4»5)i>5 suggesting that 
phosphoinositide hydrolysis may be occurring in these cells. A recent 
publication by Omann et al., (I987b)using human neutrophils showed that 
the N-formyl hexapeptide (lOnM) caused an elevation of PtdA in a similar 
manner to my investigations. They also showed, however, that 40nM 
LTB4 produced a small transient rise in PtdA, peaking at about 15 
seconds which rapidly declines towards basal. The reason for these 
discrepancies is unknown and whether LTB4 is actually causing a signifi­
cant phosphoinositide turnover in neutrophils has not been fully 
established and awaits clarification. What is certain, however, is 
that there is a qualitative and quantitative difference between the 
responses of PAP and JMLP.
When the data for each neutrophil stimulus is scaled to the same 
ma-T-inmm response, a comparison of the concentration-dependence of
176
agonist-induced transduction processes and cellular responses can 
yield valuable information on the possible cause and effect relationships 
between events* The concentration—response curves for aggregation and 
degranulation induced by all three receptor directed agonists, and for 
PtdA formation induced by 5MLP and PAP, lie to the right of the 
corresponding curves of agonist-induced elevation of ^Ca^+Ji. A similar
relationship between EMLP (Rossi et al., 1985) and PAF (Kaccache et al.,
2+
1986)—induced Ca flux and functional responses has also been reported.
As the agonist-induced functional responses (i.e. aggregation and 
degranulation) occur at concentrations of I/TB^ , PAP and TMLP greater 
than those required to evoke maximal elevation of jca^+ji, it is unlikely 
that the rise in £ca^+Ji per se mediates these neutrophil reactions. 
Consequently, if £ca^+Ji is the sole trigger for neutrophil activation, 
it must stimulate an intracellular amplification sequence that results 
in functional responses. Alternatively, one must invoke other 
mediators which act alone or in concert with elevated £ca^+Ji to evoke 
neutrophil activation. DAG, one of the immediate products of phospho­
inositide hydrolysis, would be a prime candidate as such a synergistic 
or independent mediator. However, as JMLP and PAP induce phosphoinositide 
hydrolysis at higher concentrations than Jca^+Ji elevation and that LTB4 
can induce neutrophil activation apparently independently of phospho­
inositide hydrolysis, there must exist products other than DAG which 
interact with elevated £ca^+Ji to elicit neutrophil responsiveness.
From the cumulated concentration-response curve for ionomycin-induced 
neutrophil activation, an estimation of the quantitative relationship 
between £ca^*Ji and cellular responsiveness may be determined. Rink 
et al., (1982) using quin2 loaded platelets stimulated with ionomycin 
revealed apparent Ca^+ thresholds (defined as the £ca^+Ji concentration 
at which a significant response was evident) for shape-change, 5HT release
Ml
and aggregation of approximately 500nM, 800nM and 2jaM. respectively.
A similar analysis has not been made with human neutrophils although 
Lew et al., (1986) have shown that the £ca^+Ji threshold for 
degranulation (release of enzymes from azurophil, specific and small 
secretory vesicles) was approximately 200-300nM. From our results 
£ca^+Ji thresholds were estimated to be‘v/600nM for aggregation,^ 600nM 
for NAG release,^500nM for lysozyme release, ^ 800nM for PtdA formation 
and~200nM for LTB4 production. Aggregation and degranulation were 
triggered by an approximate 400% increase in resting [ca^+]i whereas 
PtdA formation required a 600% increase. Of the various indices of 
neutrophil activation, LTB4 was the most sensitive to changes in 
[ca^+]i and was initiated by only a 50% increase in basal £ca^+Ji 
(Rossi et al., 1987a). The extreme sensitivity to changes in [ca^Ji 
could possibly be exploited to impose specific impairment of neutrophil 
LTB4 biosynthesis via modulation of £ca^+Ji. Whether these [^Ca^Ji 
thresholds reported by quin2 are confirmed, using the newer generation 
of Jca^+Ji indicators such as fura-2 and indo-1, awaits further 
investigation.
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CHAPTER 6 s REGULATION OF NEUTROPHIL ACTIVATION BY G PROTEINS
AND PROTEIN KINASE C.
1. The Role of G Proteins in Human Neutrophil Activation.
Although the role of guanine nucleotide binding regulatory 
proteins, G proteins, in the adenylate cyclase system is well 
established, their potential role in the modulation of cellular 
reactivity by agonists that operate through different transduction 
mechanisms is now emerging. In the subsequent investigations I 
utilised the bacterial toxin, pertussis toxin, which inhibits Nj or 
other similar G proteins, by NAD-ribosylation (Chapter 3)* Studies 
using this pharmacological tool may help resolve whether a G protein 
is involved, either directly or indirectly, in agonist-induced human 
neutrophil responsiveness.
1.1. Effect of Pertussis Toxin on Agonist-induced Aggregation.
Under conditions known to promote NAD-ribosylation of GTP binding 
proteins, neutrophils were pretreated with pertussis toxin (l^Pg/ml; 2 
hours) or with saline (as a control) and the aggregatory response 
elicited by the various agonists investigated. The response induced 
by all concentrations of FMLP, PAP and LTB^ was attenuated by the 
toxin. Figures 71, 72 and 73 show the effect of pertussis toxin on 
IMLP (2.5|uM), PAP (9fM) and LTB4 (l.^uM) respectively and, even at 
these high agonist concentrations, the toxin significantly reduced the 
extent of the aggregatory response. Pertussis toxin, on the other 
hand, did not affect the aggregation induced by the calcium ionophore, 
ionomycin, (figure 74) ot by the phorbol ester, PMA, (figure 75) •
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Figure 71•
The effect of pertussis toxin on IMLP-induced neutrophil 
aggregation.
Q
Neutrophils (1 x 10 cells/ml) were pretreated with pertussis 
toxin (15/ug/ml), or saline control, for 2 hours. 0.6ml samples 
of washed neutrophils (2.5 x 10'cells/ml) were added to a cuvette 
containing a teflon-coated stirring bar revolving at 600rpm. The 
cells were exposed to IMLP (2.5jJM) and the changes in light 
transmission recorded. The experiment is typical of three similar 
experiments, each performed in triplicate.
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Figure 72.
The effect of pertussis toxin on PAP-induced neutrophil aggregation.
8
Neutrophils (1 x 10 cells/ml) were pretreated with pertussis toxin 
(l5jug/ml), or saline control, for 2 hours. 0.6ml samples of washed 
neutrophils (2.5 x 10'cells/ml) were added to a cuvette containing a 
teflon-coated stirring bar revolving at 600rpm. The cells were 
exposed to PAF (SIMM) and the changes in light transmission recorded. 
The experiment is typical of three similar experiments, each performed 
in triplicate.
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Figure 73•
The effect of pertussis to3cin on LTB/pinduced neutrophil aggregation.
8
Neutrophils (1 x 10 cells/ml), were pretreated with pertussis toxin 
(l5hg/nil), or saline control, for 2 hours. 0.6ml samples of washed 
neutrophils (2.5 x lO^cells/ml) were added to a cuvette containing a 
teflon-coated stirring bar revolving at 600rpm. The cells were 
e3cposed to LTB4 (2.5pM) and the changes in light transmission 
recorded. The escperiment is typical of three similar experiments, 
each performed in triplicate.
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Figure 74*
The effect of pertussis toxin on ionomycin-induced neutrophil 
aggregation.
ft
Neutrophils (1 x 10 cells/ml) were pretreated with pertussis toxin 
(l5|ug/ml), or saline control, for 2 hours. 0.6ml samples of washed 
neutrophils (2.5 x lO^cells/ml) were added to a cuvette containing a 
teflon-coated stirring bar revolving at 600rpm. The cells were 
exposed to ionomycin (2.5pM) and the changes in light transmission 
recorded. The experiment is typical of three similar experiments, 
each performed in triplicate.
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Figure 75*
The effect of pertussis toxin on PMA-induced neutrophil aggregation.
8
Neutrophils (1 x 10 cells/ml) were pretreated with pertussis toxin 
(l5p.g/ml), or saline control, for 2 hours. 0 .6ml samples of washed 
neutrophils (2.5 x 10'cells/ml) were added to a cuvette containing a 
teflon-coated stirring bar revolving at 600rpm. The cells were 
exposed to fMA (0.5pM) and the changes in light transmission 
recorded. The experiment is typical of three similar experiments, 
each performed in triplicate.
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These observations suggest that the effect of the toxin is on receptor- 
directed. activation and not simply via non-specific effects or by a 
general reduction in neutrophil responsiveness.
1.2. Effect of Pertussis Toxin on Agonist-induced Degranulation.
The effect of pertussis toxin on agonist-induced release of NAG 
(figure 76) and lysozyme (figure 77) was next examined. Both histo­
grams clearly show that the release of NAG and lysozyme induced by 
IMLP (2.5pM), PAF ($mM) and LTB4 (l.^uM) were severely abrogated (by 
approximately 70%) by pertussis toxin pretreatment whereas enzyme 
release induced by ionomycin and PMA was unaffected.
1.5* Effect of Pertussis Toxin on Agonist-induced Elevation of [ca^*1i.
Preincubation with pertussis toxin had no significant effect on the 
resting level of [ca^+]i. However, the elevation induced by all 
concentrations of the receptor-directed agonists was attenuated by 
pertussis toxin pretreatment• Figure 78 shows representative experi­
mental traces of the responses induced by JMLP (2nM), PAF (0.9nM),
LTB4 (30nM) and ionomycin (lOOnM). Again, the response elicited by 
the ionophore in the presence of pertussis toxin was the same as the 
control ionomycin response.
1.4. Effect of Pertussis Toxin on Agonist-induced [^p]-PtdA formation.
A similar profile was observed when agonist-induced P^pl-PtdA
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Figure 76.
The effect of pertussis toxin on agonist-induced NAG release from 
human neutrophils*
Q
Neutrophils (1 x 10 cells/ml) were pretreated with pertussis toxin 
(15/ag/ml), or saline control, for 2 hours. The cells were then 
washed and aliquoted into 0 .6ml samples of 1 x 10'cells/ml and 
exposed to cytochalasin B (5;ug/ml; 10 minutes). The neutrophils
were finally challenged with an agonist for a further 10 minutes 
and NAG was measured. The results are mean values + SEN for 
three experiments, each performed in triplicate. Analysis of 
data: **P <0.01; ***P <0.001.
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The effect of pertussis toxin on agonist-induced lysozyme release 
from human neutrophils.
Q
Neutrophils (1 x 10 cells/ml) were pretreated with pertussis toxin 
(l5jig/ml), or saline control, for 2 hours. The cells were then 
washed and aliquoted into 0.6ml samples of 1 x lO^cells/ml and 
exposed to cytochalasin B ( 5 * 1 0  minutes). The neutrophils 
were finally challenged with an agonist for a further 10 minutes and 
lysozyme was measured. The results are mean values + SUM for three 
experiments, each performed in triplicate. Analysis of datas ***P 
< 0.001.
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Figure 78.
The effect of pertussis toxin on agonist-induced changes in 
fCa^+li in human neutrophilsT
Representative experimental traces of fluorescence changes in quin2 
labelled neutrophils pretreated with pertussis toxin (15/ug/ml), or 
saline control, for 2 hours. 2.0ml samples of quin2 labelled 
neutrophils (1 x lO^cells/ml), in the presence of 1.6mM external 
Ca^+ , were exposed to agonist at the concentrations indicated. 
Fluorescence responses were monitored after agonist addition and the 
appropriate [Ca^+]i calibration scale is shown on the right of the 
fluorescence record. The experiment is typical of eight similar 
experiments.
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was investigated (figure 79) • Both the responses elicited by PMLP 
(ViM; 172 + 15% of control) and PAP (SJuHj 175 + 16% of control)
were inhibited to 117 + 9% and 137 + 8% respectively. [^2p]“
PtdA formation induced by ionomycin (1/jM; 165 + 17% of control) was
unaffected with toxin pretreatment.
2. The Role of Protein Kinase C in Human Neutrophil Activation.
Hydrolysis of inositol phospholipids, catalysed by phospholipase
C yields two second messenger molecules namely [ca^+]i and 1,2-diacyl
2+
glycerol (BAG). The former acts allegedly via stimulation of Ca - 
calmodulin dependent protein kinase(s) and the latter via stimulation 
of protein kinase C. The effects of endogenous DAG on protein kinase 
C and on cellular reactivity can be mimicked by tumour-promoting 
phorbol esters, e.g. phorbol-12-myristate-13-acetate; PMA (Castagna 
et al., 1982). There is evidence emerging in a variety of cell 
systems to suggest that protein kinase C activation not only directly 
stimulates cellular activation but may also have a regulatory or 
inhibitory effect on agonist-induced cellular responsiveness. 
(Nishizuka, 1986} see Chapter 3)* In order to investigate the 
possibility that similar regulatory mechanisms operate in the human 
neutrophil, I examined the effect of PMA on the potential transduction 
processes, namely [ca^+]i elevation and phosphoinositide hydrolysis, 
involved in the neutrophil response to stimulatory agonists.
2.1. Effect of PMA on Agonist-induced Elevation of [ca^*li.
Using quin2 labelled neutrophils PMLP (5«M), LTB4 (lOnM) and
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The effect of pertussis toxin on agonist-induced L J-PtdA 
formation in human neutrophils.
Neutrophils (1 x 108cells/ml) were pretreated with pertussis toxin 
(15fig/ml), or saline control, and [32P]-orthophosphate, for 2 hours. 
The cells were then washed and aliquoted into 0.4ml samples of 
2.5 x 107cells/ml and challenged with the agonist for 120 seconds, 
at which time [52P]_ptdA levels were measured. The results are 
mean values + SEM for five experiments, each performed in triplicate. 
Analysis of ctatas *P <^0.05*
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PAP (lOnM) caused an elevation of resting value of 133nM to a 
maximum of between 280—290nM. When the cells were incubated for 
120 seconds with PMA or IMSO (control) neither altered resting 
[ca^+]i. However, PMA (l-100nM) inhibited, in a concentration- 
dependent manner, the elevation of [ca^+]i induced by all three 
agonists (figure 80),
2.2. Effect of PMA on Agonist-induced f^pl-PtdA formation.
PMA (1/uM; 120 seconds) had no effect on neutrophil j^pj-PtdA
levels when compared to its vehicle control. Figure 81 depicts the 
effect of PMA on IMLP-induced p^p]-PtdA fonnation. In these 
experiments (it*3-4) control IMLP (IjjM) elicited a 155 + 6% 
response. This was attenuated, in a concentration-dependent manner, 
by preincubation with PMA (lnM-1nM) with an IC^q value (i.e. 
concentration producing 50% inhibition of the response elicited by a 
particular agonist) of^lnM. Preincubation with PMA (lnM-1juM) also 
suppressed the response to PAP (l.fijuM) which was 182 + 12% of
control (n=3-4) with an IC50 value of ~ 50nM (figure 82). Ionomycin 
(lyuM) induced 168 + 8% of the control level of ^^pJ-PtdA (ns=4-5)j 
this stimulation was unaffected by the same concentration range of 
the phorbol ester (figure 83).
3« Discussion.
3«1> The role of G Proteins.
Over the last few years it has become apparent that G proteins
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Figure 80,
Representative traces of fluorescence changes in quin2 labelled 
neutrophils demonstrating the effect of PMA on agonist-induced 
rCa^+~li elevation. ""
n
2.0ml samples of quin2 labelled neutrophils (1 x 10 cells/ml), 
were suspended in medium containing 1•6mM external calcium and 
were preincubated for 120 seconds with PMA at the concentrations 
indicated. The cells were then exposed to the agonists and 
changes in fluorescence were monitored. The [Ca^+ji calibration 
scale is shown on the right of the fluorescence record.
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Figure 81. _ _
The effect of PMA on 1MLP (1/uM)-induced L^^J-PtdA formation.
0.4^1 samples of [^^J-orthophosphate prelabelled neutrophils 
(2.5 x 10'cells/ml) were preincubated for 120 seconds with PMA 
at the concentrations indicated. The cells were then exposed to 
TMLP (1/uM) for a further 120 seconds, at which time [32P]_ptdA 
levels were measured. The data are expressed as a percentage of 
the control formation of t 32P ]-ptdA induced by FMLP in the presence 
of the PMA vehicle, LMS0 (0.1%).
The results are mean values + SIM for three experiments, each 
performed in triplicate. Analysis of data: *P <  0.05; **P <
0 .01.
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The effect of PMA on PAF (1.QuM)-induced L^^j-PtdA formation.
0 .4ml samples of -orthophosphate prelabelled neutrophils
(2.5 x 10'cells/ml) were preincubated for 120 seconds with PHA 
at the concentrations indicated. The cells were then exposed to 
PAF (1.8/uM) for a further 120 seconds, at which time [32P]_ptdA 
levels were measured. The data are expressed as a percentage of 
the control formation of [32P]_p-tdA induced by PAF in the presence 
of the PMA vehicle, PMSO (0.1%).
The results are mean values + SEM for three experiments, each 
performed in triplicate. Analysis of data: *P <  0.05; <
0.01 .
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Figure 83. p -
The effect of PMA on ionomycin (1;uM)-induced j-PtcLA formation.
0.4ml samples of [^^J-orthophosphate prelabelled neutrophils 
(2*5 x 10'cells/ml) were preincubated for 120 seconds with PMA 
at the concentrations indicated. The cells were then exposed to 
ionomycin (1«M) for a further 120 seconds, at which time [^2P]_
PtdA levels were measured. The data are expressed as a percentage
of the control formation of [32P]_ptdA induced by ionomycin in the 
presence of the PMA vehicle, DMSO (0.1%).
The results are mean values + SEM for three experiments, each
performed in triplicate.
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play an important role not only in the adenylate cyclase system 
(Gilman, 1984) or in photoreceptor transduction processes (Fung et al., 
1981) but also in other second messenger systems such as phospholipase 
C catalysed phosphoinositide hydrolysis (Joseph, 1985). Important 
pharmacological agents which have contributed to the abundant 
literature concerning G proteins are two bacterial products, cholera 
toxin and pertussis toxin. In these investigations I utilised 
pertussis toxin which causes an ADP-ribosylation of Ni or other related 
G proteins (Chapter 3)- It is clear that pertussis toxin inhibited 
FMLP, PAF and LTB4-induced aggregation, degranulation and elevation of 
[ca^+]i and also inhibited FMLP and PAF-induced PtdA formation. Since 
pertussis toxin did not attenuate neutrophil activation elicited by 
the calcium ionophore, ionomycin; or by the phorbol ester, PMA; the 
toxin is probably acting upon receptor-coupling mechanisms and not 
simply via a non-specific mechanism or by a general reduction in 
neutrophil responsiveness.
As outlined in Chapter 3> in accordance with my observations, 
other workers have demonstrated that pretreatment of neutrophils with 
pertussis toxin inhibited a number of FMLP-induced responses including 
aggregation, enzyme release, phosphoinositide hydrolysis and [ca^+]i 
elevation (Omann et al., 1987a). There are some conflicting results 
concerning pertussis toxin inhibition of PAF-induced neutrophil 
activation. Lad et al., (1985a) using human neutrophils, showed that 
pertussis toxin inhibited PAF-induced chemotaxis, aggregation, 
superoxide generation and lysozyme release. In further investigations 
they demonstrated that this bacterial toxin diminished PAF—evoked 
elevation of [ca2+]i quin2 loaded human neutrophils (Lad et al., 
1985b). More recently this has been confirmed by Verghese et al., 
(1987). Using rabbit neutrophils Naccache et al., (1985c; 1986)
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showed that pertussis toxin inhibited PAF-induced degxanulation and 
phosphoinositide hydrolysis. They also showed that PAF causes an 
elevation of neutrophil £ca^+Ji at concentrations higher than 
phosphoinositide hydrolysis and that this elevation of [ca^+Ji was 
not affected by pertussis toxin. This led to the conclusion that 
there may exist two distinct populations of PAF receptors, at least 
in the rabbit neutrophil. ftie explanation for this apparent species 
difference between rabbit and human neutrophil is unknown. It 
remains possible that in the rabbit neutrophil experiments, the toxin 
pretreatment (O.^ug/ml; 1 hour) may have been incomplete or that 
resistance to pertussis toxin could be attributed to a small residual 
pool of unribosylated G protein that remains coupled to this receptor.
In my investigations elevation of [ca^*]i induced by PAF (all 
concentrations tested) was attenuated by pertussis toxin and that 
PAF-induced [ca^+]i elevation occurs at lower concentrations of agonist 
than does PtdA formation (Chapter 5)« Ylhether there exist two PAF 
receptors in the human neutrophil still remains to be established.
There exists the possibility that there is a receptor reserve in the 
neutrophil for both IMLP and PAF, i.e. occupancy of only a fraction of 
the receptor pool may stimulate significant phosphoinositide turnover 
(below the detection limits of the PtdA assay employed in this study) 
enough to elicit maximal elevation of [ca^+]i. However, the precise 
relationship between phosphoinositide hydrolysis and changes in [ca^+]i 
is still unclear.
Most data suggests that only receptors coupled to phospholipase 
C in haematopoetic cells are sensitive to pertussis toxin inhibition. 
For example, in human leukaemic (HL-60) cells (Brandt et al., 1985) and 
mast cells, (Nakamura and Ui, 1985) receptor-activated phosphoinositide 
hydrolysis is attenuated by pertussis toxin pretreatment. It remains 
possible that in other cell systems where pertussis toxin is not
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effective at inhibiting phosphoinositide hydrolysis that there still 
exists pertussis toxin-insensitive phospholipase C coupled G proteins.
The data concerning LTB^ indicates that neutrophil activation 
induced by this arachidonic acid metabolite is also coupled to a G 
protein. Results from Chapter 5 suggest that LTB^ may produce its 
response independently of phosphoinositide hydrolysis (at least as 
monitored by changes in PtdA formation). Since pertussis toxin 
inhibited LTB^-induced aggregation, enzyme release and £ca^+Ji 
elevation, G proteins may be involved in processes other than phospho­
lipase C activity. Indeed, recent evidence suggests that G proteins 
are involved directly in voltage-dependent calcium channels in neurones 
(Scott & Dolphin, 1986; Holz et al., 1986; -Hescheler et al., 1987) 
and in muscarinic stimulation of K+ channels in atrial cells. Whether 
G proteins exert their effects by interacting directly with chemotactic 
receptors in the human neutrophil remains to be established.
The identity of the pertussis toxin-sensitive G protein is 
unknown. However, Gierschik et al., (1986) have proposed that there 
exists a novel and distinct pertussis toxin substrate in the human 
neutrophil. They provided evidence showing that the predominant 
pertussis toxin substrate is immunochemically distinct from previously- 
identified substrates; namely Ni, Np and transducin.
In summary, it appears that agonist-induced neutrophil activation 
apparently involves a pertussis toxin-sensitive process, presumably (a) 
guanine nucleotide binding regulatory protein(s), that has (have) yet 
to be fully identified. With the development of new and improved 
techniques, a more accurate understanding of these membrane transducing 
components will be attained.
5.2. The role of protein kinase C.
Cellular activation may be regulated by at least two distinct
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2 +
molecules; Ca and MG .  Agonist receptor interaction can lead to 
the hydrolysis of phosphoinositide hydrolysis resulting in the 
formation of these two second messengers (Abdel-Latif, 1986). M G  
is thought to stimulate protein kinase C which acts to elicit its 
cellular responses independently or synergistically with elevated 
levels of £ca^+Ji. There is evidence to suggest that the tumour- 
promoting phorbol esters such as PMA can mimic the stimulatory effect 
of endogenous M G  on protein kinase C (Castagna et al., 1982).
The results clearly show that PMA is a potent activator of human 
neutrophils (Chapter 5)* Although the phorbol ester induces 
aggregation and enzyme release (principally from specific granules) 
it does not cause any significant elevation of £ca^+Ji or PtdA 
formation. Other workers have similar observations (Sha’afi
et al., 1983; Naccache et al., 1984; White et al., 1984) and^also 
shown that PMA is a potent stimulator of the respiratory burst 
(Pujita et al., 1984). Moreover, in neutrophils it has been shown 
that PMA causes protein phosphorylation in cells pre-labelled with 
[^p]— orthophosphate (Ohtsuka et al., 1986; Pontremoli et al.,
1986) and promotes translocation of protein kinase C from the 
cytosol to the membrane (Horn & Kamovski, 1986). Several investi­
gations have shown that sub-threshold concentrations of PMA or OAG 
and calcium ionophore can synergize to cause neutrophil activation 
(Penfield & Hale, 1984; Robinson et al., 1984; O'Flaherty et al.,
1984). In addition to the observed independent or synergistic 
stimulatory role, there is a great deal of evidence emerging to 
suggest that protein kinase C activation can also inhibit or modulate 
cellular activation in a wide variety of cellular systems including 
neutrophils (Nishizuka et al., 1984; 1986; Drummond & MacIntyre,
1985).
Uiis study demonstrated that preincubation of human neutrophils
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with PMA had a pronounced concentration-dependent inhibition on agonist- 
induced [ca^+Ji elevation. Similar observations were made by Naccache 
et al., (1984; 1985a)who showed that PMA inhibited iMLP, PAP and LTB4-
induced elevation of [ Ca^+]i and enzyme secretion in rabbit neutrophils. 
Inhibition of agonist-induced elevation of | C^a^ +Ji by phorbol esters 
has subsequently been shown in a large variety of other isolated cells 
including human platelets (MacIntyre et al., 1985a), rat basophilic 
leukaemia cells (Sagi-Eisenberg et al., 1985), GH3 pituitary cells 
(Drummond, 1985)» hepatocytes (Cooper et al., 1985) astrocytoma cells 
(Orellana et al., 1985) t vascular smooth muscle (Brock et al., 1986) 
and adrenal glomerulosa cells (Kojima et al., 1986).
Attenuation of agonist-induced elevation of [ca^+]i may be
2+attributed to an activation of a Ca extrusion process. Indeed,
Mottola & Borneo, (1982) showed that neutrophils exposed to PMA cause
2+an extrusion of cytoplasmic Ca to the extracellular milieu. It was 
subsequently demonstrated that an ATP-dependent calcium pump stimulated 
by PMA inhibited a rise in [ca^+]i elicited by PMLP (Lagast et al.,
1984)* If the assumption is made that the elevation of neutrophil 
[ca^+]i is produced as a consequence of inositol phosphate formation, 
one might expect that PMA may also inhibit agonist-induced phospho­
inositide hydrolysis. Clearly our results demonstrate that PMA 
inhibits PtdA formation induced by JMLP and PAF. Since measurement of 
PtdA is an indirect index of phosphoinositide hydrolysis, this 
inhibitory effect of PMA may reflect a reduction of DAG kinase activity 
and not an effect on phospholipase C activity. Other workers have 
subsequently shown that PMA does have a direct action on phosphoinositide 
hydrolysis in the neutrophil (Kato et al., 1986; Snith et al., 1987)* 
Similarly, phorbol ester produces inhibitory effects on agonist-induced 
phosphoinositide hydrolysis in a host of other cell systems. Some of
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these include platelets (MacIntyre et al., 1985a; Watson & Lapetina.,
1985), mast cells (Okano et al., 1985)» lymphocytes (Mellors et al.,
1985), vascular smooth muscle, (Brock et al., 1985; McMillan et al.,
1986), hepatocytes (Corvera et al., 1986) and glomerulosa cells (Kojima 
et al., 1986).
It is possible that protein kinase C activation could phosphorylate 
and stimulate Ins(l,4#5)P3 phosphatase (Molina y Vedia & Lapetina,
1986; Connolly et al., 1986) resulting in the removal of Ins(l,4,5)^ 
and consequently decreasing the ability of the cell to mobilise 
calcium. 'Riis may account for part of the inhibitory effect of PMA. 
However, since agonist-induced PIP2 hydrolysis and diacylglycerol 
formation are also inhibited by phorbol ester pretreatment (Brock et 
al., 1985; Zavoico et al., 1985)» inhibition of phospholipase C 
activity must also occur.
If PMA is inhibiting the formation of inositol phosphates and 
also attenuates the elevation of [ca^+]i induced by LTB4, this may 
suggest that the mechanism of action of this lipid is indeed via 
phosphoinositide hydrolysis. In an elegant investigation it was 
shown that protein kinase activators (PMA, mezerein and rac-1-0- 
myristoyl-2-acetylglycerol) inhibited the binding of LTB4 in human 
neutrophils by reducing the number of high affinity receptors to this 
eicosanoid (o’Flaherty et al., 1986a). Therefore, an inhibitory effect 
produced by PMA is not conclusive evidence for phosphoinositide 
hydrolysis involvement but may simply reflect a down regulation of 
receptors produced by protein kinase C activation.
The observed differential effects of PMA on agonist-induced PtdA 
formation is of interest. As indicated by the IC50 value for FMLP 
(inM) and for PAF (50nM), the chemotactic tripeptide seems to be 
more susceptible than the ether lipid to inhibition by PMA. This
difference may be attributed to effects of protein kinase C on other 
components of the transduction process such as regulation of receptor 
number and receptor affinity. For example, phorbol esters can 
phosphorylate alpha-) adrenoreceptors in smooth muscle (Leeb- 
Lundberg et al., 198 ) and reduce their affinity in hepatocytes 
(Corvera et al., 1986). The insulin receptor is also phosphorylated 
by protein kinase C activation (Jacobs et al., 1983). Neuroblastoma 
muscarinic acetylcholine receptors are rapidly internalised in 
response to phorbol esters (Liles et al., 1986) and PMA or OAG both 
produce a desensitisation to /3-adrenergic agonist activation of the 
adenylate cyclase system of rat reticulocytes, an effect which is 
antagonised by the proposed protein kinase Q inhibitor, H7 (1-5- 
isoquinolinesulphonyl-2-methylpiperazine)(Yamashita et al., 1986). 
Therefore, a similar effect at the iWLP receptor may explain why 
PtdA formation produced by the chemotactic tripeptide is inhibited 
with lower concentrations of PMA than required to attenuate PtdA 
production induced by the ether lipid.
It has also been reported that protein kinase C may produce its 
negative feedback effect by interfering with other important cellular 
processes, for example nucleotide cyclases (Bushfield et al., 1987), 
ion channels (Farley & Auerbach, 1986), contractile elements (inagaki 
et al., 1984) and G proteins (Halenda et al., 1986). Indeed, 3nith
et al., (1987) have recently shown that phorbol esters disrupt the 
coupling of IMLP-activated G protein to phospholipase C.
Hence, there is abundant evidence to suggest that protein kinase 
C may serve as a bidirectional regulator of cellular reactivity; DAG 
not only stimulates the cell but also may inhibit or modulate the 
stimulatory transduction processes. The precise mechanism or site of 
action and physiological relevance of this protein kinase C-induced 
dampening of cellular activity still remains to be elucidated.
zuz
CHAPTER 7: INTERACTION BETWEEN LIPID MEDIATORS OF
NEUTROPHIL ACTIVATION,
LTB4 and PAP when added exogenously are potent activators of human 
neutrophils. Stimulation of neutrophils by agents such as calcium 
ionophores will produce numerous lipid products including both LTB4 and 
PAF. These lipids produced endogenously may combine with specific 
receptors located in/on the cell surface membrane to mediate directly 
the evoked response or they may function to amplify neutrophil 
responsiveness elicited by other (exogenous) agonists. The major aim 
of the next part of my investigations was to examine the role of LTB4 
and PAF production in mediating cellular activation to exogenous agonists. 
This was attempted by (1) employing selective inhibitors of 5-lipoxygenase 
to prevent endogenous LTB4 biosynthesis and (2) utilising the specific 
PAF receptor antagonist, kadsurenone, to abolish the effect of any 
endogenous PAF production.
I investigated the effect of lipoxygenase inhibition and kadsurenone 
on ionomycin-induced LTB4 generation and on agonist-induced neutrophil 
aggregation and degranulation.
1. Effect of Lipoxygenase Inhibitorss-
1.1. On ionomycin-induced LTB4 Generation.
The effect of a wide variety of agents that interfere with eicosanoid 
production waA examined on ionomycin (ljuM)-induced LTB4 generation in 
human neutrophils. The response elicited by 1;uM ionomycin (approximately 
60ng/l0^cells) was taken as the control and the effect of the inhibitors 
(15 minute preincubation at 37°C), in the concentration range of 10nM- 
10QjuM, was expressed as a percentage of that control.
The compounds investigated were Revlon 5901 , Indomethacin (a
relatively selective cyclooxygenase inhibitor), BW755C, NDGA, ICI 
198143* AA861 and Nafazatrom. Their IC50 values were ~'8QjuM,
''/1jUM, 500nM and~1QuM respectively (figures 84 and 85).
The potency of the various inhibitors was AA861 >  BW755C> Revlon 5901^ 
NDGA/> Nafazatrom>  ICI> Indomethacin.
1.2. On agonist-induced degranulation.
Samples from the above experiments were simultaneously taken to 
investigate the effects of these agents on ionomycin-induced release 
of NAG (figures 86 and 87) and lysozyme (figures 88 and 89). The 
compounds Revlon 5901, indomethacin, ICI 198143* and AA861 at all 
concentrations tested (lOnM-IOfyiM) had no significant effect on ionomycin 
release of both NAG and lysozyme. However, the compounds BW755C,
NDGA and Nafazatrom at the high concentrations of 10-10QuM did inhibit 
enzyme release (NAG and lysozyme) to some extent (maximal inhibition 
produced by any of these agents was by NDGA which attenuated enzyme 
release by approximately 35-45%).
To assess the role of endogenous LTB4 on degranulation induced 
by receptor directed stimuli, I investigated the effects of the specific 
5-lipoxygenase inhibitor, Revlon 5901, on this response. Revlon 5901 
(15 minute preincubation) was examined on JMLP (1juM; figures 90a and 
90b), PAF (1.§uM; figures 90c and 90d) and LTB4 (1.5>>M» figures 90e 
and 90f) induced release of both NAG and lysozyme. The amount of 
enzyme release induced by the various agonists in the absence of Revlon 
5901 was taken as the control values and the effect of this compound 
was expressed as a percentage of that control. Revlon 5901 had no 
significant effect on the release of both enzymes induced by all three 
agonists.
1.5. On agonist-induced aggregation.
Aggregation, another marker of neutrophil activation, was examined in
204
100
<DC<uCT
-3"OQ
5 0 -
"O
<VO
"Oe
o>eoc:o
0 -»
Revlon 5901 
Indomethacin 
BW755C 
NDGA
T
CM]
Figure 84.
The effects of agents that interfere with eicosanoid production on 
ionomycin-induced LTB/| generation by human neutrophils#
n
0 .6ml samples of neutrophils (1 x 10 cells/ml) were pretreated for 
10 minutes with cytochalasin B (5/ug/ml) and for 15 minutes with the 
various drugs at the concentrations indicated. The cells were 
then challenged with ionomycin (1;uM) for a further 10 minutes and the 
production of LTB4 determined. The results are expressed as the 
percentage of the amount of LTB4 produced by ionomycin alone 
(approximately 60ng/ml) and are mean values + SIM for four 
experiments, each performed in triplicate.
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Figure 85.
The effect of agents that interfere with eicosanoid production on 
ionomycin-induced LTB4 generation by human neutrophils.
*7
0.6ml samples of neutrophils (1 x 10 cells/ml) were pretreated for 
10 minutes with cytochalasin B (5yUg/ml) and for 15 minutes with the 
various drugs at the concentrations indicated. The cells were then 
challenged with ionomycin (1/uM) for a further 10 minutes and the 
production of LTB4 determined. The results are expressed as the 
percentage of the amount of LTB4 produced by ionomycin alone 
(approximately 60ng/ml) and are mean values + SEM for four 
experiments, each performed in triplicate.
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Figure 86.
The effect of agents that interfere with eicosanoid production on 
ionomycin-induced NAG release by human neutrophils*
n
0 ,6ml samples of neutrophils (1 x 10 cells/ml) were pretreated for 
10 minutes with cytochalasin B (5ng/ml) and for 15 minutes with the 
various drugs at the concentrations indicated. The cells were 
then challenged with ionomycin (1>oM) for a further 10 minutes and 
the release of NAG determined. The results are expressed as the 
percentage release of NAG induced by ionomycin alone and are mean 
values + SIM for four experiments, each performed in triplicate.
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F ig u re  87.
The effect of agents that interfere with eicosanoid production on 
ionomycin-induced NAG release by human neutrophils.
7
0.6ml samples of neutrophils (1 x 10 cells/ml) were pretreated for 
10 minutes with cytochalasin B (5#ig/ml) and for 15 minutes with the 
various drugs at the concentrations indicated. The cells were then 
challenged with ionomycin (ipM) for a further 10 minutes and the 
release of NAG determined. The results are expressed as the 
percentage release of NAG induced by ionomycin alone and are mean 
values + SEM for four experiments, each performed in triplicate.
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Figure 88.
The effect of agents that interfere with eicosanoid production on 
ionomycin-induced lysozyme release by human neutrophils.
n
0 .6ml samples of neutrophils (1 x 10 cells/ml) were pretreated for 
10 minutes with cytochalasin B (5Mg/ml) and for 15 minutes with 
the various drugs at the concentrations indicated. The cells were 
then challenged with ionomycin (1juM) for a further 10 minutes and 
the release of lysozyme determined. The results are expressed as 
the percentage release of lysozyme induced by ionomycin alone and 
are mean values + S M  for four experiments, each performed in 
triplicate.
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Figure 89.
The effect of agents that interfere with eicosanoid production on 
ionomycin-induced lysozyme release by human neutrophils*
n
0 .6ml samples of neutrophils (1 x 10 cells/ml) were pretreated for 
10 minutes with cytochalasin B (5jug/ml) and for 15 minutes with 
the various drugs at the concentrations indicated. The cells were 
then challenged with ionomycin (tuM) for a further 10 minutes and 
the release of lysozyme deteimined. The results are expressed as 
the percentage release of lysozyme induced by ionomycin alone and 
are mean values + SEM for four experiments, each performed in 
triplicate.
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Figure 90.
The effect of Revlon 5901 on agonist-induced enzyme release from 
human neutrophils*
-1
0 .6ml samples of neutrophils (1 x 10 cells/ml) were pretreated, 
for 10 minutes, with cytochalasin B (5,Ug/ml) and for 15 minutes 
with Revlon 5901 at the concentrations indicated. The cells 
were then challenged with an agonist for a further 10 minutes 
and the enzyme release determined. The results are expressed 
as the percentage of the total enzyme release induced by the 
agonist alone.
(a) ETCLP (1/aM; 27.2% of total NAG).
(b) M L P  (1/iM; 58*9% of total lysozyme).
(c) PAF (1.8)uM; 21.2% of total NAG).
(d) PAF (l.QjuM; 32.0% of total lysozyme).
(e) LTB4 (1.5PM; 21.4% of total NAG).
(f) LTB4 (1.5pM; 30.3% of total lysozyme).
For each individual agonist the results are mean values ♦ SEM 
for three experiments, each performed in triplicate.
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the presence of varying concentrations of Revlon 5901. The effect 
of Revlon 5901 on control concentrations of ionomycin (1;uM), 5MLP 
(tyiM), PAP (1.§UM) and LTB4 (l.^nM) is shown in figures 91a,b,c and d 
respectively. This specific lipoxygenase inhibitor did not 
significantly affect the aggregatory response elicited by any of the 
stimuli•
2. Effect of the PAF receptor antagonist, Kadsurenone: -
2.1. On agonist-induced aggregation.
The effect of kadsurenone on agonist-induced aggregation was 
investigated. Samples were either preincubated with varying 
concentrations of the PAP receptor antagonist or with DMSO (as control) 
for 10 minutes at 37°C and aggregation was induced by PAP (l.QuM),
IMLP (lyUM) and LTB^ (1.5mM). Kadsurenone inhibited PAP-induced 
aggregation in a concentration-dependent manner with an ICtjQ value of 
^800nM (figure 92). The aggregatory responses elicited by IMLP 
(figure 93a) and LTB4 (figure 93a) were unaffected by kadsurenone 
preincuba t i on.
2.2. On agonist-induced degranulation.
Once again kadsurenone inhibited PAP (1 .QuM)-induced release of 
both NAG (figure 94) and lysozyme (figure 95) with IC^q values of 
/%'40nM and ^  10nM respectively. Degranulation induced by IMLP (figures 
96a and 96b) and LTB4 (figures 96c and 96d) was virtually unaffected 
by this specific PAP receptor antagonist. However, the high con­
centration of 1QmM kadsurenone exerted only a marginal, but significant, 
inhibitory effect on LTB4-induced secretion of lysozyme.
2.3* On ionomycin-induced LTB4 generation.
The effect of kadsurenone on ionomycin (1;uM )-induced LTB4
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Figure ,
The effect of Revlon 5901 on agonist-induced aggregation in 
human neutrophils.
n
0,6ml samples of neutrophils (2.5 x 10 cells/ml) were added to 
a cuvette containing a teflon-coated stirring bar revolving at 
600rpm. The cells were pretreated with Revlon 5901 (15 
minutes) at the concentrations indicated. The cells were then 
challenged with an agonist and the changes in light transmission 
recorded. The results are expressed as the percentage of the 
response induced by the agonist alone.
(a) Ionomycin (1jiM).
(b) IMLP (1juM).
(c) PAF (l.8pM).
(d) M B 4 (1.50UM).
For each individual agonist the results are mean values + SEM 
for three experiments, each performed in triplicate.
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Figure 92.
The effect of kadsurenone on PAF-induced aggregation in human 
neutrophils.
n
0.6ml samples of neutrophils (2.5 x 10 cells/ml) were added to a 
cuvette containing a teflon-coated stirring bar revolving at 600rpm. 
The cells were pretreated with kadsurenone for 10 minutes at the 
concentrations indicated. The cells were then challenged with 
PAF (l.QuM) and the changes in light transmission recorded. The 
results are expressed as the percentage of the response induced by 
PAF alone. The results are mean values + SEM for three experiments, 
each performed in triplicate.
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Figure 93*
The effect of kadsurenone on agonist-induced aggregation in human 
neutrophils. 7
0.6ml samples of neutrophils (2.5 x 10 cells/ml) were added to a cuvette 
containing a teflon-coated stirring bar revolving at 600rpm. The cells 
were pretreated with kadsurenone for 10 minutes at the concentrations 
indicated. The cells were then challenged with an agonist and the changes 
in light transmission recorded. The results are expressed as the 
percentage of the response induced by agonist alone.
(a) M L P  (1JAM).
(b) LTB4 (1.5HM).
For each individual agonist the results are mean values + SEM for three 
experiments, each performed in triplicate.
217
100-,
coo
<uco
co<u
a)
CD
■a<uo
■a
50-
0 J
r
### f.
-/h
10-9
T
i-8 r710 °  10' 
[Kadsurenone] M
10-6 10-5
Figure 94*
The effect of kadsurenone on PAF-induced NAG release from human 
neutrophils.
7
0.6ml samples of neutrophils (1 x 10 cells/ml) were pretreated 
for 10 minutes with cytochalasin B (5/ug/ml) and kadsurenone at 
the concentrations indicated. The cells were then challenged 
with PAF (1.8/iM) for a further 10 minutes and the release of 
NAG determined. The results are expressed as the percentage of 
the release induced by PAF alone (16.9% of total NAG). The 
results are mean values + S M  for three experiments, each performed 
in triplicate. Analysis of results: *P <0.05; ***P <^0.001.
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Figure 95.
The effect of kadsurenone on PAF-induced lysozyme release from human 
neutrophils*
n
0.6ml samples of neutrophils (1 x 10 cells/ml) were pretreated 
for 10 minutes with cytochalasin B (^ug/ml) and kadsurenone at the 
concentrations indicated. The cells were then challenged with PAF 
(l.B i^M) for a further 10 minutes and the release of lysozyme 
determined. The results are expressed as the percentage of the 
release induced by PAF alone (28.6% of total lysozyme). The 
results are mean values + SEM for three experiments, each performed 
in triplicate. Analysis of data: *-**P <  0.001.
Figure 36,
The effect of kadsurenone on agonist-induced enzyme release 
from human neutrophils*
n
0 .6ml samples of neutrophils (1 x 10 cells/ml) were pretreated, 
for 10 minutes, with cytochalasin B (5ttg/ml) and kadsurenone at 
the concentrations indicated. The cells were then challenged 
with an agonist for a further 10 minutes and the enzyme release 
determined. The results are expressed as the percentage of 
the total enzyme release induced by the agonist alone.
(a) mLP (1;uM; 21.2% of total NAG).
(b) JMLP (1uM: 32.9% of total lysozyme).
(c) LTB4 (1.5uM; 16.4% of total NAG).
(d) LTB4 (1.5juM; 26.5% of total lysozyme).
For each individual agonist the results are mean values + S01 
for three experiments, each performed in triplicate. Analysis 
of data: P* <  0.05.
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generation in human neutrophils was also examined (figure 97)* The 
response elicited by 1;uM ionomycin (approximately 60ng/ml) was taken 
as the control and the effect of kadsurenone (10 minute preincubation 
at 37°C), in the concentration range of 1nM-1QuM, was expressed as a 
percentage of that control# There was no significant reduction in 
the generation of LTB4 in the presence of this inhibitor.
3# Effect of LTB4 on agonist-induced [32p] -PtdA formation.
I/PB4, being a potent independent activator of human neutrophils, 
is also capable of potentiating the neutrophil functional responses 
evoked by other agonists. Since LTB4 did not elicit a significant 
production of [^p]-PtdA per se, there exists the possibility that this 
arachidonic acid metabolite may augment phosphoinositide metabolism 
induced by other agonists. Consequently, I investigated whether LTB4 
had an effect on agonist-induced j^pj-PtdA formation.
Suhaaximal concentrations of IMLP (O.ljuM) and PAF (0.95uM) that 
induce 1 4 3 + 9  (figure 98) and 145 + 19% (figure 99) [^^p]-PtdA 
formation respectively were used as positive controls. A preincubation 
of 2 minutes with LTB4 (0.1nM-1QuM) did not augment or attenuate 
I ^ PI-PtdA formation evoked by other agonists.
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Figure 97*
The effect of kadsurenone on ionomycin-induced LTB4 generation by 
hum an neutrophils.
0 .6ml samples of neutrophils (1 x 10^cells/ml) were pretreated for 
1C minutes with kadsurenone at the concentrations indicated and then 
challenged with ionomycin (1/iM) for a further 10 minutes and the 
production of LTB4 determined. The results are expressed as the
percentage of the amount of LTB4 produced by ionomycin alone 
(approximately 45ng/ml) and are mean values + SEM for three 
experiments, each performed in triplicate.
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Figure 98*
The effect of LTB4 on ETCLP-induced [^^J-PtdA formation.
0 .4ml samples of neutrophils (2.5 x 10'cells/ml) were pretreated 
with LTB4 for 2 minutes at the concentrations indicated. The 
cells were then challenged with EMLP (0.1;uM) for a further 2 
minutes and the production of t^^PJ-PtdA determined. The results 
are mean values + SEM for four experiments, each performed in 
triplicate.
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The effect of LTB4 on PAF-induced [^^J-PtdA formation.
0.4ml samples of neutrophils (2.5 x 10 cells/ml) were pretreated 
with LTB4 for two minutes at the concentrations indicated. The 
cells were then challenged with PAF (O.S&uM) for a further 2 minutes 
and the production of f32P]_ptdA determined. The results are mean 
values + SEM for four experiments, each performed in triplicate.
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4* Discussion.
Products derived from membrane phospholipids via activation of 
phospholipase A2? namely LTB4 and PAF, appear to be the most potent 
known stimulators of human neutrophils eliciting a whole repertoire of 
neutrophil functional responses including aggregation and degranulation. 
Many agents that activate neutrophils are also known to enhance the 
production of LTB4 and PAF. However, to what extent these products 
contribute to the activation of neutrophils induced by other stimuli 
has not been clearly elucidated. Research into this area has been 
hampered by the lack of selective biosynthesis inhibitors and specific 
receptor antagonists.
Attenuation of the intracellular levels of 5-lipoxygenase products 
by 5-lipoxygenase inhibitors may determine the role of arachidonic acid 
metabolites in neutrophil function. In this study I investigated a 
number of agents known to interfere with eicosanoid production on 
ionomycin-induced LTB4 biosynthesis. All the agents used, with varying 
degrees of potency and efficacy, inhibited production of LTB4 induced 
by the calcium ionophore (figures 84 and 85). The same seven inhibitors 
were used to determine the potential contribution of endogenous LTB4 to 
ionomycin-induced enzyme release. Of all the agents tested only NDGA 
(Showell et al., 1980), BW755C (Higgs et al., 1979) and nafazatrom (Honn 
& Dunn., 1982), at very high concentrations, inhibited enzyme release.
At these concentrations (10Q|uM), LTB4 biosynthesis was almost completely 
inhibited whereas enzyme release was only partly attenuated. The 
cyclooxygenase inhibitor, indomethacin; and the putative 5-lipoxygenase 
inhibitors, Revlon 5901 (Coutts et al., 1985)> ICI 198143 and AA861 
(Ashida et al., 1983) did not inhibit either ionomycin-induced NAG or 
lysozyme release. The fact that the inhibitory effects of certain agents 
on neutrophil degranulation did not correlate closely with the degree of
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inhibition of LTB4 biosynthesis and that other more selective 5- 
lipoxygenase inhibitors did not attenuate neutrophil activation clearly 
suggests that products of 5-lipoxygenase a re  not be involved in 
ionomycin-induced enzyme release*
In order to investigate whether a similar conclusion could be made 
with neutrophil activation induced by the receptor directed agonists,
I employed the more selective 5-lipoxygenase inhibitor, Revlon 5901, 
and studied its effect on agonist-induced degranulation and aggregation. 
This compound in the concentration range of 10nM-10QuM did not sig­
nificantly inhibit IMLP-, PAF- and LTB4-induced enzyme release or 
aggregation, suggesting that neutrophil responsiveness elicited by these 
stimuli must occur independently of LTB4 synthesis.
There are several reports in the literature suggesting that products 
of 5-lipoxygenase are indeed mediating neutrophil responsiveness elicited 
by other (exogenous) agonists. For example, Staolen & Weissmann, (1980) 
using human neutrophils demonstrated that the acetylenic derivative of 
arachidonic acid, 5*8,11,14-eicosatetraynoic acid (ETYA) inhibited 
A23187, 5MLP and zymosan induced lysosomal enzyme release. Similar 
observations were made with the putative selective inhibitor of 
lipoxygenase, 5*8,11, ELcosatriynoic acid (ETl) (Marone et al., 1983)- 
These authors concluded that products of arachidonic acid metabolism 
play an essential role in neutrophil activation and secretion. Caution 
must be taken when interpreting data using the above agents since they 
are relatively unselective and exert many other effects within the cell. 
Smith et al., (1986) demonstrated that aggregated IgG caused a 
concentration-dependent release of both lysozyme and myeloperoxidase 
that was inhibited by U-60,257 (piriprost potassium),another reported 
lipoxygenase inhibitor. These results indicate that a lipoxygenase 
product may mediate aggregated IgG enzyme release in human neutrophils.
Contrasting observations were made by Palmer & Salmon, (1985) who
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showed that although EW755C inhibited LTB4 biosynthesis in human 
neutrophils, it did not affect A23187-induced degranulation and was 
only a weak inhibitor of IMLP-induced degranulation. A recent 
investigation by Ozaki et al., (1986) compared a variety of inhibitors 
of the lipoxygenase pathway on a number of neutrophil parameters.
They showed that U-60,257 had virtually no effect on superoxide 
production and degranulation and ■ chemotaxis was only marginally 
suppressed. They also demonstrated that compounds used previously 
to implicate LTB4 involvement exert other effects within the cell.
For example, NDGA and esculitin inhibited NADPH oxidase, the enzyme
complex involved in oxygen radical production. Thus interpretation 
of data generated using such compounds is not straightforward.
Care must be taken whilst using putative 5-lipoxygenase
inhibitors since they may not be selective enough or they may 
interfere with a particular neutrophil response elicited by a 
particular agonist. However, my investigations suggest that LTB^ 
may not be involved in aggregation and degranulation induced by other 
agonists.
The inhibition of PAF production may also help determine whether 
this ether lipid is involved in neutrophil activation elicited by 
other stimuli. This again has been marred by the lack of any 
specific PAF inhibitors. One indirect approach, that various workers 
have adopted, is to inhibit phospholipase A2» Such inhibition would 
prevent the formation of PAF by preventing the breakdown of the 
alkyl-acyl-PAF to lyso-PAF, the immediate precursor of PAF. One 
must bear in mind that the use of phospholipase A2 inhibitors may 
equally well be associated with the blockade of the production of 
arachidonic acid metabolites and other lyso-derivatives. One of the 
more specific phospholipase A2 inhibitors is p-bromophenyacyl bromide
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which exerts its effect by acetylation of a histidine located on the 
active site on the enzyme (Volwerk et al.,1974). This compound has been 
shown to inhibit JftLP, A23187 and serum-treated zymosan induced 
degranulation in human neutrophils (S&olen &. Weisanann, 1980; Marone 
et al., 1983)* Perhaps a more direct way to prevent the effects of 
any PAF production induced by other agonists would be to employ 
selective PAF receptor antagonists. There are a number of such 
receptor antagonists with varying degrees of specificity (Braquet & 
Godfroid, 1986).
One such compound, that I examined in this study, is the neolignan 
isolated from a Chinese herb (Caul is piperis futokadsurae) which has 
considerable antirheumatic and antiallergic properties. This drug, 
kadsurenone as it is known, was first discovered as a potent inhibitor 
of the binding of £ -PAF to rabbit platelet membrane preparations 
where it displayed an IC^q of 0.1;uM and a Kd of 58nM (Shen et al., 
1983). Kadsurenone has also been shown to inhibit PAF-induced 
aggregation of platelets (Hwang et al., 1983) and PAF-induced 
aggregation and degranulation of human neutrophils (Shen et al., 1983)* 
The effect of this specific PAF receptor antagonist on neutrophil 
activation induced by PAF, IMLP, I/FB4 and ionomycin was investigated. 
Kadsurenone caused a concentration-dependent inhibition of PAF-induced 
aggregation, NAG release and lysozyme release with virtually no effect 
on these responses elicited by the other stimuli. In order to check 
that this compound did not interfere with LTB4 biosynthesis, by for 
example inhibiting phospholipase A2 and/or 3-iipoxygenase, kadsurenone 
was tested against ionomycin-induced LTB4. Kadsurenone did not 
attenuate I/PB4 generation.
From the above evidence, albeit circumstantial, it is suggested 
that I O 4 and PAF are not mediating neutrophil activation elicited by
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other stimuli. Whether aggregation and degranulation are the 
best indicators of neutrophil responsiveness is a matter of debate 
but, with the development of selective biosynthesis inhibitors 
and specific receptor antagonists, a more complete picture may be 
forthcoming.
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CHAPTER 8. GENERAL CONCLUSIONSt LIPID MEDIATORS OF
HUMAN NEUTROPHIL ACTIVATION.
The neutrophil is the predominant leucocyte in human 
blood and its main functions are to protect the body against 
invading organisms and to promote general tissue repair and 
maintenance. Hyperactivity of neutrophils resulting in 
the over-exuberant release of lysosomal enzymes, lipid 
autacoids and toxic oxygen metabolites may be one of the 
most important factors underlying chronic inflammatory 
conditions such as rheumatoid arthritis. Investigation 
of the control and regulatory mechanisms mediating the 
activation of isolated neutrophils may assist in the 
understanding of the in vivo function of these cells. 
Exposure of human neutrophils to a variety of particulate 
(e.g. immune complexes and zymosan) and soluble (e.g. C5a, 
EMLP, PAI and LTB4) stimuli evoke a series of cellular 
responses including chemotaxis, aggregation, degranulation 
and superoxide generation. Also formed are numerous lipid 
products derived initially from acyl hydrolase action on 
membrane phospholipids. Such acyl hydrolase activation 
results ins
(i) The liberation of arachidonic acid and its subsequent 
conversion by the 5-lipoxygenase pathway to yield 
LTB4 and 5-HETE.
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(ii) The hydrolysis of 1-O-alkyl-2-acyl-sn-glyceryl-3-
phosphorylcholine to yield free fatty acids (including 
arachidonic acid) and lyso PAF which can be converted 
to PAF by an acetyl transferase enzyme.
LTB^ and PAF may thus be formed concomitantly in activated 
neutrophils from a common precursor. Since these lipids are 
potent independent activators of human neutrophils, they may 
also act as a positive feedback mechanism promoting further 
neutrophil activation. For example, formation of C5a at sites 
of inflammation or the release of bacterial metabolites at the 
site of invasion evokes the accumulation of neutrophils. These 
activated neutrophils, by releasing LTB^ and PAF, trigger a 
second wave of neutrophil accumulation and activation. 
Alternatively, both lipids may be intracellular mediators or 
amplifiers of responses induced by other neutrophil activators 
such as C5a and FMLP.
Ultra structural changes, aggregation and the release 
of both NAG and lysozyme induced by LTB^ and PAF do not 
appear to differ markedly from the same responses evoked 
by the other receptor-directed agonist, namely iMLP (Chapter 
5), The changes in £ca^+]i and PtdA levels induced by 
PAF may well indicate that phosphoinositide hydrolysis is 
mediating neutrophil activation elicited by this ether lipid.
As these events (|Ca^+li elevation and PtdA formation) are
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pertussis toxin sensitive and are inhibited by protein 
kinase C activators, the normal agonist-induced physio­
logical response may be regulated by a G-protein and 
protein kinase C. The lack of effect of LTB^ on PtdA 
formation or on Ptdlns, PIP and PIP2 breakdown suggests 
either that this lipid stimulates cellular responsiveness 
independently of phosphoinositide hydrolysis or that the 
technique of prelabelling with -orthophosphate is too 
insensitive to detect small changes in inositol phospho­
lipid degradation. Whichever the case, the results 
suggest that there is both a quantitative and qualitative 
difference between the changes in the levels of the 
inositol phospholipids and PtdA induced by the ether lipid 
and the chemotactic tripeptide and the lack of response 
observed with the arachidonic acid metabolite. Similar 
observations have been made in the platelet where AUP causes 
an elevation of £ca^+Ji without an apparent phosphoinositide 
hydrolysis (MacIntyre et al., 1986; Fisher et al., 1985)* 
Another intriguing observation is that neutrophil activation 
elicited by LTB4 is also inhibited by pertussis toxin and by 
preincubation with PMA (ergo stimulation of a G protein 
and protein kinase C respectively; discussed in Chapter 6). 
Therefore, the precise mechanism of action of this lipid 
still remains to be established. The fact that the
r 2+1
concentration-response curve for the elevation of |_Ca Ji 
lies to the left of the curves for the other indices of 
neutrophil activation induced by all receptor-directed 
agonists may suggest that it is unlikely that the rise in
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£ca^+Ji per se mediates these responses. Consequently 
£ca^+Ji elevation may trigger an intracellular amplification 
sequence or invoke formation of other mediators which act 
alone or in concert with this divalent cation.
As chemoattractants undoubtably are present in low 
concentrations at locations distal to the initial site of 
inflammation, an attractive in vivo application of these 
latter observations may be that chemotaxis is mediated by 
an elevation of £ca^+]i. Agonist-induced neutrophil loco­
motion and rises in £ca^+Ji are usually produced by lower 
concentrations of stimuli than the other cellular responses.
As the cells move closer to the site of injury, the number 
of agonist/receptor interactions will increase with the 
increasing concentration of agonist. This, in turn, may 
trigger the other responses such as degranulation and release 
of toxic oxygen metabolites mediated, perhaps, by protein 
kinase C activation produced as a consequence of phospho­
inositide hydrolysis or by other as yet unidentified stimulus- 
response coupling mechanisms.
The results presented in Chapter 5 also show that neutro­
phils are capable of producing large amounts of LTB4 stimulated 
by the non-physiological stimulus, the calcium ionophore; 
ionomycin. However, other more physiological stimuli (PMLP 
and PAF) failed to generate similar levels of this eicosanoid. 
The observations made with the specific PAF receptor antagonist, 
kadsurenone, and the selective 5-lipoxygenase inhibitor, Revlon
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5901, indicate that release of PAF and LTB4 is unlikely 
to contribute to human neutrophil activation induced by 
other stimuli (Chapter 7)«
Whether the data reported with lipid activation of 
isolated neutrophils can be extrapolated to a more in 
vivo interpretation awaits further investigation, the 
outcome of which may help in the understanding of many 
acute and chronic inflammatory conditions.
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